




(86) Date de dépôt PCT/PCT Filing Date: 2010/03/16
(87) Date publication PCT/PCT Publication Date: 2010/09/23
(45) Date de délivrance/Issue Date: 2018/03/06
(85) Entrée phase nationale/National Entry: 2011/09/02
(86) N° demande PCT/PCT Application No.: IB 2010/000826
(87) N° publication PCT/PCT Publication No.: 2010/106436
(30) Priorité/Priority: 2009/03/18 (US61/161,089)

(51) Cl.Int./Int.Cl. *C07D 403/02* (2006.01),
A61K 31/517 (2006.01), *A61K 31/519* (2006.01),
A61K 31/5377 (2006.01), *A61K 31/55* (2006.01),
A61K 31/551 (2006.01), *A61P 9/00* (2006.01),
C07D 239/88 (2006.01), *C07D 401/02* (2006.01)
(72) Inventeur/Inventor:
HANSEN, C. HENRIK, CA
(73) Propriétaire/Owner:
RESVERLOGIX CORP., CA
(74) Agent: TORYS LLP

(54) Titre : NOUVEAUX AGENTS ANTI-INFLAMMATOIRES
(54) Title: NOVEL ANTI-INFLAMMATORY AGENTS



(III)


(57) **Abrégé/Abstract:**

Disclosed are heteroaryl compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM- 1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the heteroaryl compounds, as well as methods for their preparation.

(see formula III)

Abstract

Disclosed are heteroaryl compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM- 1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the heteroaryl compounds, as well as methods for their preparation.



(III)

NOVEL ANTI-INFLAMMATORY AGENTS

[001] This application claims the benefit of U.S. Provisional Application No. 61/161,089, filed March 18, 2009.

[002] The present invention relates to novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). The invention also includes pharmaceutical compositions comprising the novel compounds, as well as methods for their preparation.

[003] Coronary heart disease (CHD) remains a leading cause of death in industrialized nations. A primary cause of CHD is atherosclerosis, a disease characterized by the deposition of lipids in the arterial vessel wall, resulting in a narrowing of the vessel passages and, ultimately leading to hardening of the vascular system.

[004] It is generally accepted that atherosclerosis can begin with local injury to the arterial endothelium, followed by proliferation of arterial smooth muscle cells from the medial layer to the intimal layer, along with the deposition of lipids and the accumulation of foam cells in the lesion. As the atherosclerotic plaque develops, it progressively occludes more of the affected blood vessel and can eventually lead to ischemia or infarction. Thus, there is a continued effort to develop treatments to inhibit or prevent the progression of atherosclerosis in patients in need thereof.

[005] Cardiovascular disease has been linked to several causative factors, including hypercholesterolemia, hyperlipidemia, and the expression of vascular cell adhesion molecule-1 (VCAM-1) in vascular endothelial cells. VCAM-1 promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils. Certain melanoma cells can use VCAM-1 to adhere to the endothelium, and VCAM-1 may participate in monocyte recruitment to atherosclerotic sites. As a result, VCAM-1 is of interest as a drug target.

[006] The VCAM-1 gene is a member of the immunoglobulin (Ig) superfamily and encodes a cell-surface sialoglycoprotein expressed by cytokine-activated endothelial cells. This type-1 membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of atherosclerosis and rheumatoid arthritis. VCAM-1, also known as CD106, has several roles in the immune system. The VCAM-1 protein contains six or seven immunoglobulin domains, and is expressed in both large and small vessels only after endothelial cells are stimulated by cytokines.

[007] Adhesion of leukocytes to the endothelium represents a fundamental, early event in many inflammatory conditions, including atherosclerosis, autoimmune disorders, and bacterial and viral infections. Leukocyte recruitment to the endothelium begins when inducible adhesion molecule receptors on the surface of endothelial cells interact with their counter-receptors on immune cells. Vascular endothelial cells determine which type(s) of leukocyte(s) (e.g., monocytes, lymphocytes, neutrophils) are recruited, by selectively expressing specific adhesion molecules, such as VCAM-1, intracellular adhesion molecule-1 (ICAM-1), and E-selectin.

[008] In the early stage of the atherosclerotic lesion, there is localized endothelial expression of VCAM-1 and selective recruitment of mononuclear leukocytes that express the integrin counter-receptor VLA-4. Because of the selective expression of VLA-4 on monocytes and lymphocytes, but not neutrophils, VCAM-1 is important in mediating the selective adhesion of mononuclear leukocytes. Subsequent conversion of leukocytes to foamy macrophages results in the synthesis of a wide variety of inflammatory cytokines, growth factors, and chemoattractants that help expand leukocyte and platelet recruitment, smooth muscle cell proliferation, endothelial cell activation, and the extracellular matrix synthesis characteristic of maturing atherosclerotic plaques.

[009] VCAM-1 is also a mediator in inflammatory diseases. For example, it is known that the expression of VCAM-1 and ICAM-1 are increased in asthmatics (Pilewski *et al.* (1995) *Am. J. Respir. Cell Mol. Biol.* 12, 1-3; Ohkawara *et al.* (1995) *Am J. Respir. Cell Mol. Biol.* 12, 4-12). Further examples of non-cardiovascular inflammatory diseases mediated by VCAM-1 include rheumatoid and osteoarthritis, asthma, dermatitis, and multiple sclerosis. Blocking

the integrin receptors for VCAM-1 and ICAM-1 (VLA-4 and LFA-1, respectively) suppresses both early- and late-phase responses in an ovalbumin-sensitized rat model of allergic airway responses (Rabb *et al.* (1994) *Am. J. Respir. Care Med.* 149, 1186-1191). There is also increased expression of endothelial adhesion molecules, including VCAM-1, in the microvasculature of rheumatoid synovium (Koch *et al.* (1991) *Lab. Invest.* 64, 313-322; Morales-Ducret *et al.* (1992) *Immunol.* 149, 1421-31).

[010] Neutralizing antibodies directed against VCAM-1 or its counter receptor, VLA-4, can delay the onset of diabetes in a mouse model (NOD mice), which spontaneously develop the disease (Yang *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90, 10494-10498; Burkly *et al.* (1994) *Diabetes* 43, 523-534; Baron *et al.* (1994) *J. Clin. Invest.* 93, 1700-1708). Monoclonal antibodies to VCAM-1 can also have beneficial effects in animal models of allograft rejection, suggesting that inhibitors of VCAM-1 expression may also have utility in preventing transplant rejection (Oroez *et al.* (1992) *Immunol. Lett.* 32, 7-12).

[011] VCAM-1 is expressed by cells in both a membrane-bound and soluble form. The soluble form has been shown to induce chemotaxis of vascular endothelial cells *in vitro* and to stimulate an angiogenic response in rat cornea (Koch *et al.* (1995) *Nature* 376, 517-519). Inhibitors of the expression of soluble VCAM-1 have potential therapeutic value in treating diseases with an angiogenic component, including tumor growth and metastasis (Folkman & Shing (1992) *Biol. Chem.* 10931-10934).

[012] Because cardiovascular and inflammatory diseases are currently a leading cause of death and disability in the developed world, there is a strong need to identify new methods and pharmaceutical agents for its treatment. Thus, there is a need to identify and manipulate synthetic compounds that can affect the expression of mediators of the inflammatory process, such as, for example, VCAM-1.

[013] Interleukin-6 (IL-6) is a 22-27-kDa secreted glycoprotein that exhibits growth stimulatory and pro-inflammatory activities. IL-6 has also been called interferon- β 2 (IFN- β 2), IL-1-inducible 26-kDa protein, hepatocyte-stimulating factor, cytotoxic T-cell differentiation factor, and B-cell stimulatory factor (Tripathi *et*

al. (2003) *Clin. Cancer Res.* 9, 4653-4665). IL-6 was originally identified in monocytes / macrophages, fibroblasts, and endothelial cells.

[014] IL-6 is secreted by various cell types and exerts its activities by binding to a high-affinity receptor complex, consisting of two membrane glycoproteins, an 80-kDa component receptor that binds IL-6 with low affinity (IL-6R) and a signal-transducing component of 130 kDa (also known as gp130) that does not bind IL-6 itself, but is required for high-affinity binding of IL-6 by the complex. The IL-6R can be cleaved by a transmembrane metalloproteinase to yield a soluble IL-6R.

[015] IL-6 levels are rapidly elevated in the circulation in numerous infectious, inflammatory, autoimmune diseases, and in some cancers, in association with increased synthesis of other cytokines, stimulated by infection, trauma, and immunological challenge. (Tripathi *et al.* (2003) *Clin. Cancer Res.* 9, 4653-4665). IL-6 has been implicated in various diseases and disorders, including multiple myeloma (Rossi *et al.* (2005) *Bone Marrow Transplantation* 36, 771-779), lymphomas (Emilie *et al.* (1994) *Blood* 84, 2472-2479), neurological disorders, such as neurodegeneration, astrocytosis, and cerebral angiogenesis (Campbell *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90, 10061-10065), autoimmune disorders (e.g., rheumatoid arthritis), inflammatory diseases, Alzheimer's disease, myocardial infarction, Paget's disease, osteoporosis, solid tumors, prostate and bladder cancers (Tripathi *et al.* (2003) *Clin. Cancer Res.* 9, 4653-4665), septic shock, transplants, acute infections of the central nervous system, cardiac myxoma (Wijdenes *et al.* (1991) *Mol. Immunol.* 28, 1183-1192), tumor-induced cachexia (Cahlin *et al.* (2000) *Cancer Res.* 60, 5488-5489), cancer-associated depression, and cerebral edema secondary to brain tumors (Musselman *et al.* (2001) *Am. J. Psychiatry* 158, 1252-1257). Inflammation and IL-6 are now specifically thought to be linked to heart attacks (Taubes (2002) *Science* 296, 242).

[016] Generally, it is known that IL-6 is abnormally produced in some inflammatory, autoimmune, and neoplastic diseases. It has been proposed that abnormal production of IL-6 is an aspect of the mechanisms of these diseases (Hirano *et al.* (1990) *Immunol. Today*, 11, 443-449; Sehgal (1990) *Proc. Soc. Exp. Biol. Med.* 195, 183-191; Grau (1990) *Eur. Cytokine Net* 1, 203-210; Bauer *et al.*

(1991) *Ann. Hematol.* 62, 203-210; Campbell *et al.* (1991) *J. Clin. Invest.* 7, 739-742; Roodman *et al.* (1992) *J. Clin. Invest.* 89, 46-52). In particular, it is known that IL-6 is associated with neuropathological processes, and its level in blood is increased in diseases invading the central nervous system. It has been found that IL-6 increases the level of tau epitope, by stimulating the dementia-associated phosphorylation of the tau protein in neuronal cells (Quintanilla *et al.* (2004) *Exp. Cell Res.* 295, 245-257). Mice lacking IL-6 have enhanced resistance to glutamate toxicity and increased viability of neuronal cells (Fisher *et al.* (2001) *J. Neuroimmunol.* 119, 1-9). It has also been found that IL-6 amplifies a calcium influx signal for the neurotransmitter N-methyl-D-aspartate (NMDA), through voltage-sensitive calcium channels, which provides some evidence that the increased IL-6 level may play a role in inducing pathological changes in central nervous system diseases (Qiu *et al.* (1998) 18,10445-10456). It has also been reported that the abnormal expression of IL-6 is a pathogenic mechanism in other diseases, including cardiac myxoma, uterine cancer (Kishimoto *et al.* (1988) *Ann. Rev. Immunol.* 6, 485), multiple myeloma, histiocytomas (Taga *et al.* (1987) *J. Exp. Med.* 166, 967), plasmacytoma, hematological diseases, including plasma cell dyscrasias, leukemia, and lymphoma (Kishimoto (1989) *Blood* 74, 1; Taga *et al.* (1987) *J. Exp. Med.* 166, 967; Klein *et al.* (1991) *Blood* 78, 1198-1204), proliferative glomerulonephritis, activated multiclonal B-cell (types I-IV) allergic diseases, rheumatoid arthritis (Hirano *et al.* (1988) *Eur. J. Immunol.* 18, 1797), diabetes (Campbell *et al.* (1991) *J. Clin. Invest.* 87, 739-742), multiple sclerosis, Systemic Lupus Erythematosus, septic shock, bacterial infections, viral infections, osteoporosis (Roodman *et al.* (1992) *J. Clin. Invest.* 89, 46-52; Jilka *et al.* (1992) *Science* 257, 88-91), chronic immunodeficiency syndrome and autoimmune immunodeficiency syndromes, including AIDS (*Med. Immunol.* (1988) 15, 195-201), and inflammatory diseases, including inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis) (WO99/47170). It is known that IL-6 is associated with some central nervous system diseases (Frei *et al.* (1991) *J. Neuroimmunol.* 31, 147).

[017] Interleukin-6 is secreted by many advanced cancers, such as hormone-independent prostate cancer, and is believed to be a growth factor for such cancers. Additionally, the secretion of IL-6 by cancer cells is believed to

cause cachexia, the wasting syndrome characteristic of advanced cancers. Thus, reducing the level of IL-6 would be useful in treating such cancers. IL-6 also plays a key role in B cell development. Autoimmune diseases with a significant antibody component, such as rheumatoid arthritis, could be treated by decreasing IL-6 levels. Disorders involving B cell proliferation, such as multiple myeloma and B cell lymphoma, could also be treated by reducing IL-6 activity. Additionally, IL-6 plays an important role in bone remodeling by promoting bone resorption. Reducing IL-6 activity would have the effect of reducing bone resorption and could be used to treat osteoporosis.


[018] Accordingly, there have been various attempts to reduce the levels of IL-6, which are believed to be associated with the pathogenic mechanisms of these various diseases and conditions. A steroid formulation has been used for suppressing the cytokines in the art, but such medicines may causes severe side-effects, such as peptic ulcers, if administered for an extended period.

[019] Anti-IL-6 antibodies have been shown to be effective in treating several diseases and disorders. For example, anti-IL-6 monoclonal antibodies have been shown to block the proliferation of myeloma cells both *in vivo* and *in vitro* (Rossi *et al.* (2005) *Bone Marrow Transplantation* 36, 771-779). Administration of anti-IL-6 antibodies to chronic rheumatoid arthritis patients was found to alleviate the symptoms of the disease (Wendling *et al.* (1993) *J. Rheumatol.* 20, 259-262). Anti-IL-6 antibodies have also been shown to be effective in treating AIDS-associated lymphoma (Emilie *et al.* (1994) *Blood* 84, 2472-2479), and metastatic renal cell carcinoma (Blay *et al.* (1997) *Int. J. Cancer* 72, 424-430). Clinical results involving the administration of anti-IL-6 antibodies to treat various other diseases and disorders are summarized in Trikha *et al.* (2003) *Clin. Cancer Res.* 9, 4653-4665.

[020] Thus, the present invention provides non-naturally occurring compounds that are useful for regulating the expression of interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1), as well as the use of such compounds for the treatment and prevention of cardiovascular and inflammatory diseases, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, inflammatory bowel diseases, and autoimmune disease(s).

[021] Without wishing to be bound to theory, it is believed that the compounds of the invention act by inhibiting expression of IL-6 and/or VCAM-1 in the subject receiving the compound. However, regardless of the mechanism of action, administration of one or more compounds of the present invention will reduce the levels of IL-6 and/or VCAM-1 in the subject and as a result treat or reduce the incidence of cardiovascular and/or inflammatory diseases.

[022] One aspect of the invention provides a method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject comprising administering to the subject in need thereof, a therapeutically effective amount of at least one compound of Formula I:



or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q and V are independently selected from CH and nitrogen;

U is selected from C=O, C=S, SO₂, S=O, SR₁, CR₁R₂, CR₁OR₂, CR₁SR₂;

R₁ and R₂ are independently selected from hydrogen and C₁-C₆ alkyl;


R_c is selected from hydrogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

R_{a1}, R_{a2}, and R_{a3} are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, halogen, amino, amide, hydroxyl, heterocycle, and C₃-C₆ cycloalkyl, wherein R_{a1} and R_{a2} and/or R_{a2} and R_{a3} may be connected to form a cycloalkyl or a heterocycle;

R_{b2} and R_{b6} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, hydroxyl, and amino;

R_{b3} and R_{b5} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, hydroxyl, and amino, wherein

R_{b2} and R_{b3} and/or R_{b5} and R_{b6} may be connected to form a cycloalkyl or a heterocycle;




represents a 3-8 membered ring system wherein:

W is selected from carbon and nitrogen;

Z is selected from CR_6R_7 , NR_8 , oxygen, sulfur, $-\text{S}(\text{O})-$, and $-\text{SO}_2-$;

said ring system being optionally fused to another ring selected from cycloalkyl, heterocycle, and phenyl, and wherein said ring system is selected from, for example, rings having the structures



R_3 , R_4 , and R_5 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryl, aryloxy, hydroxyl, amino, amide, oxo, $-\text{CN}$, and sulfonamide;

R_6 and R_7 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, halogen, hydroxyl, $-\text{CN}$, amino, sulfonyl, acyl, and amido;

R_8 is selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, acyl, and C_3 - C_6 cycloalkyl; and

R_9 , R_{10} , R_{11} , and R_{12} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, heterocycle, hydroxyl, sulfonyl, and acyl,


provided that

if $\text{Q} = \text{CH}$, then at least one of Ra_1 , Ra_2 , and Ra_3 is not hydrogen;

if $Z = \text{NAC}$, then only one of Ra_1 , Ra_2 , or Ra_3 is hydrogen, and Ra_1 is not $-\text{OCH}_2\text{CH}_2\text{OMe}$; and

if Ra_1 and Ra_3 are both OMe , then R_8 is not $-\text{C}(\text{O})\text{CH}_2\text{OH}$.

[023] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula II:



(II)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q and V are independently selected from CH and nitrogen;

U is selected from $\text{C}=\text{O}$, $\text{C}=\text{S}$, SO_2 , $\text{S}=\text{O}$, SR_1 , CR_1R_2 , CR_1OR_2 , and CR_1SR_2 ;

R_1 and R_2 are independently selected from hydrogen and $\text{C}_1\text{-C}_6$ alkyl;

Rc is selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, and $\text{C}_3\text{-C}_6$ cycloalkyl;

Ra_1 , Ra_2 , and Ra_3 are independently selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_6$ cycloalkyl, halogen, amino, amide, hydroxyl, cycloalkyl, and heterocycle, wherein Ra_1 and Ra_2 and/or Ra_2 and Ra_3 may be connected to form a cycloalkyl or a heterocycle;

Rb_2 and Rb_6 are independently selected from hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_3\text{-C}_6$ cycloalkyl, hydroxyl, and amino;

Rb_3 and Rb_5 are independently selected from hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_6$ cycloalkyl, hydroxyl, and amino, wherein

Rb_2 and Rb_3 and/or Rb_5 and Rb_6 may be connected to form a cycloalkyl or a heterocycle;

Rn_1 is selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, and $\text{C}_3\text{-C}_6$ cycloalkyl; and


Rn_2 is selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, heterocycle, aryl, alkenyl, sulfonyl, and acyl, wherein Rn_1 and/or Rn_2 may be connected with Rb_3 and/or Rb_5 to form a 5- or 6-membered heterocyclic ring,

provided that

at least one of Ra_1 , Ra_2 , and Ra_3 are not hydrogen; and

Rn_1 and Rn_2 are not both methyl or ethyl.

[024] In other embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula III:



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is selected from CR_{12} and nitrogen;

V is selected from CH and nitrogen;

U is selected from C=O, C=S, SO_2 , S=O, SR_1 , CR_1R_2 , CR_1OR_2 , CR_1SR_2 ;

X is selected from oxygen, sulfur, SR_1 , nitrogen, NR_6R_7 , and CR_6R_7 ;

Z is selected from unsubstituted C_1 - C_6 alkyl and C_1 - C_6 alkyl substituted with one or more groups selected from C_1 - C_3 alkyl, C_1 - C_3 alkoxy, cyclopropyl, hydroxyl, amino, and halogen;

n is selected from 0, 1, 2, 3, 4, or 5;

G is selected from heterocycle, cycloalkyl, and aryl;

R_1 and R_2 are independently selected from hydrogen, and C_1 - C_6 alkyl;

R_6 , R_7 , and R_{12} are independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, heterocycle, C_1 - C_6 alkoxy, and halogen;

R_c is selected from hydrogen, C_1 - C_6 alkyl, and C_3 - C_6 cycloalkyl;

Ra_1 , Ra_2 , and Ra_3 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein Ra_1 and Ra_2 and/or Ra_2 and Ra_3 may be connected to form a cycloalkyl or a heterocycle;

Rb_2 and Rb_6 are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_6 alkenyl, hydroxyl, and amino; and

WO 2010/106436


PCT/IB2010/000826

Rb₃ and Rb₅ are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, and amino, wherein

Rb₂ and Rb₃ and/or Rb₅ and Rb₆ may be connected to form a cycloalkyl or a heterocycle;

provided that


if Ra₁ and Ra₃ are OMe, and Q = CH, then $\text{X}(\text{Z})_n^G$ is not



at least one of Ra₁, Ra₂, and Ra₃ is not hydrogen; and

if Ra₂ or Ra₃ is chloro, then Ra₁ is not hydrogen.

[025] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula IV:



(IV)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q₁ is selected from nitrogen and C-Ra₁;

Q₂ is selected from nitrogen and C-Ra₂;

Q₃ is selected from nitrogen and C-Ra₃;

V is selected from CH and nitrogen;

U is selected from C=O, C=S, SO₂, S=O, SR₁, CR₁R₂, CR₁OR₂, CR₁SR₂;

R₁ and R₂ are independently selected from hydrogen and C₁-C₆ alkyl;

Ra₁, Ra₂, and Ra₃ are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, amino, amide, and

WO 2010/106436

PCT/IB2010/000826

heterocycle, wherein Ra_1 and Ra_2 and/or Ra_2 and Ra_3 may be connected to form a cycloalkyl or a heterocycle;


Rb_2 and Rb_6 are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_6 alkenyl, hydroxyl, and amino; and

Rb_3 and Rb_5 are independently selected from hydrogen, methyl, ethyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkoxy, and amino, wherein

Rb_2 and Rb_3 and/or Rb_5 and Rb_6 may be connected to form a cycloalkyl or a heterocycle,


provided that

if Ra_3 is alkoxy, then Ra_1 is not hydrogen;

if Ra_2 is , then Rb_3 is not hydrogen; and

if Rb_2 , Rb_5 , and Rb_6 are hydrogen, then Rb_3 is not $-CH_2OH$.

[026] In a further embodiment, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula V:



(V)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is selected from CR_6 and nitrogen;

U is selected from $C=O$, $C=S$, SO_2 , $S=O$, SR_1 , CR_1R_2 , CR_1OR_2 , CR_1SR_2 ;

Y is selected from oxygen, nitrogen, sulfur, NR_6 , CR_6R_7 ;

A is C_1 - C_4 alkyl, wherein the alkyl chain may be connected to Y, D, Rb_3 and/or Rb_5 to form a cycloalkyl or heterocycle;

D may be absent or present, and if present is selected from $-OR_1$, $-NR_1R_2$;

R_1 and R_2 are independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, sulfonamide, carboxamide, acyl, and nitrile, wherein R_1 and R_2 may be connected to form a cycloalkyl or a heterocycle;

R_6 and R_7 are independently selected from hydrogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, hydroxyl, and halogen;

Ra_1 , Ra_2 , and Ra_3 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein Ra_1 and Ra_2 and/or Ra_2 and Ra_3 may be connected to form a cycloalkyl or a heterocycle;

Rb_2 and Rb_6 are independently selected from hydrogen, halogen, C_1 - C_6 alkyl, and C_3 - C_6 cycloalkyl; and

Rb_3 is selected from hydrogen, halogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, hydroxyl, and amino, wherein

Rb_2 and Rb_3 and/or Rb_5 and Rb_6 may be connected to form a cycloalkyl or a heterocycle,

provided that

at least one of Ra_1 , Ra_2 , and Ra_3 is not hydrogen; and

if Ra_1 and Ra_3 are both hydrogen, and $Y = \text{nitrogen}$, then Ra_2 is not hydrogen, $-OAc$, or $-OMe$.

[027] The invention also provides pharmaceutical compositions comprising one or more compounds of the invention, (i.e., compounds of Formula I, Formula II, Formula III, Formula IV, and Formula V, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates of compounds of Formula I, II, III, IV, and V) together with at least one pharmaceutically acceptable carrier, adjuvant, and/or excipient. In addition, methods of preparing compounds of Formula I, Formula II, Formula III, Formula IV, and Formula V, and stereoisomers, tautomers, and pharmaceutically acceptable salts and hydrates thereof are encompassed by the invention.

[028] The invention further provides methods of treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states by administering to a subject in need thereof, a therapeutically effective amount of one or more compounds of Formula I, Formula II, Formula III, Formula

IV, Formula V, or tautomers, stereoisomers, pharmaceutically acceptable salts, or hydrates of compounds of Formula I, Formula II, Formula III, Formula IV, and Formula V. The invention also includes methods of regulating the expression of interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) in a subject, such as a human, comprising administering a therapeutically effective amount of any of the compounds of the invention described herein or a pharmaceutically acceptable composition comprising one or more compounds of the invention.

Definitions

[029] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. The following abbreviations and terms have the indicated meanings throughout:

[030] As used herein, "cardiovascular disease" refers to diseases, disorders and conditions of the heart and circulatory system that are mediated by VCAM-1 and/or IL-6. Exemplary cardiovascular diseases, including cholesterol- or lipid-related disorders, include, but are not limited to, acute coronary syndrome, angina, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, cerebral infarction, congestive heart failure, congenital heart disease, coronary heart disease, coronary artery disease, coronary plaque stabilization, dyslipidemias, dyslipoproteinemias, endothelium dysfunctions, familial hypercholesterolemia, familial combined hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertension, hyperlipidemia, intermittent claudication, ischemia, ischemia reperfusion injury, ischemic heart diseases, cardiac ischemia, metabolic syndrome, multi-infarct dementia, myocardial infarction, obesity, peripheral vascular disease, reperfusion injury, restenosis, renal artery atherosclerosis, rheumatic heart disease, stroke, thrombotic disorder, transitory ischemic attacks, and lipoprotein abnormalities associated with Alzheimer's disease, obesity, diabetes mellitus, syndrome X, impotence, multiple sclerosis, Parkinson's diseases and an inflammatory diseases.

[031] As used herein, "inflammatory diseases" includes refers to diseases, disorders and conditions, that are mediated by VCAM-1 and/or IL-6.

Exemplary inflammatory diseases, include, but are not limited to, arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular inflammation, uveitis, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina, and small artery disease.

[032] "Subject" refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for both human therapy and veterinary applications. In one embodiment, the subject is a human.

[033] As used herein, "treatment" or "treating" refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating" refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient. In yet another embodiment, "treatment" or "treating" refers to inhibiting the progression of a disease or disorder, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both. In yet another embodiment, "treatment" or "treating" refers to delaying the onset of a disease or disorder. For example, treating a cholesterol disorder may comprise decreasing blood cholesterol levels.

[034] As used herein, "prevention" or "preventing" refers to a reduction of the risk of acquiring a given disease or disorder.

[035] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH₂ is attached through the carbon atom.

[036] By "optional" or "optionally" is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" encompasses both "aryl" and

"substituted aryl" as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable.

[037] As used herein, the term "hydrate" refers to a crystal form with either a stoichiometric or non-stoichiometric amount of water is incorporated into the crystal structure.

[038] The term "acyl" term as used herein refers to a carbonyl radical attached to an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycyl, aryl, or heteroaryl. Exemplary acyl groups include, but are not limited to, acetyl, formyl, propionyl, benzoyl, and the like.

[039] The term "aldehyde" or "formyl" as used herein refers to -CHO.

[040] The term "alkenyl" as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-22, 2-8, or 2-6 carbon atoms, referred to herein as (C₂-C₂₂)alkenyl, (C₂-C₈)alkenyl, and (C₂-C₆)alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, and 4-(2-methyl-3-butene)-pentenyl.

[041] The term "alkoxy" as used herein refers to an alkyl group attached to an oxygen (-O-alkyl-). An alkenyl group attached to an oxygen is "alkenyloxy" and an alkynyl group attached to an oxygen is "alkynyloxy". Exemplary alkoxy groups include, but are not limited to, groups with an alkyl group of 1-22, 1-8, or 1-6 carbon atoms, referred to herein as (C₁-C₂₂)alkoxy, (C₁-C₈)alkoxy, and (C₁-C₆)alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy and ethoxy.

[042] The term "alkyl" as used herein refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-22, 1-8, or 1-6 carbon atoms, referred to herein as (C₁-C₂₂)alkyl, (C₁-C₈)alkyl, and (C₁-C₆)alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-

pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.

[043] The term "alkynyl" as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-22, 2-8, or 2-6 carbon atoms, referred to herein as (C₂-C₂₂)alkynyl, (C₂-C₈)alkynyl, and (C₂-C₆)alkynyl, respectively. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl.

[044] The term "amide" as used herein refers to the form -NR_aC(O)(R_b)- or -C(O)NR_bR_c, wherein R_a, R_b and R_c are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen. The amide can be attached to another group through the carbon, the nitrogen, R_b, or R_c. The amide also may be cyclic, for example R_b and R_c may be joined to form a 3- to 12-membered ring, such as a 3- to 10-membered ring or a 5- or 6-membered ring. The term "amide" encompasses groups such as sulfonamide, urea, ureido, carbamate, carbamic acid, and cyclic versions thereof. The term "amide" also encompasses an amide group attached to a carboxy group, e.g., -amide-COOH or salts such as -amide-COONa, an amino group attached to a carboxy group (e.g., -amino-COOH or salts such as -amino-COONa).

[045] The term "amine" or "amino" as used herein refers to the form -NR_dR_e or -N(R_d)R_e-, where R_d and R_e are independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, carbamate, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen. The amino can be attached to the parent molecular group through the nitrogen. The amino also may be cyclic, for example any two of R_d and R_e may be joined together or with the N to form a 3- to 12-membered ring (e.g., morpholino or piperidinyl). The term amino also includes the corresponding quaternary ammonium salt of any amino group. Exemplary amino groups include alkylamino groups, wherein at least one of R_d or R_e is an alkyl group.

[046] The term "aryl" as used herein refers to a monocyclic, aromatic ring system. The aryl group can optionally be fused to one or more rings selected from aryls, cycloalkyls, and heterocyclyls. The aryl groups of this invention can be

substituted with groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone. Exemplary aryl or fused aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. Exemplary aryl groups also include, but are not limited to a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)aryl."

[047] The term "arylalkyl" as used herein refers to an alkyl group having at least one aryl substituent (e.g., -aryl-alkyl-). Exemplary arylalkyl groups include, but are not limited to, arylalkyls having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)arylalkyl."

[048] The term "aryloxy" as used herein refers to an aryl group attached to an oxygen atom. Exemplary aryloxy groups include, but are not limited to, aryloxys having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)aryloxy."

[049] The term "arylthio" as used herein refers to an aryl group attached to a sulfur atom. Exemplary arylthio groups include, but are not limited to, arylthios having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)arylthio."

[050] The term "arylsulfonyl" as used herein refers to an aryl group attached to a sulfonyl group, e.g., -S(O)₂-aryl-. Exemplary arylsulfonyl groups include, but are not limited to, arylsulfonyls having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)arylsulfonyl."

[051] The term "benzyl" as used herein refers to the group -CH₂-phenyl.

[052] The term "bicyclic aryl" as used herein refers to an aryl group fused to another aromatic or non-aromatic carbocyclic or heterocyclic ring. Exemplary bicyclic aryl groups include, but are not limited to, naphthyl or partly reduced forms thereof, such as di-, tetra-, or hexahydronaphthyl.

[053] The term "bicyclic heteroaryl" as used herein refers to a heteroaryl group fused to another aromatic or non-aromatic carbocyclic or heterocyclic ring. Exemplary bicyclic heteroaryls include, but are not limited to 5,6- or 6,6-fused systems, wherein one or both rings contain heteroatoms. The term "bicyclic heteroaryl" also encompasses reduced or partly reduced forms of fused aromatic system wherein one or both rings contain ring heteroatoms. The ring system may contain up to three heteroatoms, independently selected from oxygen, nitrogen, and sulfur. The bicyclic system may be optionally substituted with one or more groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone. Exemplary bicyclic heteroaryl's include, but are not limited to, quinazolinyl, benzothiophenyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, indolyl, quinoliny, isoquinoliny, phthalazinyl, benzotriazolyl, benzopyridinyl, and benzofuranyl.

[054] The term "carbamate" as used herein refers to the form $-R_gOC(O)N(R_h)-$, $-R_gOC(O)N(R_h)R_i-$, or $-OC(O)NR_hR_i$, wherein R_g , R_h and R_i are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen. Exemplary carbamates include, but are not limited to, arylcarbamates or heteroaryl carbamates (e.g., wherein at least one of R_g , R_h and R_i are independently selected from aryl or heteroaryl, such as pyridine, pyridazine, pyrimidine, and pyrazine).

[055] The term "carbonyl" as used herein refers to $-C(O)-$.

[056] The term "carboxy" as used herein refers to $-COOH$ or its corresponding carboxylate salts (e.g., $-COONa$). The term carboxy also includes "carboxycarbonyl," e.g. a carboxy group attached to a carbonyl group, e.g., $-C(O)-COOH$ or salts, such as $-C(O)-COONa$.

[057] The term "cyano" as used herein refers to $-CN$.

[058] The term "cycloalkoxy" as used herein refers to a cycloalkyl group attached to an oxygen.

[059] The term "cycloalkyl" as used herein refers to a saturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of 3-12 carbons, or 3-8 carbons, referred to herein as "(C₃-C₈)cycloalkyl," derived from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, and cyclopentanes. Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Cycloalkyl groups can be fused to other cycloalkyl saturated or unsaturated, aryl, or heterocyclyl groups.

[060] The term "dicarboxylic acid" as used herein refers to a group containing at least two carboxylic acid groups such as saturated and unsaturated hydrocarbon dicarboxylic acids and salts thereof. Exemplary dicarboxylic acids include alkyl dicarboxylic acids. Dicarboxylic acids may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Dicarboxylic acids include, but are not limited to succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, maleic acid, phthalic acid, aspartic acid, glutamic acid, malonic acid, fumaric acid, (+)/(-)-malic acid, (+)/(-) tartaric acid, isophthalic acid, and terephthalic acid. Dicarboxylic acids further include carboxylic acid derivatives thereof, such as anhydrides, imides, hydrazides (for example, succinic anhydride and succinimide).

[061] The term "ester" refers to the structure -C(O)O-, -C(O)O-R_j-, -R_kC(O)O-R_j-, or -R_kC(O)O-, where O is not bound to hydrogen, and R_j and R_k can independently be selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl, ether, haloalkyl, heteroaryl, and heterocyclyl. R_k can be a hydrogen, but R_j cannot be hydrogen. The ester may be cyclic, for example the carbon atom and R_j, the oxygen atom and R_k, or R_j and R_k may be joined to form a 3- to 12-membered ring. Exemplary esters include, but are not limited to, alkyl esters wherein at least one of R_j or R_k is alkyl, such as -O-

C(O)-alkyl, -C(O)-O-alkyl-, and -alkyl-C(O)-O-alkyl-. Exemplary esters also include aryl or heteroaryl esters, e.g. wherein at least one of R_j or R_k is a heteroaryl group such as pyridine, pyridazine, pyrimidine and pyrazine, such as a nicotinate ester. Exemplary esters also include reverse esters having the structure $-R_kC(O)O-$, where the oxygen is bound to the parent molecule. Exemplary reverse esters include succinate, D-argininate, L-argininate, L-lysinate and D-lysinate. Esters also include carboxylic acid anhydrides and acid halides.

[062] The term "ether" refers to the structure $-R_lO-R_m-$, where R_l and R_m can independently be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and ether. The ether can be attached to the parent molecular group through R_l or R_m . Exemplary ethers include, but are not limited to, alkoxyalkyl and alkoxyaryl groups. Ethers also includes polyethers, e.g., where one or both of R_l and R_m are ethers.

[063] The terms "halo" or "halogen" or "Hal" as used herein refer to F, Cl, Br, or I.

[064] The term "haloalkyl" as used herein refers to an alkyl group substituted with one or more halogen atoms. "Haloalkyls" also encompass alkenyl or alkynyl groups substituted with one or more halogen atoms.

[065] The term "heteroaryl" as used herein refers to a mono-, bi-, or multi-cyclic, aromatic ring system containing one or more heteroatoms, for example 1-3 heteroatoms, such as nitrogen, oxygen, and sulfur. Heteroaryls can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Heteroaryls can also be fused to non-aromatic rings. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl. Exemplary heteroaryl groups include, but are not limited to, a monocyclic aromatic ring, wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms, referred to herein as "(C₂-C₅)heteroaryl."

[066] The terms “heterocycle,” “heterocyclyl,” or “heterocyclic” as used herein refer to a saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered ring containing one, two, or three heteroatoms independently selected from nitrogen, oxygen, and sulfur. Heterocycles can be aromatic (heteroaryls) or non-aromatic. Heterocycles can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone. Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from aryl, cycloalkyl, and heterocycle. Exemplary heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, pyranal, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydropyranyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, thiomorpholinyl, thiopyranal, and triazolyl.

[067] The terms “hydroxy” and “hydroxyl” as used herein refers to -OH.

[068] The term “hydroxyalkyl” as used herein refers to a hydroxy attached to an alkyl group.

[069] The term “hydroxyaryl” as used herein refers to a hydroxy attached to an aryl group.

[070] The term “ketone” as used herein refers to the structure $-C(O)-R_n$ (such as acetyl, $-C(O)CH_3$ or $-R_n-C(O)-R_o$). The ketone can be attached to another group through R_n or R_o . R_n or R_o can be alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or aryl, or R_n and R_o can be joined to form a 3- to 12-membered ring.

[071] The term "monoester" as used herein refers to an analogue of a dicarboxylic acid wherein one of the carboxylic acids is functionalized as an ester and the other carboxylic acid is a free carboxylic acid or salt of a carboxylic acid. Examples of monoesters include, but are not limited to, to monoesters of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, oxalic, and maleic acid.

[072] The term "nitro" as used herein refers to $-\text{NO}_2$.

[073] The term "perfluoroalkoxy" as used herein refers to an alkoxy group in which all of the hydrogen atoms have been replaced by fluorine atoms.

[074] The term "perfluoroalkyl" as used herein refers to an alkyl group in which all of the hydrogen atoms have been replaced by fluorine atoms. Exemplary perfluoroalkyl groups include, but are not limited to, C_1 - C_5 perfluoroalkyl, such as trifluoromethyl.

[075] The term "perfluorocycloalkyl" as used herein refers to a cycloalkyl group in which all of the hydrogen atoms have been replaced by fluorine atoms.

[076] The term "phenyl" as used herein refers to a 6-membered carbocyclic aromatic ring. The phenyl group can also be fused to a cyclohexane or cyclopentane ring. Phenyl can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone.

[077] The term "phosphate" as used herein refers to the structure $-\text{OP}(\text{O})\text{O}_2-$, $-\text{R}_x\text{OP}(\text{O})\text{O}_2-$, $-\text{OP}(\text{O})\text{O}_2\text{R}_y-$, or $-\text{R}_x\text{OP}(\text{O})\text{O}_2\text{R}_y-$, wherein R_x and R_y can be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and hydrogen.

[078] The term "sulfide" as used herein refers to the structure $-\text{R}_z\text{S}-$, where R_z can be alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl. The sulfide may be cyclic, forming a 3 to 12-membered ring. The term "alkylsulfide" as used herein refers to an alkyl group attached to a sulfur atom.

[079] The term “sulfinyl” as used herein refers to the structure $-S(O)O-$, $-R_pS(O)O-$, $-R_pS(O)OR_q-$, or $-S(O)OR_q-$, wherein R_p and R_q can be alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydroxyl. Exemplary sulfinyl groups include, but are not limited to, alkylsulfinyls wherein at least one of R_p or R_q is alkyl, alkenyl, or alkynyl.

[080] The term “sulfonamide” as used herein refers to the structure $-(R_r)-N-S(O)_2-R_s-$ or $-R_t(R_r)-N-S(O)_2-R_s-$, where R_t , R_r , and R_s can be, for example, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, and heterocyclyl. Exemplary sulfonamides include alkylsulfonamides (e.g., where R_s is alkyl), arylsulfonamides (e.g., where R_s is aryl), cycloalkyl sulfonamides (e.g., where R_s is cycloalkyl), and heterocyclyl sulfonamides (e.g., where R_s is heterocyclyl).

[081] The term “sulfonate” as used herein refers to $-OSO_3-$. Sulfonate includes salts such as $-OSO_3Na$, $-OSO_3K$ and the acid $-OSO_3H$.

[082] The term “sulfonic acid” refers to $-SO_3H-$ and its corresponding salts (e.g., $-SO_3K-$ and $-SO_3Na-$).

[083] The term “sulfonyl” as used herein refers to the structure R_uSO_2- , where R_u can be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, and heterocyclyl (e.g., alkylsulfonyl). The term “alkylsulfonyl” as used herein refers to an alkyl group attached to a sulfonyl group. “Alkylsulfonyl” groups can optionally contain alkenyl or alkynyl groups.

[084] The term “thioketone” refers to the structure $-R_v-C(S)-R_w-$. The ketone can be attached to another group through R_v or R_w . R_v or R_w can be alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or aryl, or R_v and R_w can be joined to form a 3- to 12-membered ring.

[085] “Alkyl” groups can be substituted with or interrupted by or branched with at least one group selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, ketone, heteroaryl, heterocyclyl, hydroxyl, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thioketone,

ureido, and N. The substituents may be branched to form a substituted or unsubstituted heterocycle or cycloalkyl.

[086] "Alkenyl," "alkynyl," "alkoxy," "amino" and "amide" groups can be substituted with or interrupted by or branched with at least one group selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carbonyl, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thioketone, ureido, and N. The substituents may be branched to form a substituted or unsubstituted heterocycle or cycloalkyl.

[087] As used herein, a "suitable substituent" refers to a group that does not nullify the synthetic or pharmaceutical utility of the compounds of the invention or the intermediates useful for preparing them. Examples of suitable substituents include, but are not limited to: C₁₋₂₂, C₁₋₈, and C₁₋₆ alkyl, alkenyl or alkynyl; C₁₋₆ aryl, C₂₋₅ heteroaryl; C₃₋₇ cycloalkyl; C₁₋₂₂, C₁₋₈, and C₁₋₆ alkoxy; C₆ aryloxy; -CN; -OH; oxo; halo, carboxy; amino, such as -NH(C₁₋₂₂, C₁₋₈, or C₁₋₆ alkyl), -N(C₁₋₂₂, C₁₋₈, and C₁₋₆ alkyl)₂, -NH((C₆)aryl), or -N((C₆)aryl)₂; formyl; ketones, such as -CO(C₁₋₂₂, C₁₋₈, and C₁₋₆ alkyl), -CO((C₆ aryl) esters, such as -CO₂(C₁₋₂₂, C₁₋₈, and C₁₋₆ alkyl) and -CO₂ (C₆ aryl). One of skill in art can readily choose a suitable substituent based on the stability and pharmacological and synthetic activity of the compound of the invention.

[088] As used herein, "inhibiting" refers to blocking, suppressing, or in any other way, reducing the expression of IL-6 mRNA and/or VCAM-1 mRNA, and/or the level of protein.

[089] As used herein, "reducing" refers to reducing the overall levels of IL-6 and/or VCAM-1, e.g., by inhibiting the expression of, eliminating, and/or modifying IL-6 mRNA and/or VCAM-1 mRNA, and/or the level of protein.

[090] The term "pharmaceutically acceptable carrier" as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other

active compounds providing supplemental, additional, or enhanced therapeutic functions.

[091] The term "pharmaceutically acceptable composition" as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.

[092] The term "pharmaceutically acceptable prodrugs" as used herein represents those prodrugs of the compounds of the present invention that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. A discussion is provided in Higuchi *et al.*, "Prodrugs as Novel Delivery Systems," *ACS Symposium Series*, Vol. 14, and in Roche, E.B., ed. *Bioreversible Carriers in Drug Design*, American Pharmaceutical Association and Pergamon Press, 1987.

[093] The term "pharmaceutically acceptable salt(s)" refers to salts of acidic or basic groups that may be present in compounds used in the present compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, malate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfite, bisulfite, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds included in the present compositions, that are acidic in nature are capable of forming base salts with various

pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.

[094] The compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term "stereoisomers" when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols "R" or "S," depending on the configuration of substituents around the stereogenic carbon atom. The present invention encompasses various stereoisomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated "(±)" in nomenclature, but the skilled artisan will recognize that a structure may contain an implicit chiral center.


[095] Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution include, but are not limited to (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. Stereoisomeric mixtures can also be resolved into their component stereoisomers by well known methods, including, but not limited to chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, and/or crystallizing the compound in a chiral solvent. Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.

[096] Geometric isomers can also exist in the compounds of the present invention. The present invention encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.

Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the *E* and *Z* isomers.

[097] Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond. The arrangements of substituents around a carbocyclic ring are designated as “cis” or “trans.” The term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”


[098] The compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof.



Exemplary Embodiments


Formula I Methods and Compounds

[099] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula I:



(I)


or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:



R_3 and R_4 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, -CN, and sulfonamide; and

R_8 is selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, acyl, and C_2 - C_6 alkynyl.


[0100] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula I, wherein:



R_3 and R_4 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, -CN, and sulfonamide; and

R_9 and R_{10} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, heterocycle, sulfonyl, carbamate, carboxamide, and acyl.

[0101] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula I, wherein:



R_3 and R_4 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amido, oxo, -CN, and sulfonamide; and

R_8 is selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, acyl, and C_3 - C_6 cycloalkyl.

[0102] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula I, wherein:


U is C=O;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are independently selected from C_1 - C_6 alkoxy, hydrogen, and halogen;

R_{b2} , R_{b3} , R_{b5} , and R_{b6} are each hydrogen;



R_3 and R_4 are independently selected from hydrogen and C_1 - C_6 alkyl;

R_8 is selected from C_1 - C_6 alkyl and hydrogen; and

R_9 , R_{10} , R_{11} , and R_{12} are independently selected from C_1 - C_6 alkyl, hydrogen, acyl, and sulfonyl.

[0103] In some embodiments, the method for inhibiting the expression of, or reducing -6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula I, wherein:


U is $C=O$;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are independently selected from methoxy, hydrogen, and halogen;

R_{b2} , R_{b3} , R_{b5} , and R_{b6} are each hydrogen;



R_3 and R_4 are independently selected from hydrogen and methyl;

R_8 is selected from hydrogen, hydroxyethyl, butyl, acetyl, isopropyl, 4-hexanoyl, 4-isobutyryl, benzoyl, 4-fluorobenzoyl, 4-picolinoyl, 4-nicotinoyl, 4-isonicotinoyl, thiophene-2-carbonyl, 5-chloro-1-methyl-1H-pyrazole-4-carbonyl, 3,3,3-trifluoropropanoyl, 2,5-dichlorothiophene-3-carbonyl, cyclopropanecarbonyl, 4-fluorobenzyl, benzyl, 2,2,2-trifluoroethyl, tertbutoxycarbonyl, and formyl;

R_9 and R_{10} are independently selected from hydrogen, methyl, cyclopropylmethyl, and acetyl; and

R_{11} and R_{12} are independently selected from hydrogen, acetyl, methanesulfonyl, dimethylaminocarbonyl, benzoyl, benzyl, ethyl, and isopropyl.

[0104] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a

therapeutically effective amount of at least one compound of Formula I selected from:

5,7-dimethoxy-2-(4-morpholinophenyl)quinazolin-4(3H)-one;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-(4-hydroxypiperidin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(4-(4-isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)methanesulfonamide;

3-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-1,1-dimethylurea;

2-(4-(4-hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide;

5,7-dimethoxy-2-(4-(4-picolinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-nicotinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-isonicotinoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(5-chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(2,5-dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide;

2-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methoxyquinazolin-4(3H)-one;

2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-isopropylacetamide;

5-chloro-2-(4-(4-isopropylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-((3R,5S)-4-isopropyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-(methylamino)pyrrolidin-1-yl)phenyl)quinazolin-4(3H)-one;

tert-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)-N-methylacetamide;

2-(4-(4-(isopropylamino)piperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1-acetylpiperidin-4-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-benzyl-N-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide;

2-(6-(4-(benzylamino)piperidin-1-yl)pyridin-3-yl)-5,7-dimethoxyquinazolin-4(3H)-one;


4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperazine-1-carbaldehyde;

2-(4-(2-(1-acetylazetidin-3-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(3-(cyclopropylmethylamino)pyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; and

5,7-dimethoxy-2-(4-(4-oxopiperidin-1-yl)phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.

[0105] Another aspect of the invention provides compounds of Formula I:



(I)

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q and V are independently selected from CH and nitrogen;

U is selected from C=O and SO₂;


W is selected from carbon and nitrogen;

R_c is selected from hydrogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

R_{a1}, R_{a2}, and R_{a3} are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, halogen, amino, amide, hydroxyl, heterocycle, and C₃-C₆ cycloalkyl, wherein R_{a1} and R_{a2} and/or R_{a2} and R_{a3} may be connected to form a cycloalkyl or a heterocycle;

R_{b2} and R_{b6} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, hydroxyl, and amino;

R_{b3} and R_{b5} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, hydroxyl, and amino, wherein R_{b2} and R_{b3} and/or R_{b5} and R_{b6} may be connected to form a cycloalkyl or a heterocycle;




represents a 3-8 membered ring system wherein:

W is selected from carbon and nitrogen;

Z is selected from CR_6R_7 , NR_8 , oxygen, sulfur, $-\text{S}(\text{O})-$, and $-\text{SO}_2-$;

said ring system being optionally fused to another ring selected from cycloalkyl, heterocycle, and phenyl, and wherein said ring system is selected from, for example, rings having the structures



R_3 , R_4 , and R_5 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryl, aryloxy, hydroxyl, amino, amide, oxo, $-\text{CN}$, and sulfonamide;

R_6 , and R_7 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, halogen, hydroxyl, acyl, and $-\text{CN}$;

R_8 is selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl and acyl; and

R_9 , R_{10} , R_{11} , and R_{12} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, hydroxyl, sulfonyl, and acyl,

provided that

if $\text{Q} = \text{CH}$, then at least one of Ra_1 , Ra_2 , and Ra_3 is not hydrogen;

WO 2010/106436

PCT/IB2010/000826


if $Z = \text{NAc}$, then only one of R_{a1} , R_{a2} , and R_{a3} is hydrogen, and R_{a1} is not $-\text{OCH}_2\text{CH}_2\text{OMe}$;

if R_{a1} and R_{a3} are both OMe , then R_8 is not $-\text{C}(\text{O})\text{CH}_2\text{OH}$; and

further provided that the compound of Formula I is not 5,7-dimethoxy-2-(4-morpholinophenyl)quinazolin-4(3H)-one, 5,7-dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one, or 2-(4-(1-cyclopentylpiperidin-4-yl)phenyl)-3-methylquinazolin-4(3H)-one.

[0106] Some embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:




R_3 and R_4 are independently selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_6$ cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, $-\text{CN}$, and sulfonamide; and

R_8 is selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, acyl, and $\text{C}_3\text{-C}_6$ cycloalkyl.

[0107] Other embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:




R_3 and R_4 are independently selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_6$ cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, $-\text{CN}$, and sulfonamide; and

R_9 and R_{10} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, heterocycle, sulfonyl, carbamate, carboxamide, and acyl.

[0108] Still other embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:




R_3 and R_4 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, -CN, and sulfonamide; and

R_9 and R_{10} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, aryl, heterocycle, sulfonyl, carboxamide, carbamate, and acyl.

[0109] Certain embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:



R_3 and R_4 are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, -CN, and sulfonamide; and

R_8 is selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, acyl, and C_3 - C_6 cycloalkyl.

[0110] Some embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:


U is C=O

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are independently selected from C₁-C₆ alkoxy, hydrogen, and halogen;

R_{b2}, R_{b3}, R_{b5}, and R_{b6} are each hydrogen;



R₃ and R₄ are independently selected from hydrogen and C₁-C₆ alkyl;

R₈ is selected from C₁-C₆ alkyl, and hydrogen; and

R₉, R₁₀, R₁₁, and R₁₂ are independently selected from C₁-C₆ alkyl, hydrogen, and sulfonyl.

[0111] Other embodiments provide compounds of Formula I, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:


U is C=O

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are independently selected from methoxy, hydrogen, and halogen;

R_{b2}, R_{b3}, R_{b5}, and R_{b6} are each hydrogen;



R_3 and R_4 are independently selected from hydrogen and methyl;

R_8 is selected from hydrogen, hydroxyethyl, butyl, acetyl, isopropyl, 4-hexanoyl, 4-isobutyryl, benzoyl, 4-fluorobenzoyl, 4-picolinoyl, 4-nicotinoyl, 4-isonicotinoyl, thiophene-2-carbonyl, 5-chloro-1-methyl-1H-pyrazole-4-carbonyl, 3,3,3-trifluoropropanoyl, 2,5-dichlorothiopene-3-carbonyl, cyclopropanecarbonyl, 4-fluorobenzyl, benzyl, 2,2,2-trifluoroethyl, tertbutoxycarbonyl, and formyl;

R_9 and R_{10} are independently selected from hydrogen, methyl, cyclopropylmethyl, and acetyl; and

R_{11} and R_{12} are independently selected from hydrogen, acetyl, methanesulfonyl, dimethylaminocarbonyl, benzoyl, benzyl, ethyl, and isopropyl.

[0112] In one embodiment, compounds of Formula I are selected from:

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-(4-hydroxypiperidin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(4-(4-isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)methanesulfonamide

3-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-1,1-dimethylurea;

2-(4-(4-hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide;

5,7-dimethoxy-2-(4-(4-picolinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-nicotinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-isonicotinoypiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(5-chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(2,5-dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide;

2-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methoxyquinazolin-4(3H)-one;

2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-isopropylacetamide;

5-chloro-2-(4-(4-isopropylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-((3R,5S)-4-isopropyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-(methylamino)pyrrolidin-1-yl)phenyl)quinazolin-4(3H)-one;

tert-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)-N-methylacetamide;

2-(4-(4-(isopropylamino)piperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1-acetylpiperidin-4-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-benzyl-N-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide;

2-(6-(4-(benzylamino)piperidin-1-yl)pyridin-3-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperazine-1-carbaldehyde;


2-(4-(2-(1-acetylazetidin-3-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(3-(cyclopropylmethylamino)pyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; and

5,7-dimethoxy-2-(4-(4-oxopiperidin-1-yl)phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one, and tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

Formula II Methods and Compounds

[0113] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula II:



(II)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof,

wherein:

Q is CH;

V is N;

U is C=O;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are each C₁-C₆ alkyl;

R_{b2}, R_{b3}, and R_{b6} are each hydrogen;

R_{n1} is hydrogen;

R_{n2} is selected from sulfonyl, heterocycle, and aryl; and

R_{b5} is selected from hydrogen or may be connected with R_{n2} to form a heterocycle.

[0114] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula II, wherein:

Q is CH;

V is N;

U is C=O;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are each methoxy;

R_{b2}, R_{b3}, and R_{b6} are each hydrogen;

R_{n1} is hydrogen;

R_{n2} is selected from methanesulfonyl, pyridin-4-yl, 4-methylphenyl, and pyridin-3-yl; and


R_{b5} is selected from hydrogen or may be connected with R_{n2} to form a heterocycle selected from (2-hydroxymethyl)-1H-pyrrol-5-yl, (2-hydroxyethyl)-1H-

pyrrol-5-yl, 2-(pyrrolidin-1-yl-ylmethyl)-1H-pyrrol-5-yl, 3-(hydroxymethyl)-1H-pyrazol-5-yl, 2-(pyrrolidin-1-yl-ylethyl)-1H-pyrrol-5-yl, and 2-((dimethylamino)methyl)-1H-pyrrol-5-yl.

[0115] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula II selected from:

- 2-(4-(dimethylamino)naphthalen-1-yl)-6,7-dimethoxyquinazolin-4(3H)-one;
- 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;
- 2-(2-(hydroxymethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(2-(2-hydroxyethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;
- 2-(3-(hydroxymethyl)-1H-indazol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;
- 2-(2-((dimethylamino)methyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
- N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)methanesulfonamide;
- 5,7-dimethoxy-2-(4-(pyridin-4-ylamino)phenyl)quinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(4-(p-tolylamino)phenyl)quinazolin-4(3H)-one; and
- 5,7-dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.

[0116] Another aspect of the invention provides compounds of Formula II:



(II)

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q and V are independently selected from CH and nitrogen;

U is selected from C=O and S=O;

R₁ and R₂ are independently selected from hydrogen, and C₁-C₆ alkyl;

R_c is selected from hydrogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

R_{a1}, R_{a2}, and R_{a3} are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein R_{a1} and R_{a2} and/or R_{a2} and R_{a3} may be connected to form a cycloalkyl or a heterocycle;

R_{b2} and R_{b6} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, hydroxyl, and amino;

R_{b3} and R_{b5} are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, hydroxyl, and amino, wherein

R_{b2} and R_{b3} and/or R_{b5} and/or R_{b6} may be connected to form a cycloalkyl or a heterocycle;

R_{n1} is selected from hydrogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl; and

R_{n2} is selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocycle, aryl, alkenyl, acyl, and sulfonyl, wherein R_{n1} and/or R_{n2} may be connected with R_{b3} and/or R_{b5} to form a 5- or 6-membered heterocyclic ring,

provided that

at least one of R_{a1}, R_{a2}, and R_{a3} is not hydrogen; and

R_{n1} and R_{n2} are not both hydrogen, methyl, ethyl, or -CH₂CH₂OH.

[0117] Another embodiment provides compounds of Formula II, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is CH;

V is N;

U is C=O;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are each C₁-C₆ alkyl;

R_{b2}, R_{b3}, and R_{b6} are each hydrogen;

R_{n1} is hydrogen;

R_{n2} is selected from sulfonyl, heterocycle, and aryl; and

R_{b5} is selected from hydrogen or may be connected with R_{n2} to form a heterocycle.

[0118] Another embodiment provides compounds of Formula II, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is CH;

V is N;

U is C=O;

R_c is hydrogen;

R_{a2} is hydrogen;

R_{a1} and R_{a3} are each methoxy;

R_{b2}, R_{b3}, and R_{b6} are each hydrogen;

R_{n1} is hydrogen;

R_{n2} is selected from methanesulfonyl, pyridin-4-yl, 4-methylphenyl, and pyridin-3-yl; and


Rb₅ is selected from hydrogen or may be connected with Rn₂ to form a heterocycle selected from (2-hydroxymethyl)-1H-pyrrol-5-yl, (2-hydroxyethyl)-1H-pyrrol-5-yl, 2-(pyrrolidin-1-yl-ylmethyl)-1H-pyrrol-5-yl, 3-(hydroxymethyl)-1H-pyrazol-5-yl, 2-(pyrrolidin-1-yl-ylethyl)-1H-pyrrol-5-yl, and 2-((dimethylamino)methyl)-1H-pyrrol-5-yl.

[0119] In one embodiment, compounds of Formula II are selected from:

2-(2-(hydroxymethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(2-(2-hydroxyethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
 5,7-dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;
 2-(3-(hydroxymethyl)-1H-indazol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
 5,7-dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;
 2-(2-((dimethylamino)methyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;
 N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)methanesulfonamide;
 5,7-dimethoxy-2-(4-(pyridin-4-ylamino)phenyl)quinazolin-4(3H)-one;
 5,7-dimethoxy-2-(4-(p-tolylamino)phenyl)quinazolin-4(3H)-one; and
 5,7-dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one, and
 tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

Formula III Methods and Compounds

[0120] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula III:



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof,

wherein:

U is C=O;

Q is selected from CR₁₂ and nitrogen;

V is selected from nitrogen;

Z is selected from unsubstituted C₁-C₆ alkyl;

R₁₂ is selected from C₁-C₆ alkoxy and halogen;

R_c is selected from hydrogen and C₁-C₆ alkyl;

R_{a2} is selected from hydrogen and C₁-C₆ alkoxy;

R_{a1} and R_{a3} are independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, and heterocycle;

R_{b2} and R_{b6} are both hydrogen;

R_{b3} and R_{b5} are independently selected from hydrogen and C₁-C₆ alkyl;

X is selected from oxygen and CH₂;

n is selected from 0, 1, 2, 3, or 4; and

G is selected from heterocycle, cycloalkyl, and aryl.

[0121] In other embodiments, U is C=O in compounds of Formula III that may be used to inhibit the expression of, or reduce IL-6 and/or VCAM-1 in a subject, wherein:

Q is selected from CR₁₂ and nitrogen;

V is selected from nitrogen;

R₁₂ is selected from methoxy and chlorine;


R_c is selected from hydrogen and (pyrrolidin-1-yl)propyl;

R_{a2} is selected from hydrogen and methoxy;

R_{a1} and R_{a3} are independently selected from hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, and pyrrolidin-1-yl;

R_{b2} and R_{b6} are both hydrogen;

R_{b3} and R_{b5} are independently selected from hydrogen and methyl;



is selected from (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, and (1H-tetrazol-5-yl)methyl.

[0122] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula III selected from:

3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)quinazolin-4(3H)-one;

7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one;

5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

- 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;
- 2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;
- 5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one;
- 2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
- 3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;
- 2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;

5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;

2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;

8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;

2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxy-pyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;


N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;

2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
and

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.

[0123] Another aspect of the invention provides compounds of Formula III:



and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is selected from CR₁₂ and nitrogen;

V is selected from CH and nitrogen;

U is selected from C=O, S=O, and SO₂;

Z is selected from unsubstituted C₁-C₆ alkyl and C₁-C₆ alkyl substituted with one or more groups selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, cyclopropyl, hydroxyl, amino, and halogen;

X is selected from oxygen, nitrogen, sulfur, NR₆R₇, and CR₆R₇;

n is selected from 0, 1, 2, 3, 4, or 5;

G is selected from heterocycle, cycloalkyl, and aryl;

R₆, R₇, and R₁₂ are independently selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and halogen;

R_c is selected from hydrogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

Ra₁, Ra₂, and Ra₃ are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein Ra₁ and Ra₂ and/or Ra₂ and Ra₃ may be connected to form a cycloalkyl or a heterocycle;

Rb₂ and Rb₆ are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, hydroxyl, and amino; and

Rb₃ and Rb₅ are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, and amino, wherein

Rb₂ and Rb₃ and/or Rb₅ and Rb₆ may be connected to form a cycloalkyl or a heterocycle;


provided that

if X = oxygen and n is 3, then R_c is hydrogen;


at least one of Ra₁, Ra₂, and Ra₃ is not hydrogen;

if Ra₂ or Ra₃ is chloro, then Ra₁ is not hydrogen;

if R_{a1} and R_{a3} are OMe, and $Q = CH$, then $\text{---}X(Z)_n^G$ is not



if R_{a1} and R_{a3} are OMe and R_{a2} is hydrogen, then $\text{---}X(Z)_n^G$ is not



; and further provided that the compound of Formula III is not 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one, 2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione, 3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one, 2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one, 5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one, or 5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one.

[0124] Some embodiments provide compounds of Formula III, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is selected from CR_{12} and nitrogen;

V is selected from nitrogen;

R_{12} is selected from C_1 - C_6 alkoxy, and halogen;

R_c is selected from hydrogen and C_1 - C_6 alkyl;

R_{a2} is selected from hydrogen and C_1 - C_6 alkoxy;

R_{a1} and R_{a3} are independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogen, and heterocycle;

Rb₂ and Rb₆ are both hydrogen;

Rb₃ and Rb₅ are independently selected from hydrogen and C₁-C₆ alkyl;

X is selected from oxygen and CH₂;

n is selected from 0, 1, 2, 3, or 4; and

G is selected from heterocycle, cycloalkyl, and aryl.

[0125] Some embodiments provide compounds of Formula III, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is selected from CR₁₂ and nitrogen;

V is selected from nitrogen;

R₁₂ is selected from methoxy and chlorine;

Rc is selected from hydrogen and (pyrrolidin-1-yl)propyl;

Ra₂ is selected from hydrogen and methoxy;

Ra₁ and Ra₃ are independently selected from hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, and pyrrolidin-1-yl;

Rb₂ and Rb₆ are both hydrogen;

Rb₃ and Rb₅ are independently selected from hydrogen and methyl; and

$\begin{array}{c} \text{X} \\ \text{---} \end{array} \left(\begin{array}{c} \text{Z} \\ \text{---} \end{array} \right)_n^{\text{G}}$ is selected from (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, and (1H-tetrazol-5-yl)methyl.

[0126] In one embodiment, compounds of Formula III are selected from:

- 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;
- 2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;
- 5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one;
- 2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
- 3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;
- 2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
- 5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;

5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;

2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;

8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;

2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one;

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;

2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;


2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
and

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione, and

tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

Formula IV Methods and Compounds

[0127] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula IV:



(IV)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

U is C=O;

V is nitrogen;

Rb₂ and Rb₆ are both hydrogen;

Rb₃ and Rb₅ are independently selected from C₁-C₆ alkyl and hydrogen;

Q₂ is selected from C₁-C₆ alkyl and hydrogen; and

Q₁ and Q₃ are independently selected from hydrogen and C₁-C₆ alkoxy.

[0128] In some embodiments, U is C=O in compounds of Formula IV that may be used to inhibit the expression of, or reduce IL-6 and/or VCAM-1 in a subject, wherein

V is nitrogen;

Rb₂ and Rb₆ are both hydrogen;

Rb₃ and Rb₅ are independently selected from methyl and hydrogen;

Q₂ is selected from hydrogen, (4-methylpiperazin-1-yl)methyl, morpholinoethyl, morpholinomethyl, and (pyrrolidin-1-yl)ethyl; and

Q₁ and Q₃ are independently selected from hydrogen, benzyloxyethoxy, methoxy, methoxyethoxy, (pyrrolidin-1-yl)ethoxy, phenoxyethoxy, and isopropoxyethoxy.

[0129] In one embodiment, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula IV selected from:


7-(2-(benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-6-((4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one;
7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-6-(2-morpholinoethyl)quinazolin-4(3H)-one;
2-(2-methylpyridin-4-yl)-6-(morpholinomethyl)quinazolin-4(3H)-one;
5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-6-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H)-one;
2-(2,6-dimethylpyridin-4-yl)-5-(2-isopropoxyethoxy)-7-methoxyquinazolin-4(3H)-one; and
2-(2,6-dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.

[0130] Another aspect of the invention provides compounds of Formula IV:



and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q_1 is selected from nitrogen and C- Ra_1 ;

Q_2 is selected from nitrogen and C- Ra_2 ;

Q_3 is selected from nitrogen and C- Ra_3 ;

V is selected from CH and nitrogen;

U is selected from C=O and S=O;

Ra_1 , Ra_2 , and Ra_3 are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, amino, amide, and heterocycle, wherein Ra_1 and Ra_2 and/or Ra_2 and Ra_3 may be connected to form a cycloalkyl or a heterocycle;

Rb_2 and Rb_6 are independently selected from hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, hydroxyl, and amino; and



Rb_3 and Rb_5 are independently selected from hydrogen, methyl, ethyl, C₃-C₆ cycloalkyl, C₁-C₃ alkoxy, and amino, wherein

Rb_2 and Rb_3 and/or Rb_5 and Rb_6 may be connected to form a cycloalkyl or a heterocycle,

provided that

at least one of Ra_1 , Ra_2 , and Ra_3 is hydrogen;

if Ra_3 is alkoxy, then Ra_1 is not hydrogen;

if Ra_2 is  or , then Rb_3 is not hydrogen;

if Rb_2 , Rb_5 , and Rb_6 are hydrogen, then Rb_3 is not $-CH_2OH$; and one of Rb_3 and Rb_5 is not hydrogen.

[0131] Other embodiments provide compounds of Formula IV, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof, wherein:

U is $C=O$;

V is nitrogen;

Rb_2 and Rb_6 are both hydrogen;

Rb_3 and Rb_5 are independently selected from C_1 - C_6 alkyl and hydrogen;

Q_2 is selected from C_1 - C_6 alkyl and hydrogen; and

Q_1 and Q_3 are independently selected from hydrogen and C_1 - C_6 alkoxy.

[0132] Another embodiment provides compounds of Formula IV, and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof, wherein:

U is $C=O$;

V is nitrogen;

Rb_2 and Rb_6 are both hydrogen;

Rb_3 and Rb_5 are independently selected from methyl and hydrogen;

Q_2 is selected from hydrogen, (4-methylpiperazin-1-yl)methyl, morpholinoethyl, morpholinomethyl, and (pyrrolidin-1-yl)ethyl; and

Q_1 and Q_3 are independently selected from hydrogen, benzyloxyethoxy, methoxy, methoxyethoxy, (pyrrolidin-1-yl)ethoxy, phenoxyethoxy, and isopropoxyethoxy.

[0133] In one embodiment, compounds of Formula IV are selected from:

7-(2-(benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-6-((4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one;

7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-6-(2-morpholinoethyl)quinazolin-4(3H)-one;

2-(2-methylpyridin-4-yl)-6-(morpholinomethyl)quinazolin-4(3H)-one;

5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one;


2-(2,6-dimethylpyridin-4-yl)-6-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-(2-isopropoxyethoxy)-7-methoxyquinazolin-4(3H)-one; and

2-(2,6-dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one, and
tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

Formula V Methods and Compounds

[0134] In certain embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula V:



(V)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

U is C=O;

Ra₂ is selected from hydrogen and amino;

Ra₁ and Ra₃ are independently selected from hydrogen and C₁-C₆ alkoxy;

Q is CH;

Rb₃ is selected from hydrogen, C₁-C₆ alkyl, and C₁-C₆ alkoxy;

Rb₂ and Rb₆ are both hydrogen;

Y is selected from oxygen;

A is C₁-C₄ alkyl;

D may be absent or present, and if present is selected from hydroxy, heterocycle, and NR₁R₂; and

R₁ and R₂ are independently selected from hydrogen and C₁-C₆ alkyl.

[0135] In some embodiments, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula V, wherein:

U is C=O;

Ra₂ is selected from hydrogen and amino;

Ra₁ and Ra₃ are independently selected from hydrogen and C₁-C₆ alkoxy;

Q is CH;

Rb₃ is selected from hydrogen, methyl, and methoxy;

Rb₂ and Rb₆ are both hydrogen;

Y is selected from oxygen;

A is selected from methyl and ethyl;

D may be absent or present, and if present is selected from hydroxy, pyrrolidin-1-yl, and NR₁R₂; and

R₁ and R₂ are independently selected from hydrogen and acetyl.

[0136] In one embodiment, the method for inhibiting the expression of, or reducing IL-6 and/or VCAM-1 in a subject, comprises administering a therapeutically effective amount of at least one compound of Formula V selected from:

2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;


N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide;

2-(3,5-dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3H)-one; and

5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one, or a

stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.

[0137] Another aspect of the invention provides compounds of Formula V:



(V)

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof,

wherein:

Q is selected from CR₆ and nitrogen;

U is selected from C=O and SO₂;

Y is selected from oxygen, nitrogen, sulfur, NR₆, CR₆R₇;

A is C₁-C₄ alkyl, wherein the alkyl chain may be connected to Y, D, R_{b3} and/or R_{b5} to form a cycloalkyl or heterocycle;

D may be absent or present, and if present is selected from -OR₁, -NR₁R₂;

R₁ and R₂ are independently selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, sulfonamide, carboxamide, acyl, and nitrile, wherein R₁ and R₂ may be connected to form a cycloalkyl or a heterocycle;

R₆ and R₇ are independently selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, and halogen;

Ra₁, Ra₂, and Ra₃ are independently selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein Ra₁ and Ra₂ and/or Ra₂ and Ra₃ may be connected to form a cycloalkyl or a heterocycle;

Rb₂ and Rb₆ are independently selected from hydrogen, halogen, C₁-C₆ alkyl, and C₃-C₆ cycloalkyl; and

Rb₃ is selected from hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, and amino, wherein

Rb₂ and Rb₃ and/or Rb₅ and Rb₆ may be connected to form a cycloalkyl or a heterocycle,

provided that

at least one of Ra₁, Ra₂, and Ra₃ is not hydrogen;

if Ra_1 and Ra_3 are both hydrogen, and $Y = \text{nitrogen}$, then Ra_2 is not hydrogen, -OAc, or -OMe; and further provided that the compound of Formula V is not 2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or 2-(3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one.

[0138] Some embodiments provide compounds of Formula V and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof, wherein:

U is C=O;

Ra_2 is selected from hydrogen and amino;

Ra_1 and Ra_3 are independently selected from hydrogen and C_1 - C_6 alkoxy;

Q is CH;

Rb_3 is selected from hydrogen, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy;

Rb_2 and Rb_6 are both hydrogen;

Y is selected from oxygen;

A is C_1 - C_4 alkyl;

D may be absent or present, and if present is selected from hydroxy, heterocycle, and NR_1R_2 ; and

R_1 and R_2 are independently selected from hydrogen and C_1 - C_6 alkyl.

[0139] Some embodiments provide compounds of Formula V and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof, wherein:

U is C=O;

Ra_2 is selected from hydrogen and amino;

Ra_1 and Ra_3 are independently selected from hydrogen and C_1 - C_6 alkoxy;

Q is CH;

Rb_3 is selected from hydrogen, methyl, and methoxy;

Rb_2 and Rb_6 are both hydrogen;

Y is selected from oxygen;

A is selected from methyl and ethyl;

D may be absent or present, and if present is selected from hydroxy, pyrrolidin-1-yl, and NR_1R_2 ; and

R_1 and R_2 are independently selected from hydrogen and acetyl.

[0140] In one embodiment, compounds of Formula V are selected from:

2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide;

2-(3,5-dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3H)-one; and

5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one, and tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

Pharmaceutical Compositions

[0141] Pharmaceutical compositions of the invention comprise at least one compound of Formula I, II, III, IV, V, or tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof formulated together with one or more pharmaceutically acceptable carriers. These formulations include those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration. The most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.

[0142] Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of the invention as powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into

association at least one compound of the invention as the active compound and a carrier or excipient (which may constitute one or more accessory ingredients). The carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and may be formulated with at least one compound described herein as the active compound in a unit-dose formulation, for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound. Other pharmacologically active substances may also be present including other compounds. The formulations of the invention may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components.

[0143] For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmacologically administrable compositions can, for example, be prepared by, for example, dissolving or dispersing, at least one active compound of the invention as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. In general, suitable formulations may be prepared by uniformly and intimately admixing the at least one active compound of the invention with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet may be prepared by compressing or molding a powder or granules of at least one compound of the invention, which may be optionally combined with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, at least one compound of the invention in a free-flowing form, such as a powder or granules, which may be optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, where the powdered form of at least one compound of the invention is moistened with an inert liquid diluent.

[0144] Formulations suitable for buccal (sub-lingual) administration include lozenges comprising at least one compound of the invention in a flavored base,

usually sucrose and acacia or tragacanth, and pastilles comprising the at least one compound in an inert base such as gelatin and glycerin or sucrose and acacia.

[0145] Formulations of the invention suitable for parenteral administration comprise sterile aqueous preparations of at least one compound of Formula I, II, III, IV, V, or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof, which are approximately isotonic with the blood of the intended recipient. These preparations are administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing at least one compound described herein with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention may contain from about 0.1 to about 5% w/w of the active compound.

[0146] Formulations suitable for rectal administration are presented as unit-dose suppositories. These may be prepared by admixing at least one compound as described herein with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

[0147] Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers and excipients which may be used include VaselineTM, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof. The active compound (i.e., at least one compound of Formula I, II, III, IV, V, or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof) is generally present at a concentration of from about 0.1% to about 15% w/w of the composition, for example, from about 0.5 to about 2%.

[0148] The amount of active compound administered may be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician. For example, a dosing schedule may involve the daily or semi-daily administration of the encapsulated compound at a perceived dosage of about 1 µg to about 1000 mg. In another embodiment, intermittent administration, such as on a monthly or yearly basis, of a dose of the

encapsulated compound may be employed. Encapsulation facilitates access to the site of action and allows the administration of the active ingredients simultaneously, in theory producing a synergistic effect. In accordance with standard dosing regimens, physicians will readily determine optimum dosages and will be able to readily modify administration to achieve such dosages.

[0149] A therapeutically effective amount of a compound or composition disclosed herein can be measured by the therapeutic effectiveness of the compound. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used. In one embodiment, the therapeutically effective amount of a disclosed compound is sufficient to establish a maximal plasma concentration. Preliminary doses as, for example, determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.

[0150] Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compositions that exhibit large therapeutic indices are preferable.

[0151] Data obtained from the cell culture assays or animal studies can be used in formulating a range of dosage for use in humans. Therapeutically effective dosages achieved in one animal model may be converted for use in another animal, including humans, using conversion factors known in the art (see, e.g., Freireich et al., *Cancer Chemother. Reports* 50(4):219-244 (1966) and Table 1 for Equivalent Surface Area Dosage Factors).

Table 1. Equivalent Surface Area Dosage Factors

To:	Mouse	Rat	Monkey	Dog	Human
From:	(20 g)	(150 g)	(3.5 kg)	(8 kg)	(60 kg)

Mouse	1	1/2	1/4	1/6	1/12
Rat	2	1	1/2	1/4	1/7
Monkey	4	2	1	3/5	1/3
Dog	6	4	3/5	1	1/2
Human	12	7	3	2	1

[0152] The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. Generally, a therapeutically effective amount may vary with the subject's age, condition, and gender, as well as the severity of the medical condition in the subject. The dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.

[0153] In one embodiment, a compound of Formula I, II, III, IV, V or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, is administered in combination with another therapeutic agent. The other therapeutic agent can provide additive or synergistic value relative to the administration of a compound of the invention alone. The therapeutic agent can be, for example, a statin; a PPAR agonist, e.g., a thiazolidinedione or fibrate; a niacin, a RVX, FXR or LXR agonist; a bile-acid reuptake inhibitor; a cholesterol absorption inhibitor; a cholesterol synthesis inhibitor; a cholesteryl ester transfer protein (CETP), an ion-exchange resin; an antioxidant; an inhibitor of AcylCoA cholesterol acyltransferase (ACAT inhibitor); a tyroprohormone; a sulfonylurea-based drug; a biguanide; an alpha-glucosidase inhibitor; an apolipoprotein E regulator; a HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein; an LDL-lowering drug; an HDL-raising drug; an HDL enhancer; a regulator of the apolipoprotein A-IV and/or apolipoprotein genes; or any cardiovascular drug.

[0154] In another embodiment, a compound of Formula I, II, III, IV, V or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, is administered in combination with one or more anti-inflammatory agents. Anti-inflammatory agents can include immunosuppressants, TNF inhibitors, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), disease-

modifying anti-rheumatic drugs (DMARDS), and the like. Exemplary anti-inflammatory agents include, for example, prednisone; methylprednisolone (Medrol®), triamcinolone, methotrexate (Rheumatrex®, Trexall®), hydroxychloroquine (Plaquenil®), sulfasalazine (Azulfidine®), leflunomide (Arava®), etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), rituximab (Rituxan®), abatacept (Orencia®), interleukin-1, anakinra (Kineret™), ibuprofen, ketoprofen, fenoprofen, naproxen, aspirin, acetaminophen, indomethacin, sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac, etodolac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, diclofenac, oxaprozin, apazone, nimesulide, nabumetone, tenidap, etanercept, tolmetin, phenylbutazone, oxyphenbutazone, diflunisal, salsalate, olsalazine or sulfasalazine.

Therapeutic Methods

[0155] In one embodiment, a method of treating or preventing cardiovascular and inflammatory diseases and related disease states, characterized by altered expression of markers of inflammation such as IL-6 and/or VCAM-1 proliferation, comprises administering to a subject (e.g., a mammal, such as e.g., a human) a therapeutically effective amount of at least one compound of the invention, i.e., a compound of Formula I, II, III, IV, V, or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof. In another embodiment, at least one compound of the invention may be administered as a pharmaceutically acceptable composition, comprising one or more compounds of the invention and a pharmaceutically acceptable carrier.

[0156] In one embodiment, the inflammatory diseases and related disease states are those where inhibition of IL-6 and/or VCAM-1 proliferation is desirable.

[0157] In some embodiments, the methods of the invention comprise administering at least one compound of the invention to a subject, such as a human, as a preventative measure against cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s).

[0158] In one embodiment, at least one compound of the invention is administered as a preventative measure to a subject, such as a human, having a genetic predisposition to cardiovascular and inflammatory diseases and related disease states, such as, for example, familial hypercholesterolemia, familial combined hyperlipidemia, atherosclerosis, a dyslipidemia, a dyslipoproteinemia, arthritis, cancer, multiple sclerosis, or Alzheimer's disease.

[0159] In another embodiment, at least one compound of the present invention is administered as a preventative measure to a subject, such as a human, having a non-genetic predisposition to a disease including a cardiovascular disease or an inflammatory disorder. Examples of such non-genetic predispositions include cardiac bypass surgery and PTCA (which can lead to restenosis), an accelerated form of atherosclerosis, diabetes in women, (which can lead to polycystic ovarian disease), and cardiovascular disease (which can lead to impotence). Accordingly, compositions of the invention may be used for the prevention of one disease or disorder and concurrently treating another (e.g., prevention of polycystic ovarian disease while treating diabetes; prevention of impotence while treating a cardiovascular disease).

[0160] Angioplasty and open heart surgery, such as coronary bypass surgery, may be required to treat cardiovascular diseases, such as atherosclerosis. These surgical procedures entail using invasive surgical devices and/or implants, and are associated with a high risk of restenosis and thrombosis. Accordingly, the compounds of the invention may be used as coatings on surgical devices (e.g., catheters) and implants (e.g., stents) to reduce the risk of restenosis and thrombosis associated with invasive procedures used in the treatment of cardiovascular diseases.


[0161] In another embodiment, the compounds of the invention may be used for the prevention of one disease or disorder while concurrently treating another (e.g., prevention of polycystic ovarian disease while treating diabetes; prevention of impotence while treating a cardiovascular disease).

EXAMPLES

[0162] The invention is further illustrated by the following non-limiting examples, wherein the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.


AcOH	=	acetic acid
BINAP	=	2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
Boc	=	N-tert-butoxycarbonyl
TBDMS	=	tert-butyldimethylsilyl
dba	=	dibenzylidene acetone
DCM	=	dichloromethane
DMAP	=	dimethylaminopyridine
DMF	=	dimethylformamide
DMSO	=	dimethylsulfoxide
EDCI	=	1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide
EtOH	=	ethanol
EtOAc	=	ethyl acetate
IBX	=	1,2-benziodoxol-3(1 <i>H</i>)-one-1-hydroxy-1-oxide
MeOH	=	methanol
HOBt	=	N-hydroxybenzotriazole
THF	=	tetrahydrofuran
TEA	=	triethylamine
p-TSA	=	p-toluenesulfonic acid
TBAF	=	tetrabutylammonium fluoride
DMA	=	N,N-dimethylacetamide
DIBAL-H	=	diisobutylaluminum hydride
TPAP	=	tetrapropylammonium perruthenate
NMO	=	N-methylmorpholine N-oxide
DDQ	=	2,3-dicyano-5,6-dichloro-parabenzoquinone
DME	=	1,2-dimethoxyethane
TFA	=	trifluoroacetic acid
DPPF	=	1,1'-bis(diphenylphosphino)ferrocene
Pd(OAc) ₂	=	palladium(II) acetate
Pd(PPh ₃) ₄	=	tetrakis(triphenylphosphine)palladium(0)

Example 1. Preparation of 2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (**2**)



[0163] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (**1**) (0.68 mmol) in DMF (8 mL) was added potassium carbonate (0.68 mmol) and 2-bromoethanol (0.68 mmol). The resulting solution was stirred at room temperature overnight. Then, the mixture was diluted with water, extracted with EtOAc, washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo* to afford **2**. The material was purified by flash chromatography on silica gel, eluting with 50% to 100% of 92:7:1 $\text{CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$ in CH_2Cl_2 . The product was further purified by reverse-phase chromatography, eluting with 10% to 90% CH_3CN in H_2O , to afford the title compound (0.025 g, 9%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.45 (s, 1H), 8.08 (d, $J = 8.9$ Hz, 2H), 7.00 (d, $J = 9.1$ Hz, 2H), 6.68 (s, 1H), 6.46 (s, 1H), 4.30-4.55 (m, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.43-3.67 (m, 2H), 3.10-3.43 (m, 7H), 2.77-3.04 (m, 1H), 2.31-2.64 (m, 2H). ESI MS m/z 411 $[\text{M}+\text{H}]^+$.


Example 2. Preparation of 2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (**7**)



[0164] To a solution of 1-(N-butyl)-piperazine (**3**) (7.03 mmol) in DMF (8 mL) was added 4-fluorobenzaldehyde (**4**) (8.43 mmol) and potassium carbonate (8.43 mmol). The resulting solution was heated to 120 °C for 5 hours and diluted with water. The solution was extracted with EtOAc, washed with water, brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel to afford 4-(4-butylpiperazin-1-yl)benzaldehyde (**5**).

[0165] To a solution of 2-amino-4,6-dimethoxybenzamide (**6**) (1.19 mmol) in DMA (10 mL) was added 4-(4-butylpiperazin-1-yl)benzaldehyde (**5**) (1.09 mmol), $NaHSO_3$ (1.30 mmol), and p -TsOH (0.10 mmol). The resulting solution was heated to 155 °C for 4 hours and cooled to room temperature. The solution was diluted with water, extracted with EtOAc, washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel eluting with 10% to 50% of 92:7:1 $CHCl_3$ /MeOH/ concentrated NH_4OH in CH_2Cl_2 , to afford the compound **7** (0.06 g, 13%). ^1H NMR (300 MHz, $DMSO-d_6$): δ 11.76 (s, 1H), 8.09 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.68 (s, 1H), 6.47 (s, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.17-3.42 (m, 4H), 2.39-2.58 (m, 4H), 2.23-2.37 (m, 2H), 1.37-1.56 (m, 2H), 1.26-1.37 (m, 2H), 0.84-0.94 (m, 3H). APCI MS m/z 423 $[M+H]^+$.

Example 3. Preparation of 2-(4-(1-acetylpiperidin-4-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (**13**)



[0166] A solution of 2-(4-bromophenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one (**8**) (3.23 mmol), K_2CO_3 (9.69 mmol), $PdCl_2(dppf)$ (0.32 mmol) and *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2*H*)-carboxylate (**9**) (3.23 mmol) in DMF (50 mL) was heated to 110 °C overnight. The resulting solution was concentrated *in vacuo* and the material was purified by flash chromatography on silica gel to give *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-5,6-dihydropyridine-1(2*H*)-carboxylate (**10**).


[0167] A solution of *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-5,6-dihydropyridine-1(2*H*)-carboxylate (**10**) (0.34 mmol) in EtOH (10 mL) and HOAc (5 mL) was purged with nitrogen and 10% Pd/C (0.016 g) was added. The mixture was stirred under 1 atmosphere of hydrogen overnight. Then, the solution was filtered through CeliteTM with MeOH washings, and the filtrate was concentrated *in vacuo*. The material was purified by flash chromatography on silica gel to afford *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate (**11**).

[0168] To a solution of *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate (**11**) (0.45 mmol) in 1,4-dioxane (2 mL) was added 4 M HCl in 1,4-dioxane (1 mL). The resulting solution

was stirred at room temperature for 5 hours. Then, the mixture was concentrated *in vacuo* and the resulting material was purified by flash chromatography on silica gel to afford compound 5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3*H*)-one (**12**).


[0169] To a solution of 5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3*H*)-one (0.16 mmol) in CH₂Cl₂ (10 mL) was added Et₃N (0.32 mmol) and acetyl chloride (0.17 mmol). The resulting solution was stirred at 0 °C overnight. The solution was concentrated *in vacuo*, basified with NaHCO₃, extracted with CH₂Cl₂, and washed with water and brine. The material was dried (Na₂SO₄), filtered, and concentrated to afford the title compound **13** (0.020 g, 30%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.93 (s, 1H), 8.11 (d, *J* = 8.3 Hz, 2H), 7.40 (d, *J* = 8.3 Hz, 2H), 6.73 (s, 1H), 6.53 (s, 1H), 4.42-4.64 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.06-3.21 (m, 1H), 2.77-2.94 (m, 1H), 2.54-2.68 (m, 1H), 2.03 (s, 3H), 1.73-1.91 (m, 2H), 1.56-1.73 (m, 1H), 1.36-1.56 (m, 1H), 1.06-1.36 (m, 1H). ESI MS *m/z* 408 [M+H]⁺.

Example 4. Preparation of 2-(4-(3-(cyclopropylmethylamino)pyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one (**15**)



[0170] A suspension of 2-(4-(3-aminopyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one (**14**) (0.21 mmol) in ethanol (30 mL) was treated with PtO₂ (0.050 g) followed by cyclopropanecarbaldehyde (0.100 mL). The reaction was stirred under 1 atmosphere of hydrogen for 24 hours, filtered through Celite, with ethanol washes, concentrated, and purified by flash chromatography on silica gel, eluting to afford the title compound **15**.


Example 5. Preparation of 2-(4-(2-(1-acetylazetidin-3-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one (**19**)



[0173] To a solution of 2-isopropoxy ethanol (**21**) (57.0 mmol) in anhydrous DMF (10 mL) was added a sodium hydride (60 % suspension in mineral oil, 28.54 mmol) in small portions at room temperature under nitrogen. After the addition, the reaction mixture was stirred at room temperature for 30 minutes. Then, 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one (**20**) (2.85 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was cooled to room temperature and saturated NH_4Cl solution was added. The product was extracted with ethyl acetate (3×200 mL). The combined organic layer was washed with water, brine, dried over anhydrous Na_2SO_4 , and evaporated to give crude product (**22**) as a white solid.

[0174] 2-(2,6-Dimethyl-pyridin-4-yl)-7-fluoro-5-(2-isopropoxy-ethoxy)-3H-quinazolin-4-one (**22**) (960 mg, 2.58 mmol) was taken up in anhydrous DMF (10 mL). Sodium methoxide (25% solution in methanol, 12.9 mmol) was added. After the addition, the reaction mixture was stirred at 60 °C for 72 hours. The reaction mixture was cooled to room temperature, and quenched with saturated solution of NH_4Cl . The product was extracted with ethyl acetate (3×200 mL). The combined organic layer was washed with water, brine, dried over Na_2SO_4 , and evaporated to give crude product. The crude compound was purified by preparative HPLC, to give the title compound **23** as a white solid.


Example 7. Preparation of 2-(4-((3R,5S)-4-Acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one



[0175] To a solution of 4-fluoro-benzaldehyde (3.0 g, 0.024 mol) and 1-(2,6-dimethyl-piperazin-1-yl)-ethanone (3.0 g, 0.019 mol) in anhydrous DMF (15 mL) was added potassium carbonate (6.6 g, 0.048 mol). The reaction mixture was heated to 130 °C for 32 hours. The DMF was removed and the residue was purified by column chromatography (silica gel 230-400 mesh; eluting with 2:1 ethyl acetate and dichloromethane) to give 4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-benzaldehyde as light yellow solid (2.31 g, 46.2%).


[0176] A mixture of 2-amino-4,6-dimethoxy-nicotinamide (0.25 g, 1.26 mmol), 4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-benzaldehyde (0.43 g, 1.64 mmol), *p*-toluenesulfonic acid monohydrate (0.53 mg, 2.77 mmol) and sodium bisulfite (0.45 g, 2.52 mmol) in *N,N*-dimethylacetamide (5.0 mL) was stirred at 135 °C under N₂ for 16 hours and then cooled to room temperature. The mixture was concentrated to dryness under reduced pressure. Water (40 mL) was added to the residue and stirred for 0.5 hours. The precipitate was filtered and the solid was rinsed with water and dried over Na₂SO₄. The crude solid was purified by column chromatography (silica gel 230-400 mesh; eluting with 2.5% methanol in dichloromethane) to afford the title compound as yellow solid. Yield: 90 mg (16.3%). MP 279-279.8 °C. ¹H NMR (400 MHz, CDCl₃): δ 10.18 (s, 1H), 8.14 (d, *J* = 8.8 Hz, 2H), 6.99 (d, *J* = 8.8 Hz, 2H), 6.20 (s, 1H), 4.78 (bs, 1H), 4.12 (s, 3H), 4.02 (s, 3H), 3.70 (d, *J* = 12.0 Hz, 2H) 3.11 (d, *J* = 10 Hz, 2H), 2.18 (s, 3H), 1.40 (bs, 6H).

Example 8. Preparation of 2-(4-(4-Hydroxypiperidin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-*d*]pyrimidin-4(3H)-one



[0177] A mixture of 2-amino-4,6-dimethoxy-nicotinamide (0.60 g, 3.0 mmol), 4-(4-hydroxy-piperidin-1-yl)-benzaldehyde (0.81 g, 3.9 mmol), *p*-toluenesulfonic acid monohydrate (1.25 g, 6.6 mmol) and sodium bisulfite (1.06 g, 6.0 mmol) in *N,N*-dimethylacetamide (8.0 mL) was stirred at 135 °C under N₂ for 16 hours and then cooled to room temperature. The mixture was concentrated to dryness under reduced pressure. Water (40 mL) was added to the residue and stirred for 0.5 hours. The precipitate was filtered and the solid was rinsed with water and air-dried. The crude solid was purified by column chromatography (silica gel 230-400 mesh; eluting with 4% methanol in dichloromethane) to afford the title compound, as a yellow solid. Yield: 0.29 g (25.2%). MP 284-286 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.09 (s, 1H), 8.12 (d, *J* = 8.8 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H), 6.32 (s, 1H), 4.73 (d, *J* = 4.4 Hz, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 3.72 (m, 3H), 3.05 (m, 2H), 1.80 (m, 2H), 1.43 (m, 2H). MS (ES⁺) *m/z*: 383.06 (M+1).

Example 9. Preparation of 2-(4-((3*R*,5*S*)-4-Acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3*H*)-one




[0178] To a stirred solution of 2-amino-4,6-difluoro-benzamide (0.66 g, 3.84 mmol) and 4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-benzaldehyde (1.00 g, 3.84 mmol) in *N,N*-dimethyl acetamide (20 mL), was added sodium hydrogen sulfite (58.5 wt%, 1.04 g, 5.76 mmol) and *p*-toluenesulfonic acid monohydrate (0.88 g, 4.61 mmol) and the reaction mixture was stirred at 115 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid

was filtered off, to give 2-[4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-phenyl]-5,7-difluoro-3H-quinazolin-4-one as a yellow solid, which was used in the next step without further purification.

[0179] To a solution of 2-[4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-phenyl]-5,7-difluoro-3H-quinazolin-4-one (0.66 g, 1.60 mmol) in DMF (10 mL), a solution of sodium methoxide in methanol (25 wt%, 3.5 mL, 16.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Water was added, acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered and dried under vacuum to give crude compound, which was further purified by column chromatography (silica gel 230-400 mesh; eluting with 2% methanol solution in dichloromethane) to yield 2-[4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-phenyl]-7-fluoro-5-methoxy-3H-quinazolin-4-one as a light yellow solid.

[0180] To a solution of 2-methoxy-ethanol (1.00 g, 13.4 mmol) in dimethyl sulfoxide (4 mL), sodium hydride (60% suspension in mineral oil, 0.50 g, 12.5 mmol) was added in portions, and the reaction mixture was stirred at room temperature for 20 minutes. To this reaction mixture was added 2-[4-(4-acetyl-3,5-dimethyl-piperazin-1-yl)-phenyl]-7-fluoro-5-methoxy-3H-quinazolin-4-one (0.57 g, 1.34 mmol) and the reaction mixture was stirred at 85 °C for 24 hours. Water was added. The mixture was acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered to give crude product, which was purified by column chromatography (silica gel 230-400 mesh; eluting with 2% methanol in dichloromethane). The resulting mixture was purified by preparative HPLC to obtain the title compound as a white solid. Yield: 0.140 g (23.2%). MP 225-227°C. ¹H NMR (400 MHz, CDCl₃): δ 8.10 (d, *J* = 8.8 Hz, 2H), 7.08 (d, *J* = 8.8 Hz, 1H), 6.70 (d, *J* = 2.4 Hz, 1H), 6.49 (d, *J* = 2.4 Hz, 1H), 4.50 (bs, 1H), 4.23 (m, 2H), 4.14 (bs, 1H), 3.84 (s, 3H), 3.81 (m, 2H), 3.69 (m, 2H), 3.32 (s, 3H), 2.99 (bs, 2H), 2.07 (s, 3H), 1.25 (bs, 6H). MS (ES) *m/z*: 481.11 (*M*⁺+1).


Example 10. Preparation of 2-(4-(4-Isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0181] A mixture of 4-fluorobenzaldehyde (0.242 g, 1.95 mmol), 1-isopropylpiperazine (0.335 mL, 2.34 mmol), and K_2CO_3 (0.323 g, 2.34 mmol) in DMF (2.44 mL) was heated at 120 °C overnight. The mixture was diluted with EtOAc (200 mL), washed with 10% aqueous LiCl (3×75 mL) and brine (75 mL), dried over Na_2SO_4 , and filtered. The volatiles were removed under vacuum to yield 4-(4-isopropylpiperazin-1-yl)benzaldehyde (0.504 g) as an orange solid, which was used without further purification.


[0182] A mixture of 2-amino-4,6-dimethoxybenzamide (0.100 g, 0.510 mmol), aldehyde from above (0.118 g, 0.510 mmol), $NaHSO_3$ (94%, 0.0565 g, 0.510 mmol), and p -TsOH· H_2O (0.0097 g, 0.051 mmol) in DMA (3.40 mL) was heated at reflux for 1 hour. The mixture was diluted with EtOAc (250 mL), washed with 10% aqueous LiCl (3×75 mL) and brine (75 mL), dried over Na_2SO_4 , filtered and concentrated under vacuum. The resulting residue was purified over silica gel (12 g, CH_2Cl_2 /MeOH) and the product was freeze-dried from MeCN/ H_2O to provide the title compound (0.0632 g, 30%) as a yellow solid. ^1H NMR (300 MHz, DMSO- d_6): δ 11.74 (s, 1H), 8.09 (d, J = 9.05 Hz, 2H), 7.00 (d, J = 9.05 Hz, 2H), 6.68 (d, J = 2.31 Hz, 1H), 6.47 (d, J = 2.31 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.31-3.24 (m, 4H), 2.74-2.63 (m, 1H), 2.61-2.53 (m, 4H), 1.01 (d, J = 6.52 Hz, 6H).

Example 11. Preparation of 2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0183] Following the procedure described for Example 10, 4-(4-acetylpiperazin-1-yl)benzaldehyde was made from 1-acetylpiperazine and isolated as an orange oil in 67% yield. Following the procedure described for Example 10, the title compound was made from 4-(4-acetylpiperazin-1-yl)benzaldehyde and refluxing for 5 hours. The title compound was isolated as a yellow solid in 20% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 11.76 (s, 1H), 8.11 (d, $J = 8.97$ Hz, 2H), 7.03 (d, $J = 8.97$ Hz, 2H), 6.69 (d, $J = 2.26$ Hz, 1H), 6.47 (d, $J = 2.26$ Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.62–3.53 (m, 4H), 3.41–3.25 (m, 4H), 2.05 (s, 3H); MS (ESI) m/z 409 [$\text{C}_{22}\text{H}_{24}\text{N}_4\text{O}_4 + \text{H}$] $^+$.

Example 12. Preparation of 5,7-Dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one




[0184] A mixture of 4-(4-acetylpiperazin-1-yl)benzaldehyde (1.34 g, 5.77 mmol) and 2-amino-4,6-dimethoxybenzamide (1.03 g, 5.24 mmol) in DMA (30 mL) was treated with *p*-TsOH (0.100 g, 0.524 mmol) and NaHSO₃ (0.578 g, 5.55 mmol). The mixture was heated at 155 °C for 6 hours, cooled to room temperature, diluted with water (400 mL), and filtered to give brown solids. The filtrate was extracted with EtOAc (3×100 mL), concentrated, and combined with the brown solids from the filter cake. The combined solids were purified by silica gel chromatography, eluting with 92:7:1 CHCl₃/MeOH/concentrated NH₄OH to afford 2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one as a yellow solid (1.9 g, 90%).

[0185] A mixture of 2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (1.93 g, 4.7 mmol) and 2 M HCl (200 mL) was heated at reflux for 9 hours. Then, the mixture was cooled to room temperature, basified to pH 8 with 2 N NaOH, extracted with CH₂Cl₂ (3×300 mL), dried over anhydrous MgSO₄, filtered, and concentrated. The residue was purified by silica gel chromatography, eluting with 92:7:1 to 6:3:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (1.13 g, 66%). ^1H NMR (300 MHz, DMSO- d_6): δ 8.08

(d, $J = 8.9$ Hz, 2H), 6.99 (d, $J = 8.9$ Hz, 2H), 6.68 (d, $J = 2.3$ Hz, 1H), 6.47 (d, $J = 2.3$ Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.19-3.23 (m, 4H), 2.81-2.84 (m, 4H); APCI MS m/z 367 $[M+H]^+$.

Example 13. Preparation of N-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide



[0186] A solution of ethyl 4-fluorobenzoate (16.5 g, 98.1 mmol) and piperidin-4-ol (10.0 g, 98.8 mmol) in DMSO (20 mL) was heated at 120 °C under nitrogen for 48 hours. The mixture was cooled to room temperature, poured into water (400 mL), and the solids were filtered off, washed with water, followed by hexane, to afford ethyl 4-(4-hydroxypiperidin-1-yl)benzoate (20.0 g, 82%).

[0187] To a solution of ethyl 4-(4-hydroxypiperidin-1-yl)benzoate (8.0 g, 32.1 mmol) in CH_2Cl_2 (200 mL) was added Et_3N (23 mL, 165 mmol) under nitrogen, followed by $MsCl$ (5.6 g, 48.9 mmol). The mixture was stirred for 5 minutes, washed with water (300 mL), dried over anhydrous $MgSO_4$, filtered, and concentrated to afford ethyl 4-(4-(methylsulfonyloxy)piperidin-1-yl)benzoate as a tan solid (10.5 g, 100%).

[0188] To a solution of ethyl 4-(4-(methylsulfonyloxy)piperidin-1-yl)benzoate (10.5 g, 32.1 mmol) in DMF (50 mL) was added sodium azide (4.17 g, 64.2 mmol). The mixture was heated at 80 °C for 5 hours, cooled to room temperature, diluted with brine (300 mL), and extracted with ethyl acetate (400 mL). The organic phase was washed with brine (2×300 mL), dried over anhydrous $MgSO_4$, filtered, and concentrated, to afford ethyl 4-(4-azidopiperidin-1-yl)benzoate as a yellow solid (7.62 g, 87%).

[0189] To a solution of ethyl 4-(4-azidopiperidin-1-yl)benzoate (7.62 g, 27.8 mmol) in dioxane (190 mL) was added acetic acid (27 mL) and water (54 mL).

Then, 10% Pd/C (0.750 g) was added and the mixture was hydrogenated under 1 atmosphere of hydrogen for 5 hours. The mixture was filtered through Celite, concentrated, and 0.5 M HCl (500 mL) was added. The solution was washed with ethyl acetate (2×300 mL) and the aqueous phase basified with ammonium hydroxide, to pH 12. The aqueous phase was saturated with sodium chloride, extracted with CH₂Cl₂ (2×300 mL), dried over anhydrous MgSO₄, filtered, and concentrated, to afford ethyl 4-(4-aminopiperidin-1-yl)benzoate.


[0190] To a solution of ethyl 4-(4-aminopiperidin-1-yl)benzoate (1.65 g, 6.65 mmol) in CH₂Cl₂ (200 mL) was added Et₃N (1.35 g, 13.3 mmol), followed by acetyl chloride (0.573 g, 7.3 mmol). The reaction mixture was stirred at room temperature for 5 minutes, washed with brine (300 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated, to afford ethyl 4-(4-acetamidopiperidin-1-yl)benzoate as a white solid (1.9 g, 100%).

[0191] A solution of ethyl 4-(4-acetamidopiperidin-1-yl)benzoate (0.123 g, 0.42 mmol) in CH₂Cl₂ (10 mL) under nitrogen at -78°C was treated with DIBAL-H (1.0M in hexanes, 0.950 mL, 0.95 mmol) dropwise, via a syringe. After 20 minutes, the mixture was warmed to room temperature, stirred for 1 hour, and quenched with 10% Rochelle's salt. After stirring for 10 minutes, CH₂Cl₂ (50 mL) was added, and the stirring was continued for 15 additional minutes. The layers were separated and the aqueous phase was extracted with CH₂Cl₂ (50 mL) and ethyl acetate (50 mL). The combined organic phases were dried (MgSO₄), filtered, concentrated, and purified by flash chromatography on silica gel, eluting with 100% ethyl acetate to 10% MeOH/ethyl acetate to afford *N*-(1-(4-(hydroxymethyl)phenyl)piperidin-4-yl)acetamide as a white solid (0.025 g, 24%).

[0192] A mixture of *N*-(1-(4-(hydroxymethyl)phenyl)piperidin-4-yl)acetamide (0.380 g, 1.53 mmol), TPAP (0.026 g, 0.08 mmol), NMO (0.268 g, 2.30 mmol), and molecular sieves (3 Angstrom, 0.300 g) in CH₂Cl₂ was stirred at room temperature for 19 hours. The mixture was filtered through Celite, concentrated, and purified by flash chromatography on silica gel, eluting with 100% ethyl acetate to 10% MeOH/ethyl acetate, to afford *N*-(1-(4-formylphenyl)piperidin-4-yl)acetamide as a white solid (0.280 g, 74%).

[0193] A mixture of *N*-(1-(4-formylphenyl)piperidin-4-yl)acetamide (0.280 g, 1.14 mmol), 2-amino-4,6-dimethoxybenzamide (0.224 g, 1.14 mmol), *p*-TsOH (0.022 g, 0.114 mmol), and NaHSO₃ (0.125 g, 1.21 mmol) in DMA was heated at 155 °C for 6 hours. The reaction mixture was cooled, diluted with water (100 mL), basified with saturated NaHCO₃, and extracted with ethyl acetate (3×150 mL). The organic phase was concentrated and purified by flash chromatography on silica gel, eluting with 1:1 CH₂Cl₂/(92:7:1 CHCl₃/MeOH/concentrated NH₄OH) to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH. Further purification by reverse-phase HPLC, eluting with 10% to 90% CH₃CN in H₂O with 0.1% TFA, afforded the title compound as a yellow solid (0.140 g, 29%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.74 (s, 1H), 8.08 (d, *J* = 9.0 Hz, 2H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.01 (d, *J* = 9.0 Hz, 2H), 6.68 (d, *J* = 2.3 Hz, 1H), 6.46 (d, *J* = 2.3 Hz, 1H), 3.7-3.89 (m, 9H), 2.92-3.00 (m, 2H), 1.76-1.85 (m, 5H), 1.36-1.48 (m, 2H); APCI MS *m/z* 423 [M+H]⁺.


Example 14. Preparation of *N*-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)methanesulfonamide



[0194] A mixture of 2-(4-(4-aminopiperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one (0.105 g, 0.28 mmol), methanesulfonylchloride (0.035 g, 0.30 mmol), and Et₃N (0.057 g, 0.56 mmol) in CH₂Cl₂ (10 mL) was stirred at room temperature under nitrogen for 2 hours. The mixture was concentrated, redissolved in THF (5 mL), 2 M NaOH (5 mL) added and stirred for 20 minutes. The pH was adjusted to 8 with 1 M HCl and the mixture extracted with CH₂Cl₂ (3×150 mL). The organic phase was dried over anhydrous MgSO₄, filtered, and concentrated. The residue was purified by silica gel chromatography, eluting with 1:1 CH₂Cl₂/(92:7:1 CHCl₃/MeOH/ concentrated NH₄OH) to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH. Further purification by reverse-phase HPLC, eluting with 10% to 90% CH₃CN in H₂O with 0.1% TFA, afforded the title compound as a yellow solid (0.075 g, 58%). ¹H NMR (300 MHz, DMSO-*d*₆):

δ 11.75 (s, 1H), 8.08 (d, $J = 9.0$ Hz, 2H), 7.13 (d, $J = 7.3$ Hz, 1H), 7.00 (d, $J = 9.0$ Hz, 2H), 6.66 (d, $J = 2.3$ Hz, 1H), 6.46 (d, $J = 2.3$ Hz, 1H), 3.81-3.94 (m, 8H), 3.34-3.47 (m, 1H), 2.90 (m, 6H), 1.87-1.95 (m, 2H), 1.42-1.54 (m, 2H); ESI MS m/z 459 $[M+H]^+$.


Example 15. Preparation of 3-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-1,1-dimethylurea



[0195] A mixture of N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide (0.250 g, 0.59 mmol) and 2 M HCl (20 mL) was heated at reflux for 24 hours. The mixture was basified with 2 M NaOH to pH 8, extracted with CH_2Cl_2 (3 $\times$ 150 mL), dried over anhydrous MgSO_4 , filtered, and concentrated to afford 2-(4-(4-aminopiperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one as a yellow solid (0.215 g, 96%).


[0196] A mixture of 2-(4-(4-aminopiperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.105 g, 0.28 mmol), dimethylcarbamic chloride (0.032 g, 0.30 mmol), and Et_3N (0.085 g, 0.84 mmol) in THF (10 mL) was stirred at room temperature for 18 hours. The mixture was then heated at reflux for 24 hours, then cooled to room temperature. 2 M NaOH (20 mL) was added and the mixture was stirred for 30 minutes. The reaction mixture was adjusted to pH 8, extracted with CH_2Cl_2 (3 $\times$ 100 mL), dried over anhydrous MgSO_4 , filtered, and concentrated. The residue was dissolved in $\text{CHCl}_3/\text{MeOH}$ and concentrated, then CH_3CN was added and concentrated to afford the title compound as a white solid (0.065 g, 51%): ^1H NMR (300 MHz, CDCl_3): δ 11.72 (s, 1H), 8.08 (d, $J = 9.0$ Hz, 2H), 7.00 (d, $J = 9.0$ Hz, 2H), 6.78 (d, $J = 2.2$ Hz, 1H), 6.46 (d, $J = 2.2$ Hz, 1H), 5.99 (d, $J = 7.8$ Hz, 1H), 3.90-3.94 (m, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 3.66-3.69 (m, 1H), 2.88-2.93 (m, 2H), 2.76 (s, 6H), 1.75-1.80 (m, 2H), 1.45-1.52 (m, 2H); ESI MS m/z 452 $[M+H]^+$.

Example 16. Preparation of 2-(4-(4-Hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0197] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.120 g, 0.32 mmol) in CH_2Cl_2 (10 mL) was added Et_3N (0.06 mL, 0.48 mmol) and hexanoyl chloride (0.03 mL, 0.28 mmol). The resulting solution was stirred at room temperature for 1 hour. The mixture was concentrated *in vacuo*. The material was purified by flash chromatography, eluting with 2% to 10% of $\text{MeOH}/\text{CH}_2\text{Cl}_2$, to afford the title compound (0.050 g, 38%).
 ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.79 (s, 1H), 8.11 (d, $J = 8.7$ Hz, 2H), 7.03 (d, $J = 8.8$ Hz, 2H), 6.68 (s, 1H), 6.47 (s, 1H), 3.75-4.05 (m, 6H), 3.47-3.73 (m, 4H), 3.17-3.43 (m, 4H), 2.20-2.40 (m, 2H), 1.41-1.62 (m, 2H), 1.15-1.38 (m, 4H), 0.76-0.98 (m, 3H); APCI MS m/z 465 $[\text{M}+\text{H}]^+$.


Example 17. Preparation of 2-(4-(4-Isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0198] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.40 mmol) in CH_2Cl_2 (10 mL) was added Et_3N (0.08 mL, 0.60 mmol) and isobutyryl chloride (0.03 mL, 0.36 mmol). The resulting solution was stirred at room temperature for 1 hour. The solution was concentrated *in vacuo* and the residue was purified by flash chromatography on silica gel, eluting with 2% to 10% of $\text{MeOH}/\text{CH}_2\text{Cl}_2$. The solid was further purified by flash chromatography on silica gel, eluting with 0% to 5% of


MeOH/EtOAc, to afford the title compound (0.080 g, 50%): ^1H NMR (300 MHz, DMSO- d_6): δ 11.78 (s, 1H), 8.11 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 6.68 (s, 1H), 6.47 (s, 1H), 3.76-3.92 (m, 6H), 3.52-3.71 (m, 4H), 3.16-3.44 (m, 4H), 2.83-3.00 (m, 1H), 1.02 (d, J = 6.8 Hz, 6H); APCI MS m/z 437 $[\text{M}+\text{H}]^+$.

Example 18. Preparation of 2-(4-(4-Benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0199] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.40 mmol) in CH_2Cl_2 (10 mL) was added Et_3N (0.08 mL, 0.60 mmol) and benzoyl chloride (0.04 mL, 0.36 mmol). The resulting solution was stirred at room temperature for 3 hours. The solution was concentrated *in vacuo*. The material was purified by flash chromatography on silica gel eluting with 0% to 10% of MeOH/EtOAc to afford the title compound (0.110 g, 64%). ^1H NMR (300 MHz, DMSO- d_6): δ 11.79 (s, 1H), 8.11 (d, J = 8.7 Hz, 2H), 7.37-7.54 (m, 5H), 7.04 (d, J = 8.9 Hz, 2H), 6.68 (s, 1H), 6.47 (s, 1H), 3.61-4.03 (m, 8H), 3.23-3.62 (m, 6H); ESI MS m/z 471 $[\text{M}+\text{H}]^+$.


Example 19. Preparation of 2-(4-(4-(4-Fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0200] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.40 mmol) in CH_2Cl_2 (10 mL) was added Et_3N (0.08 mL, 0.60 mmol) and 4-fluorobenzoyl chloride (0.04 mL, 0.36 mmol). The resulting solution was stirred at room temperature for 3 hours. The

solution was concentrated *in vacuo* and the residue was purified by flash chromatography on silica gel, eluting with 0% to 10% of MeOH/EtOAc, to afford the title compound (0.080 g, 45%). ^1H NMR (300 MHz, DMSO- d_6): δ 11.79 (s, 1H), 8.11 (d, J = 8.8 Hz, 2H), 7.44-7.62 (m, 2H), 7.21-7.39 (m, 2H), 7.04 (d, J = 9.0 Hz, 2H), 6.68 (s, 1H), 6.47 (s, 1H), 3.64-3.94 (m, 8H), 3.22-3.60 (m, 6H); APCI MS m/z 489 $[\text{M}+\text{H}]^+$.

Example 20. Preparation of N-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide



[0201] To a solution of ethyl 4-(4-aminopiperidin-1-yl)benzoate (3.0 g, 12.1 mmol) in CH_2Cl_2 under nitrogen was added Et_3N (2.45 g, 24.2 mmol), followed by benzoyl chloride (1.70 g, 12.1 mmol). The mixture was stirred at room temperature overnight, washed with brine (200 mL), dried over anhydrous MgSO_4 , filtered, and concentrated. The resulting solids were triturated with hexanes to afford ethyl 4-(4-benzamidopiperidin-1-yl)benzoate as a yellow solid (4.2 g, 100%).


[0202] A solution of ethyl 4-(4-benzamidopiperidin-1-yl)benzoate (4.2 g, 11.9 mmol) in THF (400 mL) was cooled to 0°C under nitrogen and treated with DIBAL-H (1.0 M in THF, 47 mL, 47 mmol). The mixture was warmed to room temperature and stirred for 1 hour. Then, the reaction mixture was quenched with Rochelle's salt (10% aqueous), concentrated to remove the THF, brine (300 mL) was added, and the organic phase was extracted with CH_2Cl_2 (3 $\times$ 200 mL), dried over anhydrous MgSO_4 , filtered, and concentrated, to afford N-(1-(4-(hydroxymethyl)phenyl)piperidin-4-yl)benzamide as a yellow solid that was used without further purification.

[0203] To a solution of N-(1-(4-(hydroxymethyl)phenyl)piperidin-4-yl)benzamide (1.1 g, 3.5 mmol) in CH_2Cl_2 (250 mL) was added TPAP (0.123 g,

0.35 mmol) and NMO (0.623 g, 5.3 mmol). After 1 hour, the mixture was filtered through Celite, concentrated, and purified by silica gel chromatography, eluting with 30% ethyl acetate/hexanes to 100% ethyl acetate, to afford *N*-(1-(4-formylphenyl)piperidin-4-yl)benzamide as a white solid (0.350 g, 32%).

[0204] A mixture of *N*-(1-(4-formylphenyl)piperidin-4-yl)benzamide (0.350 g, 1.10 mmol), NaHSO₃ (0.180 g, 1.70 mmol) and *p*-TsOH (0.022 g, 0.11 mmol) and 2-amino-4,6-dimethoxybenzamide (0.223 g, 1.10 mmol) in DMA (10 mL) was heated at 150 °C overnight. The mixture was concentrated *in vacuo*, and the residue was dissolved in EtOAc and washed with H₂O and brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. The resulting solid was purified by silica gel chromatography eluting with 10% to 50% CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂ to afford the title compound (0.050 g, 10%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.75 (s, 1H), 8.26 (d, *J* = 7.4 Hz, 1H), 8.10 (d, *J* = 9.0 Hz, 2H), 7.83 (d, *J* = 6.9 Hz, 2H), 7.44-7.49 (m, 3H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.68 (s, 1H), 6.46 (s, 1H), 3.93-4.17 (m, 3H), 3.88 (s, 3H), 3.83 (s, 3H), 2.91-3.08 (m, 2H), 1.82-1.93 (m, 2H), 1.52-1.72 (m, 2H); APCI MS *m/z* 485 [M+H]⁺.


Example 21. Preparation of 5,7-Dimethoxy-2-(4-(4-picolinoylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one



[0205] To a solution of picolinic acid (0.066 g, 0.54 mmol) in THF (20 mL) was added HOBt (0.079 g, 0.59 mmol), EDCI (0.113 g, 0.59 mmol), Et₃N (0.08 mL, 0.59 mmol) and 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.200 g, 0.54 mmol). The resulting solution was stirred overnight at room temperature. The solution was concentrated *in vacuo* and the resulting solid was purified by flash chromatography on silica gel, eluting with 50% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, to afford the title compound (0.160 g, 62%): ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.69 (s, 1H), 8.53-8.70 (m, 1H), 8.11 (d, *J* = 8.9 Hz, 2H), 7.86-8.04 (m, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.44-7.57 (m,


1H), 7.04 (d, $J = 9.1$ Hz, 2H), 6.69 (s, 1H), 6.47 (s, 1H), 3.74-3.97 (m, 8H), 3.53-3.68 (m, 2H), 3.41-3.53 (m, 2H), 3.23-3.39 (m, 2H). APCI MS m/z 472 $[M+H]^+$.

Example 22. Preparation of 5,7-Dimethoxy-2-(4-(4-nicotinoylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one



[0206] To a solution of nicotinic acid (0.066 g, 0.54 mmol) in THF (20 mL) was added HOBt (0.079 g, 0.59 mmol), EDCI (0.113 g, 0.59 mmol), Et_3N (0.08 mL, 0.59 mmol) and 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.200 g, 0.54 mmol). The resulting solution was stirred overnight at room temperature. The solution was concentrated *in vacuo* and the resulting solid was purified by flash chromatography on silica gel, eluting with 10% to 60% of 92:7:1 $\text{CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$ in CH_2Cl_2 , to afford the title compound (0.050 g, 19%): ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.79 (s, 1H), 8.59-8.78 (m, 2H), 8.12 (d, $J = 8.8$ Hz, 2H), 7.82-7.99 (m, 1H), 7.37-7.60 (m, 1H), 7.04 (d, $J = 9.1$ Hz, 2H), 6.69 (s, 1H), 6.47 (s, 1H), 3.63-3.97 (m, 8H), 3.20-3.63 (m, 6H). APCI MS m/z 472 $[M+H]^+$.


Example 23. Preparation of 2-(4-(4-Isonicotinoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0207] To a solution of isonicotinic acid (0.083 g, 0.68 mmol) in THF (20 mL) was added HOBt (0.099 g, 0.74 mmol), EDCI (0.141 g, 0.74 mmol), Et_3N (0.10 mL, 0.74 mmol) and 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.250 g, 0.68 mmol). The resulting solution was stirred overnight at


room temperature. The solution was concentrated *in vacuo* and the resulting material was purified by flash chromatography on silica gel, eluting with 10% to 60% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, to afford the title compound (0.110 g, 34%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.79 (s, 1H), 8.58-8.79 (m, 2H), 8.12 (d, *J* = 9.0 Hz, 2H), 7.45 (d, *J* = 6.0 Hz, 2H), 7.04 (d, *J* = 9.0 Hz, 2H), 6.69 (s, 1H), 6.47 (s, 1H), 3.64-4.06 (m, 9H), 3.22-3.54 (m, 5H). APCI MS *m/z* 472 [M+H]⁺.

Example 24. Preparation of 5,7-Dimethoxy-2-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one




[0208] To a solution of 2-thiophenecarboxylic acid (0.087 g, 0.68 mmol) in THF (20 mL) was added HOBt (0.099 g, 0.74 mmol), EDCI (0.141 g, 0.74 mmol), Et₃N (0.10 mL, 0.74 mmol) and 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.250 g, 0.68 mmol). The resulting solution was stirred at room temperature for 4 hours. The solution was concentrated *in vacuo*. The material was purified by flash chromatography, eluting with 0% to 50% of 92:7:1 CHCl₃/MeOH/ concentrated NH₄OH in CH₂Cl₂, to afford the title compound (0.100 g, 30%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.78 (s, 1H), 8.12 (d, *J* = 9.0 Hz, 2H), 7.75-7.84 (m, 1H), 7.46-7.53 (m, 1H), 7.12-7.20 (m, 1H), 7.03 (d, *J* = 9.1 Hz, 2H), 6.69 (d, *J* = 2.3 Hz, 1H), 6.47 (d, *J* = 2.3 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.74-3.92 (m, 4H), 3.37-3.49 (m, 4H). APCI MS *m/z* 477 [M+H]⁺.

Example 25. Preparation of 2-(4-(4-(5-Chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0209] To a mixture of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.41 mmol) and 5-chloro-1-methyl-1H-pyrazole-4-carbonyl chloride (0.073 g, 0.41 mmol) in CH₂Cl₂ (50 mL), was added Et₃N (0.086 mL, 0.62 mmol) and the reaction stirred under nitrogen at room temperature for 1 hour. The residue was concentrated and purified by flash chromatography on silica gel, eluting with 70% CH₂Cl₂/(92:7:1 CHCl₃/MeOH/concentrated NH₄OH) to 100% (92:7:1 CHCl₃/MeOH/concentrated NH₄OH), to afford the title compound as a white solid (0.159 g, 76%). ¹H NMR (500 MHz, DMSO-*d*₆): δ 11.78 (s, 1H), 8.12 (d, *J* = 9.0 Hz, 2H), 7.77 (s, 1H), 7.04 (d, *J* = 9.1 Hz, 2H), 6.69 (d, *J* = 2.3 Hz, 1H), 6.47 (d, *J* = 2.3 Hz, 1H), 3.88 (s, 3H), 3.80-3.87 (m, 6H), 3.63-3.80 (m, 4H), 3.38-3.44 (m, 4H). APCI MS *m/z* 509 [M+H]⁺.


Example 26. Preparation of 5,7-Dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one



[0210] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.200 g, 0.54 mmol) in THF (10 mL) was added EDCI (0.105 g, 0.54 mmol), HOBt (0.074 g, 0.54 mmol), Et₃N (0.08 mL, 0.54 mmol) and trifluoropropionic acid (0.070 g, 0.54 mmol). The reaction was stirred at room temperature for 4 hours and concentrated *in vacuo*. Purification by flash chromatography, eluting with 20% to 100% of 92:7:1 CHCl₃/MeOH/concentrate NH₄OH in CH₂Cl₂, afforded the title compound (0.135 g, 52%). ¹H NMR (300 MHz,


DMSO- d_6): δ 11.78 (s, 1H), 8.10 (d, $J = 9.0$ Hz, 2H), 7.03 (d, $J = 9.0$ Hz, 2H), 6.68 (d, $J = 2.3$ Hz, 1H), 6.47 (d, $J = 2.3$ Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.70-3.78 (m, 2H), 3.60-3.67 (m, 4H), 3.34-3.38 (m, 4H). APCI MS m/z 477 $[M+H]^+$.

Example 27. Preparation of 2-(4-(4-(2,5-Dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0211] To a mixture of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.41 mmol) and 2,5-dichlorothiophene-3-carbonyl chloride (0.088 g, 0.41 mmol) in CH_2Cl_2 was added Et_3N (0.086 mL, 0.62 mmol) and the mixture stirred at room temperature under nitrogen for 30 minutes. The mixture was concentrated and purified by silica gel chromatography, eluting with 70% CH_2Cl_2 /(92:7:1 $CHCl_3$ /MeOH/concentrated NH_4OH) to 100% (92:7:1 $CHCl_3$ /MeOH/concentrated NH_4OH), to afford the title compound as a light yellow solid (0.177 g, 79%). ^1H NMR (300 MHz, DMSO- d_6): δ 11.80 (s, 1H), 8.12 (d, $J = 9.0$ Hz, 2H), 7.27 (s, 1H), 7.05 (d, $J = 9.0$ Hz, 2H), 6.69 (d, $J = 2.3$ Hz, 1H), 6.48 (d, $J = 2.3$ Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.73-3.82 (m, 2H), 3.38-3.44 (m, 6H). APCI MS m/z 545 $[M+H]^+$.

Example 28. Preparation of 2-(4-(4-(Cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0212] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.150 g, 0.40 mmol) in CH_2Cl_2 (10 mL) was

added Et₃N (0.08 mL, 0.60 mmol), and cyclopropane carbonyl chloride (0.03 mL, 0.36 mmol). The resulting solution was stirred overnight at room temperature. The solution was concentrated *in vacuo* and the material was purified by flash chromatography on silica gel eluting with 0% to 50% of 92:7:1


CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂ to afford the title compound (0.100 g, 63%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.78 (s, 1H), 8.12 (d, *J* = 8.9 Hz, 2H), 7.04 (d, *J* = 9.2 Hz, 2H), 6.63-6.74 (m, 1H), 6.39-6.52 (m, 1H), 3.73-3.95 (m, 8H), 3.51-3.73 (m, 2H), 3.21-3.49 (m, 4H), 1.93-2.10 (m, 1H), 0.56-0.83 (m, 4H). APCI MS *m/z* 435 [M+H]⁺.

Example 29. Preparation of 2-(4-(4-(4-Fluorobenzyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0213] To a solution of 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.200 g, 0.55 mmol) in DMF (5 mL) was added 4-fluorobenzyl bromide (0.07 mL, 0.55 mmol) and K₂CO₃ (0.15 g, 1.10 mmol). The reaction was stirred at room temperature for 2 hours then diluted with H₂O and the solids filtered off to afford the title compound (0.17 g, 65%) as a light brown solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.76 (br s, 1H), 8.09 (d, *J* = 8.1 Hz, 2H), 7.26-7.52 (m, 2H), 7.08-7.25 (m, 2H), 7.00 (d, *J* = 8.0 Hz, 2H), 6.68 (s, 1H), 6.46 (s, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.51 (s, 2H), 3.08-3.41 (m, 4H), 2.23-2.68 (m, 4H). APCI MS *m/z* 475 [M+H]⁺.

Example 30. Preparation of 2-(4-(4-Benzylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0214] Following the method described for Example 29 above, the title compound was made from benzyl bromide in 45% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 11.76 (s, 1H), 8.09 (d, J = 8.6 Hz, 2H), 7.26-7.43 (m, 5H), 7.00 (d, J = 8.8 Hz, 2H), 6.68 (s, 1H), 6.46 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.53 (s, 2H), 3.23-3.40 (m, 4H), 2.38-2.63 (m, 4H). APCI MS m/z 457 $[\text{M}+\text{H}]^+$.

Example 31. Preparation of 2-(4-(4-(2,2,2-Trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one




[0215] To a mixture of 2-aminobenzamide (1.0 g, 7.35 mmol) and 4-(4-acetylpiperazin-1-yl)benzaldehyde (1.71 g, 7.35 mmol) in DMA (60 mL) was added *p*-TsOH (0.140 g, 0.73 mmol) and NaHSO₃ (0.841 g, 8.1 mmol). The reaction mixture was heated at 150 °C for 21 hours, concentrated to half-volume, diluted with water (300 mL), extracted with CH₂Cl₂ (2×200 mL), washed with brine (200 mL), dried over anhydrous MgSO₄, filtered, and concentrated. The residue was purified by silica gel chromatography, eluting with 100% CH₂Cl₂ to 100% (92:7:1 CHCl₃/MeOH/ concentrated NH₄OH), to afford 2-(4-(4-acetylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one as a yellow solid (2.27 g, 89%).

[0216] A mixture of 2-(4-(4-acetylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one (2.27 g, 6.5 mmol) and 2 N HCl (100 mL) were heated at 100 °C for 4 hours. Then, the mixture was cooled to room temperature, basified to pH 8 with 2 N NaOH, extracted with CH₂Cl₂ (3×150 mL), dried over anhydrous MgSO₄, filtered, and concentrated to afford 2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one as a pale yellow solid (1.8 g, 90%).

[0217] To a mixture of 2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.325 g, 1.06 mmol) in THF (50 mL) was added Hünig's base (0.192 g, 1.48 mmol), followed by 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.295 g, 1.3 mmol). The reaction mixture was heated at reflux for 15 hours, concentrated, and purified by flash chromatography on silica gel, eluting with 100% CH₂Cl₂ to

100% ethyl acetate, to afford the title compound as an off-white solid (0.385 g, 94%). ^1H NMR (300 MHz, DMSO- d_6): δ 12.27 (br s, 1H), 8.10-8.14 (m, 3H), 7.76-7.82 (m, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.42-7.47 (m, 1H), 7.05 (d, J = 9.1 Hz, 2H), 3.21-3.34 (m, 6H), 2.73-2.78 (m, 4H). APCI MS m/z 389 $[\text{M}+\text{H}]^+$.


Example 32. Preparation of 2-(4-(4-Acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0218] A mixture of 4-fluorobenzaldehyde (1.56 g, 12.6 mmol), 1-(1,4-diazepan-1-yl)ethanone (1.5 g, 10.5 mmol), and K_2CO_3 (1.74 g, 12.6 mmol) in DMF (10 mL) were heated at 120 °C for 20 hours. The mixture was cooled to room temperature and diluted with water. The mixture was extracted with ethyl acetate and the organic phase washed with brine, dried over anhydrous MgSO_4 , filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 50% ethyl acetate/hexanes to 100% ethyl acetate to 10% methanol/ethyl acetate, to afford 4-(4-acetyl-1,4-diazepan-1-yl)benzaldehyde (1.8 g, 70%).


[0219] To a mixture of 2-amino-4,6-dimethoxybenzamide (0.377 g, 1.92 mmol) and 4-(4-acetyl-1,4-diazepan-1-yl)benzaldehyde (0.520 g, 2.11 mmol) in DMA (20 mL) was added NaHSO_3 (0.240 g, 2.3 mmol) followed by p -TsOH (0.037 g, 0.192 mmol) and the reaction heated at 150 °C for 6 hours. The mixture was cooled to room temperature, diluted with CH_2Cl_2 (150 mL), washed with brine (2×150 mL), dried over anhydrous MgSO_4 , filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 1:1 CH_2Cl_2 /92:7:1 CHCl_3 /MeOH/concentrated NH_4OH to 100% 92:7:1 CHCl_3 /MeOH/concentrated NH_4OH , to afford the title compound (0.333 g, 41%) as a yellow solid. ^1H NMR (300 MHz, CDCl_3): δ 9.12 (s, 1H), 7.88-7.91 (m, 2H), 6.78-6.82 (m, 3H), 6.42 (d, J = 2.2 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.62-3.80 (m, 6H), 3.36-3.48 (m, 2H), 1.98-2.12 (m, 5H). ESI MS m/z 421 $[\text{M}-\text{H}]^-$.

Example 33. Preparation of 2-(4-(1,4-Diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0220] A mixture of 2-(4-(4-acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.135 g, 0.32 mmol) and 2 N HCl (10 mL) was heated at 100 °C for 4 hours. Then, the reaction mixture was cooled to room temperature, basified to pH 8, and extracted with CH₂Cl₂ (8×125 mL). The residue was purified by flash chromatography on silica gel, eluting with 1:1 CH₂Cl₂/92:7:1 CHCl₃/MeOH/concentrated NH₄OH to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (0.040 g, 33%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃): δ 8.98 (s, 1H), 7.86 (d, *J* = 9.0 Hz, 2H), 6.76-6.79 (m, 3H), 6.40 (d, *J* = 2.3 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.61-3.69 (m, 5H), 3.05 (t, *J* = 4.9 Hz, 2H), 2.83 (t, *J* = 5.7 Hz, 2H), 1.92 (t, *J* = 5.4 Hz, 2H). ESI MS *m/z* 379 [M-H]⁻.

Example 34. Preparation of 5,7-Dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one




[0221] To a solution of 2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.150 g, 0.39 mmol) in DMF (20 mL) was added CH₃I (0.067 g, 0.47 mmol) and Hünig's Base (0.138 mL, 0.79 mmol). The reaction mixture was heated at 50 °C for 1.5 hours, cooled to room temperature, diluted with ethyl acetate (150 mL), washed with brine (2×100 mL), dried over anhydrous MgSO₄, filtered, and concentrated. The residue was purified by flash

chromatography on silica gel, eluting with 1:1 CH₂Cl₂/92:7:1

CHCl₃/MeOH/concentrated NH₄OH to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (0.035 g, 23%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.66 (s, 1H), 8.06 (d, *J* = 9.0 Hz, 2H), 6.78 (d, *J* = 9.0 Hz, 2H), 6.65 (d, *J* = 2.2 Hz, 1H), 6.44 (d, *J* = 2.2 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.57-3.59 (m, 2H), 3.52 (t, *J* = 6.1 Hz, 2H), 2.60-2.64 (m, 2H), 2.45-2.50 (m, 2H), 2.26 (s, 3H), 1.89-1.99 (m, 2H). ESI MS *m/z* 395 [M+H]⁺.

Example 35. Preparation of N-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide




[0222] To a solution of 4-acetamidopiperidine (2.5 g, 17.5 mmol) in DMF (10 mL) was added 4-fluorobenzaldehyde (2.2 g, 17.5 mmol) and K₂CO₃ (2.9 g, 21.2 mmol). The reaction was heated at 120 °C for 4 hours, diluted with H₂O, and extracted with EtOAc. The organics were washed sequentially with H₂O and brine, dried (Na₂SO₄), filtered, and concentrated *in vacuo*, to afford N-(1-(4-formylphenyl)piperidin-4-yl)acetamide (3.1 g, 92%).

[0223] A 60% suspension in oil of NaH (0.113 g, 2.8 mmol) was added to a 0 °C solution of N-(1-(4-formylphenyl)piperidin-4-yl)acetamide (0.700 g, 2.8 mmol) in DMF (10 mL) and stirred for 35 minutes. To this mixture was added EtI (0.23 mL, 2.8 mmol) and the reaction was warmed to room temperature for 2 hours, quenched with H₂O, and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 0% to 5% MeOH/CH₂Cl₂, afforded N-ethyl-N-(1-(4-formylphenyl)piperidin-4-yl)acetamide (0.490 g, 64%).

[0224] A mixture of N-ethyl-N-(1-(4-formylphenyl)piperidin-4-yl)acetamide (0.385 g, 1.40 mmol), NaHSO₃ (0.162 g, 1.50 mmol), and *p*-TsOH (0.024 g, 0.12

mmol) were added to a solution of 2-amino-4,6-dimethoxybenzamide (0.250 g, 1.20 mmol) in DMA (10 mL). The reaction was stirred at 150 °C for 4 hours and then cooled to room temperature overnight. The mixture was diluted with H₂O and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 2% to 10% MeOH/CH₂Cl₂, afforded the title compound (0.300 g, 55%) as a yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): mixture of rotamers δ 11.76 (s, 1H), 8.08 (d, *J* = 8.7 Hz, 2H), 7.02 (d, *J* = 8.7 Hz, 2H), 6.67 (d, *J* = 2.0 Hz, 1H), 6.46 (d, *J* = 2.0 Hz, 1H), 4.29-4.33 (m, 0.5H), 3.99-4.03 (m, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 3.12-3.25 (m, 2H), 2.81-2.93 (m, 2H), 2.07 (s, 1.5H), 2.01 (s, 1.5H), 1.59-1.74 (m, 4.5H), 1.10 (t, *J* = 6.7 Hz, 1.5H), 0.99 (t, *J* = 6.7 Hz, 1.5H). ESI MS *m/z* 451 [M+H]⁺.

Example 36. Preparation of 2-(4-((3R,5S)-4-Acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0225] A mixture of 4-fluorobenzaldehyde (2.0 g, 16.1 mmol), 2,6-dimethylpiperazine (2.2 g, 19.3 mmol), and K₂CO₃ (2.7 g, 19.3 mmol) in DMF (10 mL) was heated at 120 °C for 4 hours. Then, the reaction was diluted with H₂O and extracted with EtOAc. The organics were washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel eluting with 3% to 10% MeOH/CH₂Cl₂ afforded 4-(3,5-dimethylpiperazin-1-yl)benzaldehyde (2.0 g, 57%).

[0226] A solution of 4-(3,5-dimethylpiperazin-1-yl)benzaldehyde (1.0 g, 4.6 mmol) in CH₂Cl₂ (15 mL) was cooled to 0 °C and treated with Et₃N (0.64 mL, 4.6 mmol) followed by acetyl chloride (0.33 mL, 4.6 mmol). The reaction stirred for 30 minutes, then concentrated *in vacuo*. Purification by flash chromatography on

silica gel, eluting with 0% to 50% EtOAc/CH₂Cl₂, afforded 4-(4-acetyl-3,5-dimethylpiperazin-1-yl)benzaldehyde (1.0 g, 83%).


[0227] A mixture of 4-(4-acetyl-3,5-dimethylpiperazin-1-yl)benzaldehyde (0.580 g, 2.20 mmol), NaHSO₃ (0.260 g, 2.40 mmol), and *p*-TsOH (0.039 g, 0.20 mmol) was added to a solution of 2-amino-4,6-dimethoxybenzamide (0.400 g, 2.20 mmol) in DMA (15 mL). The reaction was stirred at 120 °C for 4 hours and then cooled to room temperature overnight. The mixture was diluted with H₂O and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 2% to 10% MeOH/CH₂Cl₂, afforded the title compound (0.400 g, 46%) as a yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.78 (br s, 1H), 8.10 (d, *J* = 8.9 Hz, 2H), 7.05 (d, *J* = 9.0 Hz, 2H), 6.68 (d, *J* = 2.3 Hz, 1H), 6.46 (d, *J* = 2.3 Hz, 1H), 4.01-4.64 (m, 2H), 3.71-3.95 (m, 8H), 2.87-3.07 (m, 2H), 2.06 (s, 3H), 1.25 (d, *J* = 6.2 Hz, 6H). ESI MS *m/z* 437 [M+H]⁺.

Example 37. Preparation of 2-(4-((3R,5S)-3,5-Dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0228] A solution of 2-(4-(4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.150 g, 0.34 mmol) in 2N HCl was heated at reflux temperature for 3 days. The reaction was cooled to room temperature, basified with 1N NaOH, and extracted with CH₂Cl₂. Purification by flash chromatography on silica gel, eluting with 0% to 15% MeOH/CH₂Cl₂, followed by further purification, eluting with 30% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH, afforded the title compound (0.040 g, 30%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.98 (br s, 1H), 8.08 (d, *J* = 9.0 Hz, 2H), 7.00 (d, *J* = 9.0 Hz, 2H), 6.68 (d, *J* = 2.3 Hz, 1H), 6.46 (d, *J* = 2.3 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.73-3.76 (m, 2H), 2.78-2.81 (m, 2H), 2.19-2.26 (m, 2H), 1.03 (d, *J* = 6.2 Hz, 6H). ESI MS *m/z* 395 [M+H]⁺.

Example 38. Preparation of 2-(4-(4-Acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0229] To a solution of 4-fluorobenzaldehyde (2.0 g, 16.1 mmol) in DMF (10 mL) was added 2-methylpiperazine (1.9 g, 19.3 mmol) and K_2CO_3 (2.7 g, 19.3 mmol). The reaction was heated at 120 °C for 6 hours, diluted with H_2O , and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*, to afford 4-(3-methylpiperazin-1-yl)benzaldehyde (2.3 g, 69%): ^1H NMR (300 MHz, $CDCl_3$): δ 9.77 (s, 1H), 7.75 (d, $J = 9.0$ Hz, 2H), 6.90 (d, $J = 9.0$ Hz, 2H), 3.67-3.83 (m, 2H), 3.07-3.18 (m, 1H), 2.81-3.06 (m, 3H), 2.50-2.62 (m, 1H), 1.46-1.73 (br s, 1H), 1.15 (d, $J = 6.3$ Hz, 3H). ESI MS m/z 205 $[M+H]^+$.

[0230] A solution of 4-(3-methylpiperazin-1-yl)benzaldehyde (1.0 g, 4.89 mmol) in methylene chloride (15 mL) was cooled to 0 °C and treated with Et_3N (0.68 mL, 4.89 mmol), followed by acetyl chloride (0.34 mL, 4.89 mmol). The resulting solution was stirred at 0 °C for 20 minutes and then concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 0% to 5% of EtOAc/ CH_2Cl_2 , to afford 4-(4-acetyl-3-methylpiperazin-1-yl)benzaldehyde (0.88 g, 73%).

[0231] To a solution of 4-(4-acetyl-3-methylpiperazin-1-yl)benzaldehyde (0.400 g, 1.62 mmol) in DMA (15 mL) was added 2-amino-4,6-dimethoxybenzamide (0.349 g, 1.78 mmol), $NaHSO_3$ (0.201 g, 1.94 mmol) and *p*-TsOH (0.030 g, 0.16 mmol). The resulting solution was heated to 155 °C for 5 hours. The mixture was cooled to room temperature, diluted with water, extracted with CH_2Cl_2 , washed with brine, dried (Na_2SO_4), filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 50% to 100% of 92:7:1 $CHCl_3$ /MeOH/concentrated NH_4OH in CH_2Cl_2 , to afford the title compound (0.150 g, 21%). ^1H NMR (300 MHz, $DMSO-d_6$): mixture


of rotamers δ 11.57 (s, 1H), 8.10 (d, J = 8.9 Hz, 2H), 6.90-7.14 (m, 2H), 6.68 (s, 1H), 6.46 (s, 1H), 4.42-4.75 (m, 0.5H), 4.03-4.42 (m, 1H), 3.61-4.02 (m, 8H), 3.41-3.60 (m, 1H), 2.85-3.13 (m, 2H), 2.63-2.85 (m, 0.5H), 1.88-2.13 (m, 3H), 1.04-1.31 (m, 3H). ESI MS m/z 423 $[M+H]^+$.

Example 39. Preparation of N-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide



[0232] A solution of 2-(4-(3-aminopyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.150 g, 0.41 mmol) in CH_2Cl_2 (10 mL) was treated with Et_3N (0.114 mL, 0.82 mmol), cooled to 0 °C, and acetyl chloride (0.029 mL, 0.41 mmol) was added. The mixture was stirred for 2 hours at room temperature, concentrated, and purified by flash chromatography on silica gel, eluting with 1:1 CH_2Cl_2 /92:7:1 CHCl_3 /MeOH/concentrated NH_4OH to 100% 92:7:1 CHCl_3 /MeOH/concentrated NH_4OH . The mixture was further purified by flash chromatography on silica gel, eluting with 9:1 methylene chloride/methanol, to afford the title compound (0.130 g, 78%) as a yellow solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.67 (s, 1H), 8.18 (d, J = 6.8 Hz, 1H), 8.14 (d, J = 6.8 Hz, 2H), 6.66 (d, J = 2.3 Hz, 1H), 6.60 (d, J = 9.0 Hz, 2H), 6.44 (d, J = 2.3 Hz, 1H), 4.36-4.39 (m, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.13-3.59 (m, 5H), 2.15-2.22 (m, 1H), 1.90-1.94 (m, 1H), 1.82 (s, 3H). ESI MS m/z 409 $[M+H]^+$.


Example 40. Preparation of 2-(4-(4-Isopropylpiperazin-1-yl)phenyl)-8-methoxyquinazolin-4(3H)-one



[0233] To a solution of 2-amino-3-methoxy benzoic acid (2.0 g, 11.90 mmol) in THF (30 mL) was added EDCI (2.7 g, 14.3 mmol), HOBT (1.9 g, 14.3 mmol) and NMM (1.6 mL, 14.3 mmol). The reaction was stirred at room temperature for 2 hours and then NH_4OH (1 mL) in H_2O (1 mL) was added. After stirring overnight, the reaction was diluted with H_2O and extracted with CH_2Cl_2 . The organics were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. The solids were suspended in Et_2O and filtered off to afford 2-amino-3-methoxybenzamide (1.1 g, 56%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.71 (br s, 1H), 7.19 (d, $J = 8.1$ Hz, 1H), 7.08 (br s, 1H), 6.87 (d, $J = 7.1$ Hz, 1H), 6.45-6.53 (m, 1H), 6.26 (br s, 2H), 3.78 (s, 3H).

[0234] A mixture of 4-(4-isopropylpiperazin-1-yl)benzaldehyde (0.562 g, 2.40 mmol), NaHSO_3 (0.310 g, 2.90 mmol), and *p*-TsOH (0.046 g, 0.24 mmol) was added to a solution of 2-amino-3-methoxybenzamide (0.400 g, 2.40 mmol) in DMA (15 mL). The reaction was stirred at 120 °C overnight. The mixture was diluted with H_2O and saturated NaHCO_3 and extracted with CH_2Cl_2 . The organics were washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel eluting with 0% to 10% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ afforded the title compound (0.140 g, 15%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 12.27 (s, 1H), 8.10 (d, $J = 8.9$ Hz, 2H), 7.64-7.70 (m, 1H), 7.31-7.39 (m, 2H), 7.03 (d, $J = 9.1$ Hz, 2H), 3.93 (s, 3H), 3.27-3.32 (m, 4H), 2.64-2.75 (m, 1H), 2.56-2.59 (m, 4H), 1.00 (d, $J = 6.6$ Hz, 6H). ESI MS m/z 379 $[\text{M}+\text{H}]^+$.

Example 41. Preparation of N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-isopropylacetamide



[0235] To the solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (5.0 g, 25.09 mmol) in methanol (35 mL) was added isopropylamine (1.07 mL, 12.54 mmol), acetic acid (0.94 mL, 16.30 mmol) and sodium cyanoborohydride (1.0 g,

16.30 mmol). The resulting solution was stirred at room temperature for 1 hour, then quenched with water. The solution was concentrated *in vacuo* and redissolved in ethyl ether. The organics were extracted with 0.1 N HCl. The aqueous extracts were basified with 1 N NaOH (pH > 8) and extracted with ethyl ether. The organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*, to afford *tert*-butyl 4-(isopropylamino)piperidine-1-carboxylate (1.2 g, 41%) as a clear liquid.


[0236] To a 0 °C solution of *tert*-butyl 4-(isopropylamino)piperidine-1-carboxylate (1.2 g, 5.19 mmol) in CH₂Cl₂ (18 mL) was added Et₃N (1.44 mL, 10.38 mmol) followed by acetyl chloride (0.55 mL, 7.78 mmol). The resulting solution was stirred for 2.5 hours, then concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 0% to 5% of EtOAc/CH₂Cl₂, to afford *tert*-butyl 4-(*N*-isopropylacetamido)piperidine-1-carboxylate (0.88 g, 59%).

[0237] A solution of *tert*-butyl 4-(*N*-isopropylacetamido)piperidine-1-carboxylate (0.880 g, 3.09 mmol) in hydrogen chloride (4.0 M solution in 1,4-dioxane, 10 mL) was stirred at room temperature overnight. The resulting solution was concentrated *in vacuo*, basified with aqueous saturated NaHCO₃, and extracted with EtOAc. The organics were dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 50% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂. The residue was further purified by flash chromatography on silica gel, eluting with 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH, to afford *N*-Isopropyl-*N*-(piperidin-4-yl)acetamide hydrogen chloride (0.260 g, 45%) as a clear liquid.

[0238] To a solution of *N*-isopropyl-*N*-(piperidin-4-yl)acetamide hydrogen chloride (0.260 g, 1.41 mmol) in DMF (5 mL) was added 4-fluorobenzaldehyde (0.18 mL, 1.69 mmol) and K₂CO₃ (0.233 g, 1.69 mmol). The resulting solution was heated to 120 °C overnight, and cooled. The cooled solution was diluted with water and extracted with CH₂Cl₂. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 0% to 5% MeOH/CH₂Cl₂, to afford *N*-(1-(4-formylphenyl)piperidin-4-yl)-*N*-isopropylacetamide (0.290 g, 71%).

[0239] To a solution of *N*-(1-(4-formylphenyl)piperidin-4-yl)-*N*-isopropylacetamide (0.300 g, 1.04 mmol) in DMA (10 mL) was added 2-amino-4,6-dimethoxybenzamide (0.204 g, 1.04 mmol), NaHSO₃ (0.129 g, 1.24 mmol) and *p*-TsOH (0.019 g, 0.10 mmol). The resulting solution was heated to 155 °C overnight and then cooled to room temperature. The solution was diluted with water, extracted with CH₂Cl₂, washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel eluting, with 30% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, to afford the title compound (0.100 g, 20%). ¹H NMR (300 MHz, DMSO-*d*₆): mixture of rotamers δ 11.66 (s, 1H), 8.07 (d, *J* = 8.3 Hz, 2H), 6.89-7.15 (m, 2H), 6.67 (s, 1H), 6.46 (s, 1H), 3.90-4.11 (m, 3H), 3.88 (s, 3H), 3.83 (s, 3H), 2.80-3.02 (m, 2H), 2.39-2.66 (m, 1H), 1.92-2.06 (m, 3H), 1.63-1.82 (m, 2H), 1.32-1.47 (m, 1H), 1.21-1.32 (m, 3H), 1.08-1.21 (m, 4H). ESI MS *m/z* 463 [M-H]⁻.


Example 42. Preparation of 5-Chloro-2-(4-(4-isopropylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one



[0240] A solution of 2-amino-6-chlorobenzamide (0.314 g, 1.85 mmol) and 4-(4-isopropylpiperazin-1-yl)benzaldehyde (0.430 g, 1.85 mmol) in DMA (25 mL) were treated with *p*-TsOH (0.035 g, 0.185 mmol) and NaHSO₃ (0.212 g, 2.04 mmol), and the mixture was heated at 140 °C for 18 hours. Then, the mixture was cooled, diluted with CH₂Cl₂ (200 mL), and washed with saturated NaHCO₃ (100 mL). The organic phase was dried over anhydrous MgSO₄, filtered, concentrated, and purified by silica gel chromatography, eluting with 1:1 CH₂Cl₂/92:7:1 CHCl₃/MeOH/ concentrated NH₄OH to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH to 100% 6:3:1 CHCl₃/MeOH/concentrated NH₄OH. The resulting solids were rechromatographed with 9:1 CH₂Cl₂/MeOH to afford the title compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.24 (br s, 1H), 8.11 (d, *J* = 8.8 Hz,

2H), 7.66-7.71 (m, 1H), 7.59 (d, $J = 7.9$ Hz, 1H), 7.42 (d, $J = 7.4$ Hz, 1H), 7.03 (d, $J = 8.6$ Hz, 2H), 3.28-3.34 (m, 4H), 2.64-2.73 (m, 1H), 2.55-2.59 (m, 4H), 1.01 (d, $J = 6.4$ Hz, 6H). ESI MS m/z 383 $[M+H]^+$.


Example 43. Preparation of 2-(4-((3R,5S)-4-isopropyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0241] To a mixture of 4-(3,5-dimethylpiperazin-1-yl)benzaldehyde (1.0 g, 4.6 mmol) and K_2CO_3 (1.3 g, 9.2 mmol) in CH_3CN (10 mL) was added 2-iodopropane (2.3 mL, 22.9 mmol) and the reaction was stirred at reflux temperature overnight. Additional 2-iodopropane (2.3 mL, 22.9 mmol) and K_2CO_3 (1.3 g, 9.2 mmol) were added and the reaction was continued to reflux overnight. The mixture was concentrated *in vacuo* and purified by flash chromatography on silica gel, eluting with 1% to 10% MeOH/ CH_2Cl_2 , to afford 4-(4-isopropyl-3,5-dimethylpiperazin-1-yl)benzaldehyde (0.550 g, 46%).


[0242] A mixture of 4-(4-isopropyl-3,5-dimethylpiperazin-1-yl)benzaldehyde (0.400 g, 1.50 mmol), $NaHSO_3$ (0.195 g, 1.80 mmol), and *p*-TsOH (0.030 g, 0.15 mmol) was added to a solution of 2-amino-4,6-dimethoxybenzamide (0.400 g, 2.40 mmol) in DMA (10 mL). The reaction was stirred at 140 °C for 4 hours, then at room temperature overnight. The mixture was diluted with H_2O and extracted with CH_2Cl_2 . The organics were washed with brine, dried (Na_2SO_4), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 1% to 10% MeOH/ CH_2Cl_2 , followed by reverse-phase chromatography, eluting with 10% to 90% CH_3CN in H_2O , afforded the title compound (0.114 g, 17%). ^1H NMR (300 MHz, $DMSO-d_6$): δ 11.68 (s, 1H), 8.09 (d, $J = 8.9$ Hz, 2H), 6.78 (d, $J = 9.0$ Hz, 2H), 6.66 (s, 1H), 6.44 (s, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.41-3.44 (m, 2H), 3.11-3.23 (m, 5H), 1.00-1.03 (m, 12H). ESI MS m/z 437 $[M+H]^+$.

Example 44. Preparation of 5,7-Dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3H)-one



[0243] To a solution of *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate (0.210 g, 0.45 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in 1,4-dioxane (1 mL). The resulting solution was stirred at room temperature for 5 hours. Then, the mixture was concentrated *in vacuo* and the resulting material was purified by flash chromatography on silica gel, eluting with 0% to 10% of MeOH/CH₂Cl₂. The residue was further purified by flash chromatography on silica gel, eluting with 100% of 92:7:1 CHCl₃/MeOH /concentrated NH₄OH followed by 100% of 6:3:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (0.030 g, 18%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.11 (d, *J* = 8.3 Hz, 2H), 7.37 (d, *J* = 8.2 Hz, 2H), 6.73 (s, 1H), 6.53 (s, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 2.92-3.20 (m, 2H), 2.56-2.81 (m, 3H), 2.35-2.57 (m, 2H), 1.67-1.88 (m, 2H), 1.38-1.67 (m, 2H). ESI MS *m/z* 366 [M+H]⁺.


Example 45. Preparation of 5,7-Dimethoxy-2-(4-(3-(methylamino)pyrrolidin-1-yl)phenyl)quinazolin-4(3H)-one



[0244] A mixture of *N*-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)-*N*-methylacetamide (0.500 g, 1.18 mmol) and 2 N HCl (80 mL) was heated at 100 °C for 4 hours, cooled, basified to pH 9, extracted with CH₂Cl₂ (2×200 mL), dried (MgSO₄), filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 1:1 CH₂Cl₂/92:7:1 CHCl₃/MeOH/concentrated NH₄OH to 100% 92:7:1 CHCl₃/MeOH/concentrated NH₄OH to 6:3:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (0.210 g, 47%) as a pale yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.65 (br

s, 1H), 8.08 (d, $J = 8.7$ Hz, 2H), 6.65 (s, 1H), 6.55 (d, $J = 7.8$ Hz, 2H), 6.43 (s, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.46-3.49 (m, 1H), 3.38-3.42 (m, 1H), 3.26-3.28 (m, 2H), 3.07-3.10 (m, 1H), 2.31 (s, 3H), 2.08-2.11 (m, 1H), 1.81-1.84 (m, 1H). ESI MS m/z 381 $[M+H]^+$.

Example 46. Preparation of Tert-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate




[0245] A solution of 2-(4-bromophenyl)-5,7-dimethoxyquinazolin-4(3H)-one (1.1 g, 3.23 mmol), K_2CO_3 (1.3 g, 9.69 mmol), $PdCl_2(dppf)$ (0.261 g, 0.32 mmol) and *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.0 g, 3.23 mmol) in DMF (50 mL) was heated to 110 °C overnight. The resulting solution was concentrated *in vacuo* and the material was purified twice by flash chromatography on silica gel, eluting with 0% to 5% of MeOH/ CH_2Cl_2 . The residue was further purified by flash chromatography on silica gel, eluting with 10% to 50% of EtOAc/ CH_2Cl_2 , to afford *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (0.030 g, 49%) as a light yellow solid.

[0246] A solution of *tert*-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (0.160 g, 0.34 mmol) in EtOH (10 mL) and HOAc (5 mL) was purged with nitrogen, and 10% Pd/C (0.016 g) was added. The mixture was stirred under 1 atmosphere of hydrogen overnight. Then, the solution was filtered through Celite, with MeOH washings, and the filtrate was concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 30% to 70% of 92:7:1 $CHCl_3$ /MeOH/ concentrated NH_4OH in CH_2Cl_2 , to afford the title compound (0.160 g, 100%). ^1H NMR (300 MHz, $DMSO-d_6$): δ 11.91 (s, 1H), 8.11 (d, $J = 8.3$ Hz, 2H), 7.40 (d, $J = 8.5$ Hz, 2H), 6.73 (s, 1H), 6.53 (s, 1H), 4.00-4.22 (m, 2H), 3.89 (s, 3H),

3.85 (s, 3H), 2.65-2.97 (m, 3H), 1.68-1.88 (m, 2H), 1.48-1.68 (m, 2H), 1.42 (s, 9H). ESI MS m/z 466 $[M+H]^+$.


Example 47. Preparation of *N*-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)-*N*-methylacetamide



[0247] A solution of 4-fluorobenzaldehyde (2.01 g, 16.2 mmol) and *N*-methyl-*N*-(pyrrolidin-3-yl)acetamide (1.92 g, 13.5 mmol) in DMF (20 mL) was treated with K_2CO_3 (2.24 g, 16.2 mmol). The mixture was heated at 120 °C under nitrogen for 18 hours, cooled to room temperature, diluted with ethyl acetate (150 mL), washed with brine, dried (Na_2SO_4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 100% ethyl acetate to 10% methanol/ethyl acetate, to afford *N*-(1-(4-formylphenyl)pyrrolidin-3-yl)-*N*-methylacetamide.


[0248] A solution of 2-amino-4,6-dimethoxybenzamide (0.797 g, 4.07 mmol) and *N*-(1-(4-formylphenyl)pyrrolidin-3-yl)-*N*-methylacetamide (1.0 g, 4.07 mmol) in DMA (75 mL) was treated with $NaHSO_3$ (0.466 g, 4.5 mmol) and *p*-TsOH (0.078 g, 0.41 mmol). The mixture was heated at 150 °C for 15 hours, cooled to room temperature, diluted with CH_2Cl_2 (200 mL), and washed with saturated $NaHCO_3$ (100 mL) and water (200 mL). The organic phase was dried over anhydrous $MgSO_4$, filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 1:1 CH_2Cl_2 /92:7:1 $CHCl_3$ /MeOH/concentrated NH_4OH to 100% 92:7:1 $CHCl_3$ /MeOH/concentrated NH_4OH , to afford the title compound (1.5 g, 88%) as a light brown solid. ^1H NMR (300 MHz, $DMSO-d_6$): δ 11.68 (s, 1H), 8.10 (d, J = 8.8 Hz, 2H), 6.55-6.67 (m, 3H), 6.44 (d, J = 2.2 Hz, 1H), 4.67-5.22 (m, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.43-3.60 (m, 2H), 3.22-3.26 (m, 2H), 2.76-2.89 (m, 3H), 1.91-2.27 (m, 5H). ESI MS m/z 423 $[M+H]^+$.

Example 48. Preparation of 2-(4-(4-(isopropylamino)piperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0249] A solution of *N*-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-*N*-isopropylacetamide (0.130 g, 0.27 mmol) in 2 N HCl (8 mL) was heated to reflux and stirred overnight. The resulting solution was cooled to room temperature, basified with 2 N NaOH (pH 14), and extracted with CH₂Cl₂. The solution was concentrated *in vacuo* and the residue was purified by flash chromatography on silica gel, eluting with 30% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, to afford the title compound (0.060 g, 52%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.07 (d, *J* = 9.0 Hz, 2H), 6.99 (d, *J* = 9.1 Hz, 2H), 6.67 (s, 1H), 6.46 (s, 1H), 3.75-3.95 (m, 8H), 2.81-2.99 (m, 3H), 2.69-2.79 (m, 1H), 1.79-1.92 (m, 2H), 1.14-1.37 (m, 3H), 0.97 (d, *J* = 6.1 Hz, 6H). ESI MS *m/z* 423 [M+H]⁺.

Example 49. Preparation of 5,7-Dimethoxy-2-(4-(3-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one



[0250] A solution of 2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.340 g, 0.80 mmol) in 2 N HCl (5 mL) was heated to reflux and stirred for 3 days. Then, the resulting solution was cooled to room temperature, basified with 2 N NaOH, extracted with CH₂Cl₂, and concentrated *in vacuo*. The material was purified by flash chromatography on silica gel, eluting with 50% to 100% of 92:7:1 CHCl₃/MeOH/concentrate NH₄OH in CH₂Cl₂, to afford the title compound (0.03 g, 9%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.76 (s, 1H), 8.08 (d, *J* = 8.9 Hz, 2H), 6.99 (d, *J* = 9.1 Hz, 2H), 6.67 (s, 1H), 6.46 (s, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.62-3.79 (m, 2H), 2.90-3.04 (m, 1H), 2.57-2.85 (m, 4H), 2.20-2.39 (m, 1H), 1.03 (d, *J* = 6.3 Hz, 3H). ESI MS *m/z* 381 [M+H]⁺.

Example 50. Preparation of N-Benzyl-N-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide



[0251] To a solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (10.0 g, 50.2 mmol) and benzylamine (2.7 mL, 25.1 mmol) in MeOH (30 mL) was added HOAc (1.9 mL, 32.6 mmol), followed by NaCNBH₃ (2.0 g, 32.6 mmol) and the reaction was stirred at room temperature overnight. The resulting mixture was quenched with H₂O (5 mL) and concentrated *in vacuo*. The residue was diluted with 0.1 N HCl and washed with Et₂O. The aqueous layer was then basified with 2 N NaOH and extracted with Et₂O. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*, to afford *tert*-butyl 4-(benzylamino)piperidine-1-carboxylate (8.1 g, 56%).


[0252] To a solution of *tert*-butyl 4-(benzylamino)piperidine-1-carboxylate (8.1 g, 28.0 mmol) and Et₃N (7.8 mL, 56.0 mmol) in CH₂Cl₂ (100 mL) was added acetyl chloride (2.4 mL, 33.5 mmol) and the reaction was stirred at room temperature overnight, then concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 30% to 60% EtOAc/CH₂Cl₂, afforded *tert*-butyl 4-(*N*-benzylacetamido)piperidine-1-carboxylate (9.3 g, 99%).

[0253] A solution of *tert*-butyl 4-(*N*-benzylacetamido)piperidine-1-carboxylate (9.3 g, 28.0 mmol) in dioxane (20 mL) and 4 M HCl/dioxane (14.0 mL, 56.0 mmol) was stirred at room temperature overnight and then concentrated *in vacuo*. The residue was basified with 2 N NaOH and extracted with EtOAc. The organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated *in vacuo*, to afford *N*-benzyl-*N*-(piperidin-4-yl)acetamide (4.4 g, 67%).

[0254] To a solution of *N*-benzyl-*N*-(piperidin-4-yl)acetamide (1.5 g, 6.3 mmol) and 2-(6-chloropyridin-3-yl)-5,7-dimethoxyquinazolin-4(3*H*)-one (1.0 g, 3.2 mmol) in DMF (15 mL) was added K₂CO₃ (0.875 g, 6.3 mmol) and the reaction


was heated at reflux temperature overnight. The resulting mixture was concentrated *in vacuo* and purified by flash chromatography on silica gel, eluting with 1% to 10% MeOH/CH₂Cl₂, to afford the title compound (0.500 g, 30%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.84 (s, 1H), 8.86 (s, 1H), 8.22 (d, *J* = 9.2 Hz, 1H), 7.33-7.37 (m, 1H), 7.14-7.27 (m, 4H), 6.88-6.96 (m, 1H), 6.66 (d, *J* = 1.5 Hz, 1H), 6.46 (d, *J* = 1.5 Hz, 1H), 4.44-4.58 (m, 4.5H), 4.10-4.20 (m, 0.5H), 3.87 (s, 3H), 3.83 (s, 3H), 2.86-2.98 (m, 2H), 2.25 (s, 1.5H), 1.95 (s, 1.5H), 1.45-1.77 (m, 4H). ESI/APCI MS *m/z* 514 [M+H]⁺.

Example 51. Preparation of 2-(6-(4-(Benzylamino)piperidin-1-yl)pyridin-3-yl)-5,7-dimethoxyquinazolin-4(3H)-one




[0255] A solution of *N*-benzyl-*N*-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide (0.200 g, 0.39 mmol) in 2 N HCl (15 mL) was refluxed for 3 days. The resulting mixture was basified with 2 N NaOH and extracted with CH₂Cl₂. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 10% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, afforded the title compound (0.110 g, 60%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.11 (br s, 1H), 8.89 (d, *J* = 2.3 Hz, 1H), 8.22-8.26 (m, 1H), 7.28-7.37 (m, 4H), 7.18-7.23 (m, 1H), 6.91 (d, *J* = 7.2 Hz, 1H), 6.67 (d, *J* = 2.2 Hz, 1H), 6.46 (d, *J* = 2.2 Hz, 1H), 4.27-4.31 (m, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 3.76 (s, 2H), 3.00-3.11 (m, 2H), 2.62-2.69 (m, 1H), 1.88-1.91 (m, 2H), 1.25-1.31 (m, 2H). ESI MS *m/z* 472 [M+H]⁺.

Example 52. Preparation of 4-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperazine-1-carbaldehyde




[0256] A mixture of methyl formate (75 mL) and 5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one (0.300 g, 0.82 mmol) was heated at reflux for 48 hours. The mixture was concentrated, and purified by silica gel chromatography, eluting with 1:1 CH₂Cl₂/92:7:1 CHCl₃/MeOH/concentrated NH₄OH, to afford the title compound (0.320 g, 99%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.79 (br s, 1H), 8.10-8.19 (m, 3H), 7.06 (d, *J* = 9.1 Hz, 2H), 6.69 (d, *J* = 2.3 Hz, 1H), 6.48 (d, *J* = 2.3 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.46-3.59 (m, 4H), 3.32-3.38 (m, 4H). APCI MS *m/z* 393 [M-H]⁺.

Example 53. Preparation of 5,7-Dimethoxy-2-(4-(4-oxopiperidin-1-yl)phenyl)pyrido[2,3-*d*]pyrimidin-4(3H)-one



[0257] To a solution of 2-[4-(4-hydroxy-piperazin-1-yl)-phenyl]-5,7-dimethoxy-3H-pyrido[2,3-*d*]pyrimidin-4-one (160 mg, 0.418 mmol) in DMSO (4.0 mL), 1,2-benziodoxol-3(1H)-one-1-hydroxy-1-oxide (IBX) (178 mg, 0.635 mmol) was added and the reaction mixture was kept at 50 °C for 16 hours. Water was added and the precipitated solid was filtered to give crude product, which was purified by column chromatography (silica gel 230-400 mesh; eluting with 3% methanol in dichloromethane) to obtain the title compound as a yellow solid. Yield: 0.70 g (44.0%). MP > 350°C. ¹H NMR (400 MHz, CDCl₃): δ 12.15 (s, 1H), 8.18 (d, *J* = 9.2 Hz, 2H), 7.02 (d, *J* = 9.2 Hz, 2H), 6.33 (s, 1H), 3.95 (s, 3H), 3.90 (s, 3H), 3.77 (t, *J* = 6.4 Hz, 4H), 2.45 (t, *J* = 6.4 Hz, 4H).

Example 54. Preparation of 2-(2-(Hydroxymethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one




[0258] To a solution of *N*-(4-formyl-phenyl)-acetamide (1.25 g, 7.67 mmol) in trifluoroacetic acid (70 mL) was slowly added thallium(III)trifluoroacetate (5.00 g, 9.20 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Then, a solution of sodium iodide (1.19 g, 7.95 mmol) in water (10 mL) was added slowly. The color changed to dark purple and a lot of solid was formed. Stirring continued at room temperature for 16 hours. Solvent was evaporated to half of the volume, and water (50 mL) was added. The pH was adjusted to approximately 13 with 4 N NaOH solution. The mixture was extracted with ethyl acetate (2×100 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated on a rotary evaporator. The solid obtained was washed with ethyl acetate (2×5 mL), ether (2×10 mL), and dried under vacuum to give *N*-(4-formyl-2-iodo-phenyl)-acetamide as an off-white solid. Yield: 0.760 g (34%).

[0259] To a degassed solution of *N*-(4-formyl-2-iodo-phenyl)-acetamide (0.760 g, 2.63 mmol) in anhydrous DMF (20 mL) were added bis(triphenylphosphine)palladium(II) dichloride (90 mg, 0.13 mmol), copper (I) iodide (0.03 g, 0.13 mmol), 1,1,3,3-tetramethyl guanidine (1.51 g, 13.1 mmol), and propargyl alcohol (0.210 g, 3.68 mmol). The reaction mixture was stirred at room temperature for 2 hours and then at 80 °C for 24 hours under nitrogen. Solvent was evaporated under reduced pressure. Water (100 mL) was added and the mixture was extracted with ethyl acetate (200 mL). The organic phase was backwashed with water (2×100 mL), brine (100 mL), and dried over anhydrous Na₂SO₄. Solvent was evaporated and crude compound was purified by the Simpliflash system (60% ethyl acetate in hexanes as eluent) to give 2-hydroxymethyl-1*H*-indole-5-carbaldehyde as a pale yellow solid. Yield: 0.10 g (22%).

[0260] To a solution of 2-hydroxymethyl-1*H*-indole-5-carbaldehyde (90 mg, 0.51 mmol) and 2-amino-4,6-dimethoxy-benzamide (0.15 g, 0.77 mmol) in *N,N*-dimethylacetamide (5 mL) were added sodium hydrogen sulfite (58.5 wt%) (0.14 g, 0.77 mmol) and *p*-toluenesulfonic acid (20 mg, 0.10 mmol). The reaction

mixture was stirred at 120 °C for 16 hours under nitrogen, cooled to room temperature, and concentrated under reduced pressure. Water (20 mL) was added. The separated solid was filtered, washed with water (20 mL) and ether (20 mL), and dried under vacuum. Crude compound was purified by column chromatography (silica gel 230-400 mesh; 0-5% methanol in CH₂Cl₂ as eluent), to give the title compound as an off-white solid. Yield: 0.06 g (33%). MP 264-265°C. ¹H NMR (400 MHz, DMSO-d₆): δ 11.85 (br s, 1H), 11.36 (s, 1H), 8.39 (s, 1H), 7.93 (dd, *J* = 8.6 and 1.6 Hz, 1H), 7.44 (d, *J* = 9.0 Hz, 1H), 6.73 (d, *J* = 2.3 Hz, 1H), 6.49 (d, *J* = 2.4 Hz, 1H), 6.41 (s, 1H). 5.34 (t, *J* = 5.8 Hz, 1H), 4.63 (d, *J* = 5.5 Hz, 2H), 3.90 (s, 3H), 3.85 (s, 3H).

Example 55. Preparation of 2-(2-(2-Hydroxyethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one



[0261] To a stirred solution of 4-amino-3-iodo-benzoic acid methyl ester (11.1 g, 40.0 mmol) in pyridine (80 mL) was added acetyl chloride (3.30 g, 42.0 mmol) at 0 °C under nitrogen. Stirring continued at 0 °C for 30 minutes. The ice-bath was removed, and stirring continued at room temperature for 16 hours. Pyridine was evaporated under reduced pressure. The residue was taken in ethyl acetate (300 mL). The organic phase was washed with 2 N aqueous HCl (200 mL), water (200 mL), brine (200 mL), and then dried over anhydrous Na₂SO₄. Removal of solvent gave 4-acetylamino-3-iodo-benzoic acid methyl ester as a white solid. Yield: 12.71 g (99%).

[0262] Lithium aluminium hydride (2.43 g, 64.1 mmol) was taken in a dry, three-necked, round bottom flask. Anhydrous THF (80 mL) was added and cooled to -10 °C. A solution of 4-acetylamino-3-iodo-benzoic acid methyl ester (10.2 g, 32.0 mmol) in anhydrous THF (60 mL) was added dropwise at -10 °C over a period of 45 minutes under nitrogen. Stirring was continued at -10 °C for 1 hour. The reaction mixture was quenched with saturated sodium sulfate aqueous solution. The reaction mixture was then filtered, and the filtrate was concentrated.

The solid was washed with methanol. The combined organic phases were dried over anhydrous Na_2SO_4 . The solvent was evaporated. The crude compound was purified by the Simpliflash system (5% methanol in CH_2Cl_2 as eluent), to give *N*-(4-hydroxymethyl-2-iodo-phenyl)-acetamide as a white solid. Yield: 6.36 g (68%).

[0263] To a solution of IBX (0.93 g, 3.3 mmol) in dimethylsulfoxide (3.5 mL) was added *N*-(4-hydroxymethyl-2-iodo-phenyl)-acetamide (0.87 g, 3.0 mmol) and the reaction mixture was stirred at room temperature for 1 hour. Water (50 mL) was added and the solid was separated by filtration, and washed with ethyl acetate (20 mL). The filtrate was collected and extracted with ethyl acetate (200 mL). The organic phase was washed with brine (100 mL) and dried over anhydrous Na_2SO_4 . Removal of solvent gave *N*-(4-formyl-2-iodo-phenyl)-acetamide as a light brown solid. Yield: 0.82 g (95%).


[0264] To a degassed solution of *N*-(4-formyl-2-iodo-phenyl)-acetamide (0.810 g, 2.82 mmol) in DMF (25 mL) and triethylamine (5 mL) were added $\text{PdCl}_2(\text{PPh}_3)_2$ (0.10 g, 0.14 mmol) and copper (I) iodide (0.16 g, 0.85 mmol). A degassed solution of but-3-yn-1-ol (0.27 g, 0.29 mmol) in DMF (8 mL) and triethylamine (2 mL) was added at 80 °C over a period of 1 hour under nitrogen. After the addition, the reaction mixture was stirred at 80 °C for 4 hours, cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with ethyl acetate (200 mL). The organic phase was washed with brine (100 mL) and dried over anhydrous Na_2SO_4 . Removal of solvent gave *N*-[4-formyl-2-(4-hydroxy-but-1-ynyl)-phenyl]-acetamide as a brown solid. Crude yield: 0.85 g (100%). The crude material was used in next step without further purification.

[0265] To a solution of *N*-[4-formyl-2-(4-hydroxy-but-1-ynyl)-phenyl]-acetamide (0.85 g, approximately 2.80 mmol) in THF (20 mL) was added a THF solution of TBAF (6.0 mL, 6.0 mmol) and the reaction mixture was stirred at reflux for 36 hours under nitrogen and cooled to room temperature. Solvent was evaporated and the residue was taken in ethyl acetate (200 mL). The organic phase was washed with water (2×100 mL), brine (100 mL) and dried over anhydrous Na_2SO_4 . Solvent was evaporated; crude compound was purified by

simpliflash system (50% ethyl acetate in hexanes as eluent) to give 2-(2-hydroxy-ethyl)-1*H*-indole-5-carbaldehyde as yellow solid. Yield: 0.31 g (58% for two steps).

[0266] To a solution of 2-(2-hydroxy-ethyl)-1*H*-indole-5-carbaldehyde (0.300 g, 1.58 mmol) and 2-amino-4,6-dimethoxy-benzamide (0.370 g, 1.90 mmol) in *N,N*-dimethylacetamide (5 mL) were added sodium hydrogen sulfite (58.5 wt%) (0.350 g, 1.90 mmol) and *p*-toluenesulfonic acid monohydrate (60 mg, 0.32 mmol). The reaction mixture was stirred at 120 °C for 16 hours under nitrogen and cooled to room temperature. The solvent was evaporated under reduced pressure. Water (20 mL) was added and the solid was separated by filtration, washed with water (30 mL) and dried under vacuum. Crude compound was purified by the Simpliflash system (5:20:75 methanol / ethyl acetate / CH₂Cl₂ as eluent) to give the title compound as an off-white solid. Yield: 0.22 g (38%). MP 237-238°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.83 (br s, 1H), 11.20 (s, 1H), 8.34 (s, 1H), 7.90 (d, *J* = 8.2 Hz, 1H), 7.37 (d, *J* = 8.6 Hz, 1H), 6.73 (d, *J* = 1.9 Hz, 1H), 6.48 (d, *J* = 1.9 Hz, 1H), 6.30 (s, 1H), 4.81 (t, *J* = 5.1 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.75 (q, *J* = 6.63 Hz, 2H), 2.89 (t, *J* = 7.0 Hz, 2H).

Example 56. Preparation of 5,7-Dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1*H*-indol-5-yl)quinazolin-4(3*H*)-one



[0267] To a mixture of 5-bromo-1*H*-indole-2-carboxylic acid (1.0 g, 4.2 mmol), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (1.1 g, 5.9 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (0.62 g, 4.6 mmol) in THF (20 mL) was added 4-methylmorpholine (NMM) (0.65 mL, 5.9 mmol). After 10 minutes, pyrrolidine (0.73 mL, 8.8 mmol) was added. The mixture was stirred at room temperature under nitrogen for 17 hours. The solvent was removed under reduced pressure. Water was added, stirred for 0.5 hours. The solid was filtered, washed with water, and dried in air to afford (5-bromo-1*H*-indol-2-yl)-pyrrolidin-1-yl-methanone as a pale yellow solid. Yield: 1.2 g (95%).


[0268] To a suspension of (5-bromo-1*H*-indol-2-yl)-pyrrolidin-1-yl-methanone (0.53 g, 1.8 mmol) in THF (50 mL) at 0 °C was slowly added lithium aluminum hydride (0.20 g, 5.4 mmol). The mixture was stirred under nitrogen at 0 °C for a while and the cooling bath was allowed to warm to room temperature. The mixture was then stirred at room temperature for 17 hours. The reaction was quenched by careful, successive, dropwise addition of water (0.2 mL), 15% NaOH aqueous solution (0.2 mL), and water (0.6 mL). The solid was filtered and washed with MeOH and CH₂Cl₂. The filtrate was concentrated to dryness, and dried under vacuum, to give 5-bromo-2-pyrrolidin-1-ylmethyl-1*H*-indole as a white solid. Yield: 0.45 g (90%).

[0269] To a suspension of potassium hydride (30 wt% dispersion in mineral oil) (96 mg, 0.72 mmol) in ether (20 mL) at 0 °C was added 5-bromo-2-pyrrolidin-1-ylmethyl-1*H*-indole (0.20 g, 0.72 mmol). After stirring for 30 minutes, the reaction mixture was cooled to -78 °C, and *t*-BuLi solution (1.7 M in pentane; 0.93 mL, 1.58 mmol) was added. The mixture was stirred at -78 °C for 15 minutes, then at -20 °C for approximately 3 min, and then it was cooled down to -78 °C again. DMF was added. The mixture was stirred under nitrogen at -78 °C for a while and the cooling bath was allowed to warm to room temperature. Saturated NaHCO₃ aqueous solution (approximately 5 mL) was added. The mixture was extracted with dichloromethane. The organic solution was dried over Na₂SO₄, and concentrated to dryness to afford a mixture of the desired product and starting material, at about a 1:1 ratio, from the NMR spectrum. The crude product (approximately 0.2 g) was used for next reaction without any further purification.

[0270] A mixture of 2-amino-4,6-dimethoxy-benzamide (0.20 g, 1.0 mmol), crude 2-pyrrolidin-1-ylmethyl-1*H*-indole-5-carbaldehyde (0.23 g, 1.0 mmol), *p*-toluenesulfonic acid monohydrate (0.38 g, 2.0 mmol), and sodium bisulfite (0.42 g, 4.0 mmol) in *N,N*-dimethylacetamide (5 mL) was stirred at 115 °C under N₂ for 17 hours and cooled to room temperature. The mixture was diluted with saturated Na₂CO₃ aqueous solution and concentrated to dryness under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with CH₂Cl₂:7.0 M NH₃ in MeOH (95:5), to afford the title compound as a yellow solid. Yield: 87 mg (22%). MP 168-169.5 °C (decomposition). ¹H NMR (400 MHz, CDCl₃): δ 9.05 (s, 1H), 8.22 (s, 1H), 7.85 (d, 1H), 7.43 (d, 1H), 6.84 (s, 1H), 6.45

(s, 1H), 6.43 (s, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.81 (s, 2H), 2.57 (m, 4H), 1.81 (m, 4H).

Example 57. Preparation of 2-(3-(Hydroxymethyl)-1H-indazol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one



[0271] To a solution of sodium nitrite (20.0 g, 290.0 mmol) in THF (1000 mL) and water (50 mL) was added 1H-indole-5-carboxylic acid methyl ester (5.00 g, 28.5 mmol). The mixture was cooled to 0 °C and aqueous 6 N HCl (70 mL) was added dropwise at 0 °C. After stirring for 3 days at room temperature, solvent was evaporated, and extracted with ethyl acetate (3×200 mL). The combined organic phase was washed brine (200 mL) and dried over anhydrous Na₂SO₄. The solvent was evaporated. The residue was purified by the Simpliflash system (20-30% ethyl acetate in hexanes as eluent), to give 3-formyl-1H-indazole-5-carboxylic acid methyl ester as a yellow solid. Yield: 1.47 g, (25%).

[0272] To a solution of 3-formyl-1H-indazole-5-carboxylic acid methyl ester (0.37 g, 1.80 mmol) in anhydrous methanol (15 mL) was added sodium borohydride (68 mg, 1.80 mmol) in small portions at 0 °C. After the addition, the reaction mixture was stirred at 0 °C for 30 minutes. Solvent was evaporated; water (100 mL) was added and the mixture was extracted with ethyl acetate (150 mL). The organic phase was washed with brine (100 mL) and dried over anhydrous Na₂SO₄. Solvent was evaporated to give 3-hydroxymethyl-1H-indazole-5-carboxylic acid methyl ester as a yellow solid. Yield: 0.32 g (87%).

[0273] To a solution of 3-hydroxymethyl-1H-indazole-5-carboxylic acid methyl ester (0.32 g, 1.55 mmol) in a mixture of anhydrous dichloromethane and THF (2:1, 60 mL) was added pyridinium p-toluene sulfonate (0.08 g, 0.31 mmol) and then 3,4-dihydro-2H-pyran (0.19 g, 2.32 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours under nitrogen. Solvent was evaporated; water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL). The organic phase was washed with brine (100 mL) and dried

over anhydrous Na_2SO_4 . Removal of solvent gave 3-(tetrahydro-pyran-2-yloxymethyl)-1*H*-indazole-5-carboxylic acid methyl ester as a yellow gummy material. Yield: 0.55 g (crude). This product was used in next step without further purification.


[0274] 3-(Tetrahydro-pyran-2-yloxymethyl)-1*H*-indazole-5-carboxylic acid methyl ester (0.53 g crude, approximately 1.55 mmol) was taken in anhydrous THF (20 mL) and cooled to $-10\text{ }^\circ\text{C}$. A solution of lithium aluminium hydride (1.0 M solution in THF, 0.12 g, 3.10 mmol) was added drop-wise at $-10\text{ }^\circ\text{C}$ over a period of 15 minutes under nitrogen. Stirring continued at $-10\text{ }^\circ\text{C}$ for 1 hour and the reaction was then allowed to warm to room temperature and stirring continued at room temperature for 16 hours. The reaction mixture was carefully quenched with saturated aq. saturated ammonium chloride solution (100 mL). Then, reaction mixture was diluted with ethyl acetate (100 mL). The organic phase was separated, washed with brine (50 mL) and dried over anhydrous Na_2SO_4 . Solvent was evaporated to give [3-(tetrahydro-pyran-2-yloxymethyl)-1*H*-indazol-5-yl]-methanol as a yellow gummy material. Yield: 0.40 g (crude). This product was used in the next step without further purification.

[0275] To a solution of [3-(tetrahydro-pyran-2-yloxymethyl)-1*H*-indazol-5-yl]-methanol (0.40 g, 1.50 mmol) in DMSO (3 mL), IBX (0.42 g, 1.50 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours under nitrogen. Water (50 mL) was added; the separated solid was filtered, and the solid was washed with ethyl acetate (100 mL). The filtrate was collected and the organic phase was separated, washed with brine (100 mL), and dried over anhydrous Na_2SO_4 . Removal of solvent gave 3-(tetrahydro-pyran-2-yloxymethyl)-1*H*-indazole-5-carbaldehyde as an off-white solid. Yield: 0.33 g (84%).

[0276] To a solution of 3-(tetrahydro-pyran-2-yloxymethyl)-1*H*-indazole-5-carbaldehyde (0.32 g, 1.23 mmol) and 2-amino-4,6-dimethoxy-benzamide (0.24 g, 1.23 mmol) in *N,N*-dimethylacetamide (10 mL) were added NaHSO_3 (58.5 wt%, 0.27 g, 1.48 mmol) and *p*-toluenesulfonic acid monohydrate (0.05 g, 0.25 mmol); the reaction mixture was heated at $120\text{ }^\circ\text{C}$ for 16 hours, then cooled to room temperature. Solvent was removed under reduced pressure. The residue was diluted with water (100 mL). The separated solid was filtered and washed with water and dried under vacuum. The residue was purified by the Simpliflash

system (0-5% methanol in CH₂Cl₂ as eluent) to give the title compound as an off-white solid. Yield: 30 mg (7%). MP 264-266°C. ¹H NMR (400 MHz, CD₃OD): δ 8.60 (s, 1H), 8.10 (d, J = 8.98 Hz, 1H), 7.65 (d, J = 8.98 Hz, 1H), 6.85 (d, J = 1.95 Hz, 1H), 6.55 (d, J = 1.95 Hz, 1H), 5.05 (s, 2H), 3.96 (s, 6H).

Example 58. Preparation of 5,7-Dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one



[0277] To a stirred solution of 4-amino-3-iodo-benzoic acid methyl ester (11.1 g, 40.0 mmol) in anhydrous pyridine (80 mL) was added acetyl chloride (3.30 g, 42.0 mmol) at 0 °C under nitrogen. Stirring was continued at 0 °C for 30 minutes. The ice-bath was removed, and stirring continued at room temperature for 16 hours. Pyridine was evaporated under reduced pressure. The residue was taken in ethyl acetate (300 mL). The organic phase washed with 2 N aqueous HCl (200 mL), water (200 mL), brine (200 mL), and was dried over anhydrous Na₂SO₄. Removal of solvent gave 4-acetylamino-3-iodo-benzoic acid methyl ester as a white solid. Yield: 12.7 g (99%).

[0278] To but-3-yn-1-ol (40.0 g, 570.0 mmol) and 3,4-dihydro-2H-pyran (48.0 g, 570.0 mmol) in anhydrous dichloromethane (350 mL) was added pyridium p-toluenesulfonate (0.45 g, 1.80 mmol). The mixture was stirred at room temperature for 16 hours. Solvent was evaporated, and the residue was purified by vacuum distillation to give 2-but-3-ynyloxy-tetrahydro-pyran as a light yellow liquid. Yield: 60.0 g (68%).

[0279] To a degassed solution of 4-acetylamino-3-iodo-benzoic acid methyl ester (41.4 g, 130 mmol) in DMF (200 mL) and triethylamine (40 mL) were added PdCl₂(PPh₃)₂ (3.99 g, 5.68 mmol) and copper (I) iodide (7.43 g, 39.0 mmol). A degassed solution of 2-but-3-ynyloxy-tetrahydro-pyran (30.1 g, 195 mmol) in DMF (100 mL) and triethylamine (20 mL) was added at 80 °C over a period of 1 hour under nitrogen. After the addition, the reaction mixture was stirred at 80 °C for 2 hours and then cooled to room temperature. Solvent was evaporated under

reduced pressure. Ethyl acetate (200 mL) was added. The solid was filtered, and washed with ethyl acetate. The ethyl acetate solution was washed with brine, and dried over anhydrous Na₂SO₄. The organic phase was concentrated to dryness, to afford 66.8 g crude 4-acetylamino-3-[4-(tetrahydro-pyran-2-yloxy)-but-1-ynyl]-benzoic acid methyl ester. This was used in next step without further purification.

[0280] A solution of crude 4-acetylamino-3-[4-(tetrahydro-pyran-2-yloxy)-but-1-ynyl]-benzoic acid methyl ester (33.4 g, approximately 65 mmol) in anhydrous THF (300 mL) was mixed with a 1.0 M solution of tetrabutylammonium fluoride in THF (110 mL, 110 mmol); the reaction mixture was stirred at 90 °C for 4 hours under nitrogen, and then cooled to room temperature. Solvent was evaporated and the residue was taken in ethyl acetate (300 mL). The organic phase was washed with water (300 mL), brine (200 mL), and dried over anhydrous Na₂SO₄. The solvent was evaporated and the crude compound was purified by column chromatography on silica gel, eluting with hexanes and ethyl acetate (3:1), to give 2-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indole-5-carboxylic acid methyl ester. Yield: 14.9 g (76%).

[0281] Lithium aluminum hydride (3.38 g, 89.0 mmol) in anhydrous THF (100 mL) was cooled to -30 °C. 2-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indole-5-carboxylic acid methyl ester (13.5 g, 44.5 mmol) in anhydrous THF (100 mL) was added dropwise. The reaction mixture was stirred at -20 °C for 1 hour and then at room temperature for 4 hours. The reaction mixture was cooled to 0 °C and water (6 mL) was added slowly. Ammonium chloride solution (200 mL) was added and extracted with ethyl acetate (2×200 mL). The organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. The solvent was evaporated to give {2-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indol-5-yl}-methanol as a white solid. Yield: 11.50 g (94%).

[0282] {2-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indol-5-yl}-methanol (11.5 g 41.7 mmol) in anhydrous DMSO (45 mL) was added IBX (12.3 g, 43.8 mmol) and the reaction was stirred at room temperature for 2 hours. The reaction mixture was poured into water (300 mL) and extracted with ethyl acetate (300 mL), the organic phase was washed with water, then brine, and was purified by column chromatography on silica gel, eluting with dichloromethane, to give 2-[2-

(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indole-5-carbaldehyde as a white solid. Yield: 8.50 g (75%).


[0283] To a solution of 2-amino-4,6-dimethoxy-benzamide (6.10 g, 31.1 mmol) and 2-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indole-5-carbaldehyde (8.50 g, 31.1 mmol) in *N,N*-dimethylacetamide (45 mL) was added NaHSO₃ (58.5 wt%, 6.08 g, 34.2 mmol) and *p*-TSA (0.60 g, 3.11 mmol). The reaction mixture was heated at 115 °C for 16 hours and then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure, the residue was diluted with water (50 mL) and the solid was collected and mixed with dichloromethane (100 mL), ether (100 mL), and then filtered to give a mixture of 5,7-dimethoxy-2-{2-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indol-5-yl}-3*H*-quinazolin-4-one and 2-[2-(2-hydroxy-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid, which was used in next step without further purification. Yield: 7.50 g (crude).

[0284] A mixture of 5,7-dimethoxy-2-{2-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1*H*-indol-5-yl}-3*H*-quinazolin-4-one and 2-[2-(2-hydroxy-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one (7.50 g, 16.6 mmol) was dissolved in anhydrous methanol (60 mL). 1.0 M HCl in ether (42 mL) was added and the reaction was stirred at room temperature for 2 hours. The solid was filtered and the mother liquor was evaporated to dryness and the residue was combined with the solid. Sodium bicarbonate solution (200 mL) was added and stirred for 1 hours. The separated solid was filtered and washed with cold water and dried under vacuum to give 2-[2-(2-hydroxy-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 6.2 g (55%; 3 steps).

[0285] To a solution of 2-[2-(2-hydroxy-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one (6.20 g, 16.9 mmol) in anhydrous DMF (25 mL) was added carbon tetrabromide (6.47 g, 19.5 mmol) and triphenylphosphine (5.11 g, 19.5 mmol). The reaction mixture was stirred at 40 °C for 16 hours. DMF was removed under vacuum and water (150 mL) was added. The separated solid was filtered and mixed with ether (150 mL) and heated for 10 minutes. The solid was filtered and dried under vacuum to give 2-[2-(2-bromo-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 6.1 g (84%).

[0286] To a solution of 2-[2-(2-bromo-ethyl)-1*H*-indol-5-yl]-5,7-dimethoxy-3*H*-quinazolin-4-one (6.10 g, 14.2 mmol) in anhydrous DMF (45 mL) was added pyrrolidine (6.07 g, 85.4 mmol) and the reaction mixture was stirred at 45 °C for 15 hours. DMF was removed under reduced pressure, the residue was taken in water (150 mL), and stirred for 30 minutes. Separated solid was filtered, washed with water, and dried under vacuum. Crude compound was purified by column chromatography (silica gel 230-400 mesh, eluting with 5% 7.0 M ammonia in methanol solution in dichloromethane) to give the title compound as a white solid. Yield: 3.4 g (57%). MP 215-217°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.79 (s, 1H), 11.21(s, 1H), 8.31 (s, 1H), 7.88 (dd, *J* = 8.8 and 1.6 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 1H), 6.71 (d, *J* = 2.4 Hz, 1H), 6.46 (d, *J* = 2.4 Hz, 1H), 6.28 (s, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.89 (t, *J* = 8.0 Hz, 2H), 2.74 (t, *J* = 8.0 Hz, 2H), 2.48 (m, 4H), 1.67 (m, 4H).

Example 59. Preparation of 2-(2-((Dimethylamino)methyl)-1*H*-indol-5-yl)-5,7-dimethoxyquinazolin-4(3*H*)-one



[0287] To a solution of 5-bromo-1*H*-indole-2-carboxylic acid (2.40 g, 10.0 mmol) in THF (100 mL) were added EDCI (2.11 g, 30.0 mmol), HOBT (1.49 g, 11.0 mmol). The reaction mixture was stirred at room temperature for 10 minutes. Then, a solution of *N,N*-dimethyl amine (2.0 M solution in THF, 15 mL, 30.0 mmol) was added. The mixture was stirred for 16 hours at room temperature. Solvent was evaporated, the residue was taken in ethyl acetate (200 mL), and water (200 mL) was added. The organic phase was separated; the aqueous phase was extracted with ethyl acetate (200 mL). The combined organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. Solvent was evaporated and dried under vacuum to give 5-bromo-1*H*-indole-2-carboxylic acid dimethylamide as an off-white solid. Yield: 2.56 g (96%).

[0288] 5-Bromo-1*H*-indole-2-carboxylic acid dimethylamide (1.34 g, 5.00 mmol) was taken in anhydrous THF (50 mL) (suspension), and cooled to -20 °C. A


solution of lithium aluminium hydride (1.0 M solution in THF, 10.0 mL, 10.0 mmol) was added dropwise at -20 °C over a period of 15 minutes under nitrogen, and allowed to warm to 10 °C; stirring was continued at 10 °C for 1 hour. The reaction mixture was carefully quenched with aq. saturated ammonium chloride solution (10 mL). The reaction mixture was diluted with ethyl acetate (150 mL). The organic phase was separated, washed with water (100 mL), then brine (100 mL), and dried over anhydrous Na₂SO₄. Solvent was evaporated, to give (5-bromo-1*H*-indole-2-ylmethyl)-dimethyl amine as an off-white solid. Yield: 1.27 g (crude).

[0289] To a cold (0 °C) solution of potassium hydride (suspension in mineral oil, 0.79 g, 5.90 mmol) in anhydrous THF (60 mL) was added a solution of (5-bromo-1*H*-indole-2-ylmethyl)-dimethyl amine (1.24 g, 4.90 mmol) in anhydrous THF (20 mL) was added dropwise at 0 °C over a period of 15 minutes under nitrogen. Stirring was continued for 30 minutes at 0 °C, then cooled to -10 °C. *n*-Butyl lithium (1.6 M solution in hexanes, 7.4 mL, 11.7 mmol) was added rapidly. Stirring was continued at -10 °C for 1 h. Then, anhydrous DMF (5.0 mL) was added, and the mixture was allowed to warm to room temperature over 2 h. The reaction mixture was carefully quenched with 1N aq. HCl (10 mL). The reaction mixture was diluted with ethyl acetate (150 mL). The organic phase was separated, washed with water (100 mL), then brine (100 mL), and dried over anhydrous Na₂SO₄. The solvent was evaporated to give 2-dimethylaminomethyl-1*H*-indole-5-carbaldehyde as an orange-colored gummy material. Yield: 0.91 g (crude). This product was used in next step without further purification.

[0290] To a solution of 2-dimethylaminomethyl-1*H*-indole-5-carbaldehyde (0.88 g crude, 4.35 mmol) and 2-amino-4,6-dimethoxy-benzamide (0.85 g, 4.35 mmol) in *N,N*-dimethylacetamide (15 mL) were added sodium hydrogen sulfite (58.5 wt%, 0.95 g, 5.22 mmol) and *p*-toluenesulfonic acid (0.99 g, 5.22 mmol). The reaction mixture was stirred at 120 °C for 5 hours under nitrogen, then cooled to room temperature, and concentrated under reduced pressure. 30% aqueous sodium carbonate (50 mL) was then added. The separated solid was filtered, washed with water (50 mL), and dried under vacuum. Crude compound was purified by the Simpliflash system (0-5% methanol in CH₂Cl₂ and 7 N ammonia in methanol 5% in CH₂Cl₂ as eluent) to give the title compound as an off-white solid. Yield: 0.83 g (50%). MP 187-188 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.82 (s,

1H), 11.34 (s, 1H), 8.38 (s, 1H), 7.93 (d, $J = 8.59$ Hz, 1H), 7.40 (d, $J = 8.59$ Hz, 1H), 6.73 (s, 1H), 6.49 (s, 1H), 6.40 (s, 1H), 3.90 (s, 3H), 3.85 (s, 3H), 3.57 (s, 2H), 2.21 (s, 6H).


Example 60. Preparation of *N*-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)methanesulfonamide



[0291] A mixture of 4-bromobenzaldehyde (0.250 g, 1.40 mmol), methanesulfonamide (0.154 g, 1.62 mmol), copper iodide (0.0510 g, 0.270 mmol), *N,N*-dimethylglycine (0.0280 g, 0.270 mmol), and potassium phosphate tribasic (0.716 g, 3.38 mmol) in DMF (5.00 mL) was stirred at reflux for 16 hours. The mixture was diluted with EtOAc (50 mL), washed with water (50 mL), and then saturated aqueous LiCl (5 mL). The combined aqueous layers were then back-extracted with EtOAc (50 mL). The organic layers were combined, washed with brine (50 mL), dried over Na_2SO_4 , filtered, and the solvent was removed under reduced pressure, to provide *N*-(4-formylphenyl)methanesulfonamide (0.161 g, 58%) as a yellow oil.


[0292] A mixture of *N*-(4-formylphenyl)methanesulfonamide (0.161 g, 0.0800 mmol), 2-amino-4,6-dimethoxybenzamide (0.159 g, 0.0800 mmol), NaHSO_3 (94%, 0.00460 g, 0.0240 mmol), and *p*-TsOH $\cdot\text{H}_2\text{O}$ (0.0125 g, 0.120 mmol) in DMA (1.00 mL) was heated at 155 °C for 16 hours. The mixture was diluted with EtOAc (50 mL), washed with water (2 $\times$ 50 mL), then brine (50 mL), dried over Na_2SO_4 , filtered, and the solvent was removed under vacuum. The residue was purified over silica gel (12 g, $\text{CH}_2\text{Cl}_2/\text{MeOH}$) and the product was freeze-dried from MeCN/ H_2O to provide the title compound (0.0341 g, 11%) as a pale yellow solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.94 (s, 1H), 10.21 (s, 1H), 8.16 (d, $J = 8.76$ Hz, 2H), 7.30 (d, $J = 8.76$ Hz, 2H), 6.72 (d, $J = 2.25$ Hz, 1H), 6.52 (d, $J = 2.25$ Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.09 (s, 3H). MS (ESI) m/z 376 $[\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_5\text{S}+\text{H}]^+$.

Example 61. Preparation of 5,7-Dimethoxy-2-(4-(pyridin-4-ylamino)phenyl)quinazolin-4(3H)-one



[0293] A mixture of compound 2-(4-bromophenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.200 g, 0.554 mmol), 4-aminopyridine (0.0573 g, 0.609 mmol), $\text{Pd}_2(\text{dba})_3$ (0.0025 g, 0.0028 mmol), Xantphos (0.0018 g, 0.0031 mmol), and Cs_2CO_3 (0.253 g, 0.776 mmol) in 1,4-dioxane (2.22 mL) under nitrogen was heated at 105 °C for 2 days. The mixture was cooled to room temperature, diluted with EtOAc (200 mL), washed with water (3×75 mL), then brine (75 mL), dried over anhydrous Na_2SO_4 , filtered, and the solvent was removed under vacuum. The resulting residue was purified over silica gel (12 g, EtOAc/ CHCl_3 /MeOH/ NH_4OH), to provide the title compound as a white solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.90 (s, 1H), 9.19 (s, 1H), 8.29 (d, J = 6.29 Hz, 2H), 8.17 (d, J = 8.75 Hz, 2H), 7.30 (d, J = 8.75 Hz, 2H), 7.05 (d, J = 6.29 Hz, 2H), 6.72 (d, J = 2.26 Hz, 1H), 6.51 (d, J = 2.26 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H). MS (ESI) m/z 375 [$\text{C}_{21}\text{H}_{18}\text{N}_4\text{O}_3 + \text{H}$] $^+$.


Example 62. Preparation of 5,7-Dimethoxy-2-(4-(p-tolylamino)phenyl)quinazolin-4(3H)-one



[0294] To a mixture of $\text{Pd}(\text{OAc})_2$ (0.0112 g, 0.0166 mmol) and (S)-(-)-BINAP (0.0155 g, 0.0249 mmol) was added a degassed solution of toluene/ t -BuOH (5:1, 3.00 mL) and the mixture was heated at 100 °C for 1 minute. In a second flask, 2-(4-bromophenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.300 g, 0.831 mmol) and degassed toluene/ t -BuOH (5:1, 4.00 mL) was heated at 100 °C for 1 minute, t -BuOK (0.130 g, 1.17 mmol) was added, and the mixture heated until most of the solids dissolved. This mixture was then cooled, additional t -BuOK


(0.130 g, 1.17 mmol) was added, followed by *p*-toluidine (0.107 g, 0.997 mmol), the Pd catalyst/ligand mixture, and additional toluene/*t*-BuOH (5:1, 3.00 mL). The reaction was heated at 105 °C for 3 days, then cooled to room temperature, diluted with water (100 mL), and extracted with EtOAc (2×100 mL). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered, and the solvent was removed under vacuum. The resulting residue was purified over silica gel (4 g, CH₂Cl₂/MeOH) and the product was freeze-dried from MeCN/H₂O to provide the title compound (0.0212 g, 6%) as a yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.71 (s, 1H), 8.54 (s, 1H), 8.06 (d, *J* = 8.82 Hz, 2H), 7.18-6.99 (m, 6H), 6.67 (d, *J* = 2.21 Hz, 1H), 6.47 (d, *J* = 2.21 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 2.27 (s, 3H). MS (ESI) *m/z* 388 [C₂₃H₂₁N₃O₃+H]⁺.

Example 63. Preparation of 5,7-Dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one



[0295] A mixture of 2-(4-bromophenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.200 g, 0.55 mmol), 3-aminopyridine (0.057 g, 0.61 mmol), Cs₂CO₃ (0.253 g, 0.776 mmol), Xantphos (0.002 g, 0.003 mmol), and Pd₂(dba)₃ (0.003 g, 0.003 mmol) in dioxane (2 mL) were combined in a microwave tube under nitrogen and irradiated at 300 W, 105 °C for 30 minutes. Then, DMF (1 mL) was added and the flask was irradiated for 1 hour at 300 W, 105 °C. Then, the mixture was concentrated and purified by silica gel chromatography, eluting with 92:7:1 CHCl₃/MeOH/concentrated NH₄OH. The residue was further purified by reverse-phase HPLC, eluting with 10% to 90% CH₃CN in H₂O with 0.1% TFA, to afford the title compound (0.105 g, 51%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.83 (s, 1H), 8.82 (s, 1H), 8.44 (d, *J* = 2.4 Hz, 1H), 8.11-8.16 (m, 3H), 7.59-7.62 (m, 1H), 7.31-7.35 (m, 1H), 7.13 (d, *J* = 8.7 Hz, 2H), 6.68 (d, *J* = 1.8 Hz, 1H), 6.46 (d, *J* = 1.8 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H). APCI MS *m/z* 375 [M+H]⁺.

Example 64. Preparation of 4-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide




[0296] To a solution of 4-hydroxypiperidine (5.0 g, 49 mmol) in THF (70 mL) was added triethylamine (14.4 mL, 103 mmol) and dimethylcarbamy chloride (9.0 mL, 98 mmol) slowly. The mixture was stirred at room temperature for 1.5 hours. The white precipitate was filtered off, washed with THF. The THF solution was concentrated to dryness then purified with column chromatography (SiO₂, MeOH / CH₂Cl₂ = 1:19) to afford 4-hydroxypiperidine-1-carboxylic acid dimethylamide as colorless oil. Yield: 7.8 g (94%).

[0297] 4-Hydroxypiperidine-1-carboxylic acid dimethylamide (1.45 g, 8.40 mmol), 4-hydroxbenzenaldehyde (1.02 g, 8.40 mmol) and triphenylphosphine (3.31 g, 12.6 mmol) were stirred in THF (6 mL). Diisopropylazodicarboxylate (2.51 mL, 12.6 mmol) was added dropwise to the reaction mixture at room temperature over the course of 5 minutes. The mixture was stirred at room temperature for 21 hours, concentrated, and purified by column chromatography (SiO₂, hexanes / ethyl acetate = 1:1 to neat ethyl acetate), to afford 4-(4-formylphenoxy)-piperidine-1-carboxylic acid dimethylamide a white solid. Yield: 0.7 g (30%).

[0298] To a 100 mL round-bottom flask was added 2-amino-4,6-dimethoxybenzamide (196 mg, 1.00 mmol), 4-(4-formylphenoxy)-piperidine-1-carboxylic acid dimethylamide (300 mg, 1.10 mmol), *p*-toluenesulfonic acid monohydrate (21 mg, 0.10 mmol), sodium hydrogensulfite (216 mg, 1.20 mmol) and dimethylacetamide (5 mL). The mixture was stirred at 115 °C under N₂ for 17 hours and cooled to room temperature. Water (20 mL) was added and stirred for 0.5 hours. The precipitate was filtered off, washed with water, and air dried. The crude product was purified by column chromatography (SiO₂, neat ethyl acetate, then ethyl acetate / methanol = 19:1, then CH₂Cl₂ / methanol = 19:1) to afford the title compound as a white solid. Yield: 110 mg (24%). MP 248-249°C. ¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 8.15 (d, *J* = 8.8 Hz, 2H), 7.10 (d, *J* = 8.8 Hz, 2H), 6.72 (s, 1H), 6.51 (s, 1H), 4.71-4.69 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.44-3.39 (m, 2H), 3.06-2.99 (m, 2H), 2.74 (s, 6H), 2.00-1.96 (m, 2H), 1.64-1.59 (m, 2H).

Example 65. Preparation of 2-(4-(1-Acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0299] To a solution of 4-hydroxypiperidine (5.00 g, 49.4 mmol) in anhydrous THF (30 mL) and triethylamine (10 mL, 75 mmol) was added acetyl chloride (3.52 mL, 49.4 mmol). After the addition, the mixture was stirred for another 2 hours at room temperature. The solid formed was filtered and the mother liquid was concentrated to yield 5.0 g of crude product, which was purified by column chromatography on silica gel (230-400 mesh), using 5% methanol in dichloromethane as eluent, to give 1-(4-hydroxy-piperidin-1-yl)-ethanone. Yield: 2.40 g (34%).

[0300] To a solution of 1-(4-hydroxy-piperidin-1-yl)-ethanone (1.00 g, 6.90 mmol), 4-hydroxybenzaldehyde (0.854 g, 6.90 mmol) and triphenylphosphine (1.83 g, 6.90 mmol) in THF (10 mL) was added dropwise diisopropyl azodicarboxylate (DIAD) (1.41 g, 6.90 mmol). The reaction mixture was stirred at room temperature for 16 hours, THF was evaporated, and the residue was purified by column chromatography, using dichloromethane:ethyl acetate:methanol (1:2:0.05) as eluent, to give 4-(1-acetyl-piperidin-4-yloxy)-benzaldehyde. Yield: 0.40 g (23%).

[0301] To a solution of 2-amino-4, 6-dimethoxy-benzamide (0.20 g, 1.0 mmol) and 4-(1-acetyl-piperidin-4-yloxy)-benzaldehyde (0.25g, 1.0 mmol) in *N,N*-dimethyl acetamide (5 mL), NaHSO_3 (0.20g, 1.1 mmol) and *p*-TSA (20 mg, 0.10 mmol) were added and the reaction mixture was heated at 115 °C for 16 hours. The reaction mixture was cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure. The residue was diluted with water and the solid was collected; the crude product was purified by column chromatography on silica gel (230-400 mesh), using 5% methanol in CH_2Cl_2 as eluent, to give the title compound. Yield: 0.2 g (47%). MP 275-277°C. ^1H NMR (400 Hz, CDCl_3): δ 11.94 (s, 1H), 8.16 (d, 2H), 7.10 (d, 2H), 6.70 (d, 1H), 6.50 (d, 1H), 4.76 (m, 1H), 3.88 (s,


3H), 3.82 (s, 3H), 3.70 (m, 1H), 3.30 (m, 2H), 3.20 (m, 1H), 2.04 (s, 3H), 1.95 (m, 2H), 1.64 (m, 1H), 1.52 (m, 1H).

Example 66. Preparation of 2-(4-(2-(Isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0302] To a suspension of 2-[4-(2-bromoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.50 g, 1.15 mmol) in anhydrous DMF (9 mL) was added isoindoline (0.41 mL, 3.46 mmol) and the reaction mixture was stirred at room temperature for 16 hours under nitrogen. The solvent was removed under reduced pressure and the residue was triturated with water (50 mL). The separated solid was filtered, washed with water and ether, and dried under vacuum to give the title compound as a white solid. Yield: 0.45 g (83%). MP 202-202.5°C. ¹H NMR (400 MHz, CDCl₃): δ 10.09 (br s, 1H), 7.77 (s, 2H), 7.22 (br s, 4H), 6.83 (d, *J* = 2.4 Hz, 1H), 6.46 (d, *J* = 2.4 Hz, 1H), 4.11 (s, 4H), 4.03 (t, *J* = 6.0 Hz, 2H), 3.96 (s, 3H), 3.93 (s, 3H), 3.22 (t, *J* = 6.0 Hz, 2H), 2.42 (s, 6H).

Example 67. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one



[0303] To a stirred solution of 2-amino-6-methoxy-benzoic acid (3.00 g, 17.9 mmol) in THF (90 mL), EDCI (7.89 g, 41.1 mmol) and HOBt (7.95 g, 51.9 mmol) were added and stirred at room temperature for 30 minutes then *N*-methylmorpholine (6.15 g, 60.0 mmol) and aqueous 50% v/v NH₄OH (12 mL, 171.4 mmol) was added. The mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the residue was extracted with ethylacetate (4×100 mL), the combined organic phase was washed with water and brine, and dried over anhydrous sodium sulfate; the


solvent was evaporated to give 2-amino-6-methoxy-benzamide as an off-white solid. Yield: 1.90 g, (65%).

[0304] To a solution of 2-amino-6-methoxy-benzamide (1.00 g, 6.01 mmol) and 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (1.28 g, 6.59 mmol) in *N,N*-dimethylacetamide (15 mL) were added NaHSO₃ (58.5 wt%, 0.68 g, 6.50 mmol) and p-TSA (0.23 g, 1.20 mmol) and the reaction mixture was heated at 115 °C for 20 hours, and cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure. The residue was diluted with water (50 mL), stirred for 30 minutes, and then filtered. The solid was suspended in dichloromethane (30 mL), stirred for 1 h, filtered, and dried under vacuum to give 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 1.1 g (55%).

[0305] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3*H*-quinazolin-4-one (1.10 g, 3.20 mmol) in anhydrous *N,N*-dimethylformamide (16 mL) were added triphenylphosphine (0.92 g, 3.50 mmol) and carbontetrabromide (1.17 g, 3.50 mmol). The reaction mixture was stirred at room temperature for 16 hours. DMF was removed under reduced pressure. The residue was purified by column chromatography (silica gel 230-400 mesh; 3% methanol in dichloromethane as eluent) to give 2-[4(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 0.60 g (46%).

[0306] To a solution of 2-[4(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3*H*-quinazolin-4-one (0.50 g, 1.20 mmol) in *N,N*-dimethylformamide (10 mL) was added pyrrolidine (0.53 g, 7.40 mmol) and the reaction mixture was stirred at room temperature for 15 hours. DMF was removed under reduced pressure, the residue was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.25 g (52%). MP 157-158°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.95 (s, 1H), 7.89 (s, 2H), 7.70 (t, *J* = 8.19 Hz, 1H), 7.24 (d, *J* = 7.8 Hz, 1H), 6.99 (d, *J* = 8.1 Hz, 1H), 3.91-3.89 (m, 2H), 3.87 (s, 3H), 2.82 (t, *J* = 6.2 Hz, 2H), 2.53-2.50 (m, 4H), 2.30 (s, 6H), 1.69 (m, 4H). MS (ES⁺) *m/z*: 394.61(M+1).

Example 68. Preparation of 5,7-Dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one



[0307] To a solution of 2-amino-4,6-dichloro-benzoic acid (4.12 g, 20.0 mmol) in THF (120 mL) were added EDCI (4.22 g, 22.0 mmol), HOBt (2.70 g, 20.0 mmol) and N-methylmorpholine (2.22 g, 22.0 mmol). The reaction mixture was stirred at room temperature for 20 minutes, then 50% (v/v) aqueous NH_4OH solution (2.8 mL, 40.0 mmol) was added. The mixture was stirred for 20 hours at room temperature. The solvent was evaporated, the residue was taken in ethyl acetate (200 mL), and water (200 mL) was added. The organic phase was separated; the aqueous phase was extracted with ethyl acetate (200 mL). The combined organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. The solvent was evaporated and dried under vacuum to give 2-amino-4,6-dichloro-benzamide as an off-white solid. Yield: 3.83 g (93%).


[0308] To a solution of 2-amino-4,6-dichloro-benzamide (1.54 g, 7.50 mmol) and 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (1.46 g, 7.50 mmol) in N,N-dimethylacetamide (15 mL) were added sodium hydrogen sulfite (58.5 wt%, 1.51 g, 8.25 mmol) and p-toluenesulfonic acid monohydrate (0.28 g, 1.50 mmol). The reaction mixture was stirred at 120 °C for 16 hours under nitrogen, and then cooled to room temperature. Solvent was evaporated under reduced pressure. Water (100 mL) was added. The separated solid was filtered, washed with water (50 mL), and dried under vacuum. Crude compound was further washed with ether and dried under vacuum to give 5,7-dichloro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-3H-quinazolin-4-one as a white solid. Yield: 2.42 g (85%).

[0309] To a solution of 5,7-dichloro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethylphenyl]-3H-quinazolin-4-one (1.14 g, 3.00 mmol) in anhydrous DMF (15 mL) was added carbon tetrabromide (1.10 g, 3.30 mmol). Then,

triphenylphosphine (0.86 g, 3.30 mmol) was added in small portions. The reaction mixture was stirred at room temperature for 16 hours under nitrogen. Solvent was evaporated under reduced pressure. The residue was washed with ethyl acetate (50 mL) and dried under vacuum to give 2-[4-(2-bromo-ethoxy)-3,5-dimethylphenyl]-5,7-dichloro-3*H*-quinazolin-4-one as a white solid. Yield: 0.46 g (35%).

[0310] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethylphenyl]-5,7-dichloro-3*H*-quinazolin-4-one (0.44 g, 1.00 mmol) in anhydrous DMF (10 mL) was added pyrrolidine (0.28 g, 4.00 mmol). The reaction mixture was stirred at room temperature for 6 hours under nitrogen. Solvent was evaporated under reduced pressure. Water (50 mL) was added. The separated solid was filtered, washed with water (20 mL), and dried under vacuum. The crude compound was purified by the Simpliflash system (0-5% methanol in CH₂Cl₂ and 5% methanol (containing 7.0 M ammonia) in CH₂Cl₂ as eluent) to give the title compound as a white solid. Yield: 0.31 g (72%). MP 209-210°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.39 (br s, 1H), 7.90 (s, 2H), 7.71 (d, *J* = 1.95 Hz, 1H), 7.60 (d, *J* = 1.95 Hz, 1H), 3.91 (t, *J* = 5.85 Hz, 2H), 2.83 (t, *J* = 6.05 Hz, 2H), 2.55 (m, 4H), 2.31 (s, 6H), 2.01 (m, 4H). MS (ES+) *m/z* 432.54 (100%), 434.49 (90%).

Example 69. Preparation of 2-(3,5-Dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3*H*)-one




[0311] To a solution of 2-(4-hydroxy-3,5-dimethyl-phenyl)-5,7-dimethoxy-3*H*-quinazolin-4-one (0.70 g, 2.14 mmol) in anhydrous THF (50 mL) were added triphenyl phosphine (1.69 g, 6.43 mmol), 3-bromo-1-propanol (0.60 g, 4.34 mmol) and *N,N*-diisopropylethyl amine (0.42 g, 3.22 mmol). To this stirred solution was added diethyl azodicarboxylate (1.13 g, 6.43 mmol). The reaction mixture was stirred at room temperature for 48 hours under nitrogen. Ethyl acetate (400 mL)

was added; the organic phase was separated, washed with water (100 mL), then brine (100 mL), and dried over anhydrous Na_2SO_4 . Solvent was removed under reduced pressure. The crude material was purified by the Simpliflash system (5:95 ethyl acetate:hexane as eluent) to give 2-[4-(3-bromo-propoxy)-3,5-dimethyl-phenyl]-3-(3-bromo-propyl)-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 0.765 g (63%).

[0312] To a solution of 2-[4-(3-bromo-propoxy)-3,5-dimethyl-phenyl]-3-(3-bromo-propyl)-5,7-dimethoxy-3*H*-quinazolin-4-one (0.76 g, 1.35 mmol) in DMF (10 mL) were added pyrrolidine (0.77 g, 10.77 mmol). The reaction mixture was stirred at room temperature for 16 hours. Then, water was added and product was extracted with ethyl acetate (2×200 mL). The combined organic layer was washed with water, then brine, and dried over Na_2SO_4 . Solvent was evaporated to give the title compound as a white solid. Yield: 0.12 g (16%). MP 109-111°C. ^1H NMR (400 MHz, CDCl_3): δ 8.16 (s, 2H), 6.93 (d, J = 2.4 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 4.71 (t, J = 6.4 Hz, 2H), 3.94 (s, 3H), 3.93 (s, 3H), 3.87 (t, J = 6.0 Hz, 2H), 2.75 (m, 4H), 2.60 (m, 8H), 2.37 (s, 6H), 2.16 (m, 2H), 2.05 (m, 2H), 1.82 (m, 8H). MS (ES) m/z : 549.75 ($M+1$). Analysis calculated for $\text{C}_{32}\text{H}_{44}\text{N}_4\text{O}_4 \cdot 0.5\text{H}_2\text{O}$ (FW 557.73), %: C, 68.91; H, 8.13; N, 10.05. Found, %: C, 68.71; H, 8.56; N, 9.74.


Example 70. Preparation of 2-(4-(2-(4-Acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one



[0313] To a suspension of 2-[4-(2-bromoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.35 g, 0.81 mmol) in anhydrous DMF (9 mL) was added 1-acetylpiperazine (0.31 g, 2.42 mmol) and the reaction mixture was stirred at room temperature under nitrogen for 32 hours. Solvent was removed under reduced pressure and water (50 mL) was added. The separated solid was filtered, washed with water and ether, and dried under vacuum, to give the title compound as a white solid. Yield: 0.28 g (72%). MP 213-214°C. ^1H NMR (400 MHz, CDCl_3): δ 9.87 (br s, 1H), 7.74 (s, 2H), 6.83 (d, J = 2.4 Hz, 1H), 6.46 (d, J =


2.4 Hz, 1H), 3.97 (s, 3H), 3.95 (t, $J = 6.0$ Hz, 2H), 3.93 (s, 3H), 3.69 (t, $J = 5.0$ Hz, 2H), 3.53 (t, $J = 5.0$ Hz, 2H), 2.84 (t, $J = 5.6$ Hz, 2H), 2.62 (t, $J = 5.0$ Hz, 2H), 2.57 (t, $J = 5.0$ Hz, 2H), 2.39 (s, 6H), 2.11 (s, 3H). MS (ES⁻) m/z 479.65 (100%, M-1).

Example 71. Preparation of 2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0314] To a solution of 2-[4-(2-bromoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-3H-quinazolin-4-one (0.12 g, 0.27 mmol) in acetone (5 mL) was added imidazole (0.18 g, 2.70 mmol) and Cs₂CO₃ (0.26 g, 0.80 mmol). The reaction mixture was stirred at room temperature for 16 hours. Solvent was removed under reduced pressure, and the residue was purified by column chromatography (silica gel 230-400 mesh; 3% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.04 g (35%). MP 218-219°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.80 (br s, 1H), 7.83 (s, 2H), 7.72 (s, 1H), 7.29 (s, 1H), 6.92 (s, 1H), 6.70 (d, $J = 2.4$ Hz, 1H), 6.49 (d, $J = 2.4$ Hz, 1H), 4.36 (t, $J = 4.8$ Hz, 2H), 4.02 (t, $J = 4.8$ Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 2.06 (s, 6H). MS (ES) m/z : 419.57 (M-1).

Example 72. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one



[0315] To a stirred solution of 2-amino-4-methoxy-benzoic acid (3.00 g, 17.9 mmol) in THF (90 mL), EDCI (7.89 g, 41.1 mmol) and HOBt (7.95 g, 51.9 mmol) were added and stirred at room temperature for 30 minutes. Then, N-methylmorpholine (6.15 g, 60.0 mmol) and aqueous 50% (v/v) NH₄OH (12 mL, 171.4 mmol) were added. The mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the residue


was extracted with ethyl acetate (4×100 mL). The combined organic phase was washed with water, then brine, and dried over anhydrous sodium sulfate. Solvent was evaporated to give 2-amino-4-methoxy-benzamide as an off-white solid. Yield: 1.80 g, (60%).

[0316] To a solution of 2-amino-4-methoxy-benzamide (1.00 g, 6.01 mmol) and 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (1.28 g, 6.59 mmol) in *N,N*-dimethylacetamide (15 mL) were added NaHSO₃ (58.5 wt%, 0.68 g, 6.50 mmol) and p-TSA (0.23 g, 1.20 mmol) and the reaction mixture was stirred at 115 °C for 16 hours, and cooled to room temperature. Solvent was removed under reduced pressure. The residue was diluted with water (50 mL), stirred for 30 minutes, and then filtered. The solid was suspended in dichloromethane (30 mL), stirred for 1 hour, filtered, and dried under vacuum, to give 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-7-methoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 1.20 g (58%).

[0317] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-7-methoxy-3*H*-quinazolin-4-one (1.20 g, 3.52 mmol) in anhydrous DMF (15 mL) were added triphenylphosphine (1.00 g, 3.80 mmol) and carbontetrabromide (1.27 g, 3.80 mmol). The reaction mixture was stirred at room temperature for 16 hours. DMF was removed under reduced pressure. The residue was purified by column chromatography (silica gel 230-400 mesh; 3% methanol in dichloromethane as eluent) to give 2-[4(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-7-methoxy3*H*-quinazolin-4-one as an off-white solid. Yield: 0.37 g (26%).


[0318] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-7-methoxy-3*H*-quinazolin-4-one (0.30 g, 0.74 mmol) in DMF (5 mL) was added pyrrolidine (0.31 g, 4.36 mmol) and the reaction mixture was stirred at room temperature for 15 hours. DMF was removed under reduced pressure, and the residue was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.13 g (44%). MP 218-220°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.13 (br s, 1H), 8.03 (d, *J* = 8.98 Hz, 1H), 7.90 (s, 2H), 7.16 (d, *J* = 2.3 Hz, 1H), 7.07 (dd, *J* = 8.9 and 2.7 Hz, 1H), 3.92-3.89 (m, 5H), 2.83 (t, *J* = 5.8 Hz, 2H), 2.54-2.50 (m, 4H), 2.31 (s, 6H), 1.73 (m, 4H). MS (ES⁺) *m/z*: 394.62(M+1).

Example 73. Preparation of 2-(3,5-Dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0319] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.17 g, 0.39 mmol) in *N,N*-dimethylformamide (0.5 mL) was added *N*-methylpiperazine (0.44 mL, 3.92 mmol) and the reaction mixture was stirred at room temperature for 15 hours. *N,N*-dimethylformamide was removed under reduced pressure. The residue was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 60 mg (33.8%). MP 180-182°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.76 (s, 1H), 7.89 (s, 2H), 6.73 (d, *J* = 2.4 Hz, 1H), 6.51 (d, *J* = 2.4 Hz, 1H), 3.88 (m, 5H), 3.84 (s, 3H), 2.68 (t, *J* = 5.6 Hz, 2H), 2.50 (br s, 4H), 2.32 (br s, 4H), 2.30 (s, 6H), 2.15 (s, 3H). MS (ES⁺) *m/z*: 453.21 (M+1).


Example 74. Preparation of 2-(3,5-Dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0320] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.34 g, 0.78 mmol) in DMF (10 mL) was added piperidine (0.27 g, 3.14 mmol). The reaction mixture was stirred at room temperature for 16 hours. Then, water was added and the product was extracted with ethyl acetate (2×200 mL). The combined organic layer was washed with water, then brine, and dried over anhydrous Na₂SO₄. Solvent was evaporated to give the title compound as a white solid. Yield: 0.33 g (96%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.80 (br s, 1H), 7.87 (s, 2H), 6.72 (d, *J* = 2.4 Hz, 1H), 6.49 (d, *J* =

2.0 Hz, 1H), 3.86 (m, 6H), 3.82 (s, 2H), 2.63 (t, $J = 5.6$ Hz, 2H), 2.42 (m, 4H), 2.28 (s, 6H), 1.50 (m, 4H), 1.37 (m, 2H). MS (ES) m/z 438.63 (M+1).

Example 75. Preparation of 5,7-Dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one



[0321] To a solution of 4-hydroxy-3-methylbenzaldehyde (1.10 g, 8.08 mmol) in anhydrous DMF (12 mL) was added K_2CO_3 (2.23 g, 16.16 mmol) and ethylene carbonate (1.42 g, 16.16 mmol) at room temperature. The resulting reddish-orange suspension was stirred at 110 °C for 6 hours under nitrogen. DMF was removed and the residue was diluted with water (50 mL) and dichloromethane (50 mL). The organic phase was separated, and the aqueous phase was extracted with dichloromethane (2×20 mL). The combined organic phase was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure to obtain 4-(2-hydroxy-ethoxy)-3-methylbenzaldehyde as a brown oil. Yield: 1.46 g (100 %).


[0322] To a solution of 4-(2-hydroxy-ethoxy)-3-methylbenzaldehyde (1.46 g, 8.08 mmol) and 2-amino-4,6-dimethoxybenzamide (1.58 g, 8.08 mmol) in *N,N*-dimethylacetamide (20 mL) were added $NaHSO_3$ (58.5 wt%, 2.20 g, 12.12 mmol) and *p*-toluenesulfonic acid monohydrate (0.38 g, 2.02 mmol). The reaction mixture was stirred at 110 °C for 16 hours, then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure. The residue was triturated with water (50 mL). The resulting slurry was filtered and solid was washed with water, ether, and hexanes to obtain 2-[4-(2-hydroxy-ethoxy)-3-methyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a beige solid. Yield: 2.75 g (95%).

[0323] Tetrabromomethane (3.26 g, 9.82 mmol) was added to a solution of triphenylphosphine (2.58 g, 9.82 mmol) in anhydrous DMF (20 mL) at 0 °C. A solution of 2-[4-(2-hydroxy-ethoxy)-3-methyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (1.75 g, 4.91 mmol) in DMF (7 mL) was then added dropwise and stirred

the reaction mixture at room temperature for 16 hours. The solvent was removed under reduced pressure and the residue was diluted with water (50 mL) and extracted with dichloromethane (4×25 mL). The combined organic phase was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed and the solid was triturated with ether. The resulting slurry was filtered and washed with ether several times (to remove the triphenylphosphine oxide) and finally with a solution of dichloromethane-ether (1:1) to obtain 2-[4-(2-bromo-ethoxy)-3-methyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 0.70 g (34%).

[0324] To a suspension of 2-[4-(2-bromo-ethoxy)-3-methyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.70 g, 1.67 mmol) in anhydrous DMF (9 mL) was added pyrrolidine (0.55 mL, 6.68 mmol) and the reaction mixture was stirred at room temperature under nitrogen for 20 hours. Solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel 230-400 mesh; 9% methanol in dichloromethane as eluent) to give the title compound as an off-white solid. Yield: 0.62 g (90.6%). MP 230-231°C. ¹H NMR (400 MHz, CDCl₃): δ 9.96 (br s, 1H), 7.91-7.89 (m, 2H), 6.93 (d, J = 7.6 Hz, 1H), 6.82 (d, J = 2.4 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 4.21 (t, J = 6.0 Hz, 2H), 3.98 (s, 3H), 3.93 (s, 3H), 2.98 (t, J = 6.0 Hz, 2H), 2.69 (br s, 4H), 2.32 (s, 3H), 1.84-1.81 (m, 4H). MS (ES⁻) *m/z* 408.13 (M-1, 100%), MS (ES⁺) *m/z* 410.14 (M+1, 75%).

Example 76. Preparation of 3-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione




[0325] To a mixture of urea (5.00 g, 83.0 mmol) in anhydrous toluene (13 mL) was added chloroacetyl chloride (6.6 mL, 83.0 mmol) and the reaction mixture was heated to reflux for 2 hours. The reaction mixture was cooled to room temperature and toluene was removed by filtration. The resulting solid was further washed with toluene (10 mL) and mixed with water (100 mL). The solid was

filtrated and washed with cold water (50 mL) and dried to give (2-chloroacetyl)-urea as a white solid. Yield: 10.3 g (91%).

[0326] (2-Chloroacetyl)-urea (0.68 g, 5.00 mmol) and isopropylamine (0.86 mL, 10.0 mmol) in DMF (10 mL) was stirred for 6 h at room temperature and then heated to 135 °C for 4 hours. DMF was removed under vacuum and the residue was purified by column chromatography (silica gel 230-400 mesh; eluting with hexane: dichloromethane: ethyl acetate 2.5:1.0:0.5) to give 1-isopropyl-imidazolidine-2,4-dione as a white solid. Yield: 0.20 g (28%).

[0327] To a solution of 1-isopropyl-imidazolidine-2,4-dione (0.10 g, 0.70 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (60% in mineral oil, 31 mg, 0.77 mmol) and the reaction mixture was stirred for 10 minutes. Then, 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one (0.32 g, 0.73 mmol) was added. The reaction mixture was stirred at 55 °C for 16 hours, then poured into water (100 mL). The solid was filtered and dried. The crude compound was purified by column chromatography (silica gel 230-400 mesh; eluting with 2:1 ethyl acetate and dichloromethane) to give the title compound as a white solid. Yield: 0.09 g (26.0 %). MP 219-221°C. ¹H NMR (400 MHz, DMSO): δ 9.64 (s, 1H), 7.69 (s, 2H), 6.82 (d, J = 2.4 Hz, 1H), 6.45 (d, J = 2.4 Hz, 1H), 4.42 (m, 1H), 4.02 (m, 2H), 3.98 (m, 2H), 3.96 (s, 3H), 3.92 (s, 3H), 3.85 (s, 2H), 2.32 (s, 6H) 1.22 (d, J = 6.4 Hz, 6H). MS (ES⁺) m/z: 495.16 (M+1).

Example 77. Preparation of 2-(3,5-Dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0328] To a solution of 4-hydroxy-3, 5-dimethyl benzaldehyde (5.0 g, 33.29 mmol) in DMF (30 mL) were added 3-bromo propan-1-ol (5.56 g, 39.95 mmol) and Cs₂CO₃ (16.24 g, 50.0 mmol). Then, the reaction mixture was stirred at room temperature for 48 hours. Then, water was added and the products were extracted with ethyl acetate (2×250 mL). The combined organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous


Na₂SO₄. Removal of solvent gave 4-(3-hydroxypropoxy)-3,5-dimethyl benzaldehyde as a colorless liquid. Yield: 5.38 g (77%).

[0329] To a solution of 2-amino-4, 6-dimethoxy-benzamide (1.3 g, 6.63 mmol) and 4-(3-hydroxypropoxy)-3,5-dimethyl benzaldehyde (1.38 g, 6.63 mmol) in N,N-dimethyl acetamide (10 mL), NaHSO₃ (1.30 g, 7.3 mmol), and p-TSA (252 mg, 1.32 mmol) were added and the reaction mixture was heated at 115 °C for 26 hours, then cooled to room temperature. The solvent was removed under reduced pressure. Then, water (100 mL) was added and stirred for 1 hour at room temperature. The separated solids were filtered and dried. The solids were again washed with diethyl ether to give crude product 2-[4-(3-hydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one as an off-white solid. Yield: 1.69 g (66%).

[0330] To a solution of 2-[4-(3-hydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one (1.39 g, 3.62 mmol) in DMF (15 mL) were added PPh₃ (1.04 g, 3.98 mmol) and CBr₄ (1.32 g, 3.98 mmol). The reaction mixture was stirred at room temperature for 16 hours. Then, solvent was removed under reduced pressure. The residue was triturated with ether and ethyl acetate. The solids were dried and purified by the Simpliflash system, using 2% methanol in CH₂Cl₂, to give 2-[4-(3-bromo-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one as a white solid. Yield: 940 mg (58%).

[0331] To a solution of 2-[4-(3-bromo-propoxy)-3, 5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one (340 mg, 0.76 mmol) in DMF (10 mL) was added pyrrolidine (433 mg, 6.08 mmol). Then, the reaction mixture was stirred at room temperature for 16 hours. Then, water was added and the solids were filtered. The solids were washed with water and dried to give the title compound as a white solid. Yield: 307 mg (92%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.80 (s, 1H), 7.87 (s, 2H), 6.71 (d, J = 2.0 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 3.86 (s, 3H), 3.82 (m, 5H), 2.59 (t, J = 6.8 Hz, 2H), 2.42 (m, 4H), 2.26 (s, 6H), 1.89 (m, 2H), 1.67 (m, 4H). MS (ES) *m/z*: 438.16 (M+1).


Example 78. Preparation of 5,7-Dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one



[0332] Carbon tetrabromide (0.26 g, 0.77 mmol) was added to a solution of triphenylphosphine (0.24 g, 0.92 mmol) in anhydrous DMF (5 mL) at 0 °C. A solution of 2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.21 g, 0.61 mmol) in DMF (2 mL) was then added dropwise and stirred at room temperature for 16 hours. Solvent was removed under reduced pressure and the residue was diluted with water (10 mL) and extracted with dichloromethane (4×10 mL). The combined organic phase was washed with brine and dried over anhydrous magnesium sulfate. Solvent was removed and the residual solid was triturated with ether. The resulting slurry was filtered and washed with ether several times (to remove the triphenylphosphine oxide) and finally with a solution of dichloromethane-ether (1:4) to obtain 2-[4-(2-bromo-ethoxy)-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 0.25 g (quantitative).

[0333] To a suspension of 2-[4-(2-bromo-ethoxy)-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.25 g, 0.61 mmol) in anhydrous DMF (10 mL) was added pyrrolidine (0.20 mL, 2.45 mmol) and the reaction mixture was stirred at room temperature under nitrogen for about 20 hours. Solvent was removed under reduced pressure and the residual solid was triturated with water. The resulting slurry was filtered and washed with ether and hexanes. The crude product was purified by column chromatography (silica gel 230-400 mesh; 10% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.11 g (44%). MP 226-227°C. ¹H NMR (400 MHz, CDCl₃): δ 10.08 (br s, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 1.95 Hz, 1H), 6.45 (d, J = 1.95 Hz, 1H), 4.21 (t, J = 5.6 Hz, 2H), 3.99 (s, 3H), 3.93 (s, 3H), 2.97 (t, J = 5.6 Hz, 2H), 2.68 (br s, 4H), 1.84 (br s, 4H). MS (ES⁺): *m/z* 198.65 (100%), 396.10 (M+1, 70%).

Example 79. Preparation of 2-(3,5-Dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3*H*)-one




[0334] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.80 g, 4.00 mmol) and 4-(3-hydroxy-propyl)-3,5-dimethyl-benzaldehyde (0.98 g, 5.1 mmol) in *N,N*-dimethylacetamide (15 mL) were added NaHSO_3 (58.5 wt%, 0.80 g, 4.40 mmol) and *p*-TSA (0.155 g, 0.81 mmol) and the reaction mixture was heated at 115 °C for 16 hours, then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure. The residue was diluted with water (50 mL), stirred for 30 minutes, and then filtered and washed with water. The crude compound was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane as eluent) to give 2-[4-(3-hydroxy-propyl)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 1.10 g (73%).

[0335] To a solution of 2-[4-(3-hydroxy-propyl)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (1.00 g, 2.70 mmol) in anhydrous *N,N*-dimethylformamide (15 mL) were added triphenylphosphine (0.78 g, 3.00 mmol) and carbon tetrabromide (1.00 g, 3.00 mmol). The reaction mixture was stirred at room temperature for 16 hours. DMF was removed under reduced pressure. The residue was purified by column chromatography (silica gel 230-400 mesh; 3% methanol in dichloromethane as eluent) to give 2-[4-(3-bromo-propyl)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 0.60 g (51%).

[0336] To a solution of 2-[4-(3-bromo-propyl)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.40 g, 0.92 mmol) in *N,N*-dimethylformamide (10 mL) was added pyrrolidine (0.39 g, 5.52 mmol) and the reaction mixture was stirred at room temperature for 16 hours. DMF was removed under reduced pressure, the residue was purified by column chromatography (silica gel 230-400 mesh; 5% methanol ammonia in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.27 g (69%). MP 194-196°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.79 (br s, 1H), 7.81 (s, 2H), 6.72 (d, J = 2.3 Hz, 1H), 6.50

(d, J = 2.3 Hz, 1H), 4.00 (s, 3H), 3.87 (s, 3H), 2.67-2.63 (m, 2H), 2.49-2.46 (m, 6H), 2.33 (s, 6H), 1.70-1.67 (m, 4H), 1.59-1.53 (m, 2H). MS (ES⁺) *m/z*: 422.17(M+1).

Example 80. Preparation of 2-(3,5-Dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0337] To a solution of 4-hydroxy-3,5-dimethyl benzaldehyde (5.00 g, 33.3 mmol) in DMF (30 mL) were added 4-bromo-butan-1-ol (6.11 g, 39.9 mmol) and Cs₂CO₃ (16.2 g, 50.0 mmol). The reaction mixture was stirred at room temperature for 48 hours, then water (100 mL) was added, and the products were extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous Na₂SO₄. Solvent was removed and the crude product was purified by the Simpliflash system, using 40% ethyl acetate in hexane as eluent, to give 4-(4-hydroxybutoxy)-3,5-dimethyl benzaldehyde as a colorless liquid. Yield: 0.66 g (7%).


[0338] To a solution of 2-amino-4,6-dimethoxy-benzamide (497 mg, 2.53 mmol) and 4-(4-hydroxybutoxy)-3,5-dimethyl benzaldehyde (660 mg, 2.53 mmol) in *N,N*-dimethyl acetamide (10 mL), NaHSO₃ (58.5 wt%, 496 mg, 2.79 mmol) and *p*-TSA (96 mg, 0.50 mmol) were added and the reaction mixture was heated at 115 °C for 16 hours and then cooled to room temperature. The solvent was removed under reduced pressure. Water (100 mL) was added and stirred for 1 hour at room temperature. The solid separated was filtered and dried. The solid was further washed with diethyl ether to give product 2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 1.69 g (82%).

[0339] To a solution of 2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (675 mg, 1.69 mmol) in DMF (10 mL) were added PPh₃ (489 mg, 1.86 mmol) and CBr₄ (619 mg, 1.86 mmol). The reaction mixture

was stirred at room temperature for 16 hours. Solvent was removed under reduced pressure. The residue was triturated with ether and ethyl acetate. The solid was dried and then purified by the Simpliflash system using 5% methanol in CH_2Cl_2 as the eluent to give 2-[4-(4-bromo-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 494 mg (63%).

[0340] To a solution of 2-[4-(4-bromo-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (494 mg, 1.07 mmol) in DMF (10 mL) was added pyrrolidine (609 mg, 8.57 mmol). The reaction mixture was stirred at room temperature for 16 hours. Water (100 mL) was added and the product was extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with water, then brine, and dried over anhydrous Na_2SO_4 . Solvent was evaporated to give the title compound as a white solid. Yield: 278 mg (57%). MP 180-181°C. ^1H NMR (400 MHz, CDCl_3): δ 7.68 (s, 2H), 6.83 (d, $J = 2.4$ Hz, 1H), 6.46 (d, $J = 2.4$ Hz, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.83 (t, $J = 6.4$ Hz, 2H), 2.56 (m, 6H), 2.36 (s, 6H), 1.88 (m, 2H), 1.79 (m, 6H). MS (ES) m/z : 452.21 ($M+1$).

Example 81. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3*H*)-one



[0341] To a solution of 2-amino-3-methoxy benzoic acid (5.00 g, 29.9 mmol) in THF (50 mL) were added EDCI (6.88 g, 35.9 mmol), HOBt (4.85 g, 35.9 mmol), *N*-methylmorpholine (3.60 g, 35.9 mmol), and aqueous ammonia (50% v/v, 30 mL). Then, the reaction mixture was stirred at room temperature for 48 hours. Then, water was added and the product was extracted with ethyl acetate (2×250 mL). The combined organic phase was washed with water, then brine, and dried over anhydrous Na_2SO_4 . Removal of solvent gave product 2-amino-3-methoxy-benzamide as a light orange solid. Yield: 1.70 g (34%).


[0342] To a solution of 2-amino-3-methoxy-benzamide (700 mg, 4.22 mmol) and 4-(2-hydroxyethoxy)-3,5-dimethyl benzaldehyde (823 mg, 4.22 mmol) in *N,N*-dimethyl acetamide (10 mL) were added NaHSO_3 (58.5 wt%, 841 mg, 4.64

mmol) and p-TSA (160 mg, 0.84 mmol). The reaction mixture was heated at 115 °C for 16 hours, then cooled to room temperature. Solvent was removed under reduced pressure. Water (100 mL) was added and stirred for 1 hour at room temperature. The solid separated was filtered and dried. The solid was further washed with diethyl ether to give crude product 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-8-methoxy-3*H*-quinazolin-4-one as an off-white solid. Yield: 1.2 g (84%).

[0343] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-8-methoxy-3*H*-quinazolin-4-one (1.20 g, 3.53 mmol) in DMF (10 mL) were added PPh₃ (1.02 g, 3.88 mmol) and CBr₄ (1.29 g, 3.88 mmol). The reaction mixture was stirred at room temperature for 16 hours. Solvent was removed under reduced pressure. The residue was triturated with ether and ethyl acetate. The solid was dried under vacuum and purified by the Simpliflash system, using 2% methanol in CH₂Cl₂ as eluent, to give 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-8-methoxy-3*H*-quinazolin-4-one as a white solid. Yield: 0.547 g (38%).


[0344] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-8-methoxy-3*H*-quinazolin-4-one (537 mg, 1.33 mmol) in DMF (10 mL) was added a pyrrolidine (758 mg, 10.66 mmol). The reaction mixture was stirred at room temperature for 16 hours. Water (100 mL) was added and the solid separated was filtered and dried under vacuum. The solid was triturated with ether and dried to give the title compound as a white solid. Yield: 232 mg (44%). MP 231-232°C. ¹H NMR (400 MHz, CDCl₃): δ 10.30 (s, 1H), 7.90 (dd, J = 8.0 Hz, 1H), 7.806 (br s, 2H), 7.42 (t, J = 8.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 4.04 (s, 3H), 3.95 (t, J = 6.4 Hz, 2H), 2.93 (t, J = 6.0 Hz, 2H), 2.65 (m, 4H), 2.40 (s, 6H), 1.84 (m, 4H). MS (ES) *m/z*: 394.15 (M+1).

Example 82. Preparation of 3-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione



[0345] To a suspension of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.50 g, 1.35 mmol) in THF (20 mL), were added 5-phenyl-imidazolidine-2,4-dione (0.24 g, 1.35 mmol) and triphenyl phosphine (0.35 g, 1.35 mmol), then diethyl azodicarboxylate (0.43 mL, 2.70 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Solvent was evaporated *in vacuo* and the residue was washed with dichloromethane and ether. The residue was dissolved in acetic acid and purified by preparative HPLC. The compound was further washed with dichloromethane and ether (1:1, 20 mL) to obtain the title compound as a white solid. Yield: 0.07 g (10%). MP 219.6-221.4°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.81 (s, 1H), 7.86 (s, 2H), 7.37 (m, 5H), 6.71 (s, 1H), 6.48 (s, 1H), 3.94 (m, 4H), 3.86 (s, 3H), 3.82 (s, 3H), 2.18 (s, 6H). MS (ES) *m/z*: 529.29 (*M*⁺+1).

Example 83. Preparation of 3-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione




[0346] Hydantoin (0.80 g, 8.00 mmol) was dissolved in DMF (10 mL) and cooled to 0 °C. Sodium hydride (60% in mineral oil, 88 mg, 2.20 mmol) was added. The mixture was stirred at room temperature for 3 hours. 4-(Bromomethyl)benzaldehyde (0.40 g, 2.00 mmol) was added. The mixture was stirred at room temperature for 2.5 days. Saturated aqueous NH₄Cl (1 mL) was added. The mixture was concentrated to dryness. Water (10 mL) was added, extracted with dichloromethane, and the organic phase was dried over anhydrous Na₂SO₄. Solvent was removed and the crude compound was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in CH₂Cl₂ as eluent) to give 4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde as a white solid. Yield: 0.28 g (64%).

[0347] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.19 g, 0.98 mmol) in *N,N*-dimethylacetamide (4 mL) were added 4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde (0.19 g, 0.89 mmol), sodium hydrogen sulfite (58.5 wt%,

0.24 g, 1.30 mmol) and *p*-toluenesulfonic acid monohydrate (34 mg, 0.18 mmol) and the reaction mixture was stirred at 115 °C for 17 hours under nitrogen, then cooled to room temperature. The precipitate was filtered, washed with methanol, water, then methanol, and dried in air. The solid was suspended in hot DMSO (approximately 3 mL); saturated aqueous NaHCO₃ (approximately 3 mL) and water were added. The solid was filtered, washed with water, then methanol, and air dried to give the title compound as a light yellow solid. Yield: 0.16 g (46%). MP 317-318°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.05 (s, 1H), 8.17 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 6.74 (d, *J* = 2.0 Hz, 1H), 6.54 (d, *J* = 2.0 Hz, 1H), 4.61 (s, 2H), 4.02 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H). MS (ES⁺) *m/z*: 395.09 (M+1).

Example 84. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one



[0348] To a suspension of 2-amino-5-methoxy-benzoic acid (5.00 g, 30.0 mmol) in THF (50 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.50 g, 39.0 mmol), 1-hydroxybenzotriazole (4.50 g, 33.0 mmol) and 4-methylmorpholine (3.6 mL, 33.0 mmol) and the reaction mixture was stirred at room temperature for 1 hours. Then, 50% aqueous NH₃ (8 mL, 105.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Water (100 mL) was added and the product was extracted with ethyl acetate. Solvent was evaporated *in vacuo* and the residue was washed with ether to give 2-amino-5-methoxy-benzamide as a white solid. Yield: 2.62 g (53%).


[0349] To a stirred solution of 2-amino-5-methoxy-benzamide (2.62 g, 15.80 mmol) and 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (3.23 g, 16.60 mmol) in *N,N*-dimethyl acetamide (20 mL), were added sodium hydrogen sulfite (58.5 wt%, 3.44 g, 19.00 mmol) and *p*-toluenesulfonic acid monohydrate (0.60 g, 3.20 mmol) and the reaction mixture was stirred at 115 °C for 16 hours. Solvent was evaporated *in vacuo*, water (50 mL) was added, and the separated solid was

filtered. The solid was triturated with ether to give 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-6-methoxy-3*H*-quinazolin-4-one as a white solid. Yield: 3.56 g (66%).

[0350] To a suspension of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-6-methoxy-3*H*-quinazolin-4-one (1.50 g, 4.41 mmol) in *N,N*-dimethylformamide (15 mL), carbon tetrabromide (1.60 g, 4.85 mmol), and triphenylphosphine (1.30 g, 4.85 mmol) were added and the reaction mixture was stirred at room temperature for 16 hours. The solvent was evaporated *in vacuo* and the product was purified by the Simpliflash system, using 1-2% methanol in CH₂Cl₂ as eluent, to give 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-6-methoxy-3*H*-quinazolin-4-one as a white solid. Yield: 1.77 g (quantitative).

[0351] To a suspension of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-6-methoxy-3*H*-quinazolin-4-one (1.94 g, 4.80 mmol) in *N,N*-dimethylformamide (20 mL), pyrrolidine (4 mL) was added and the reaction mixture was stirred at room temperature for 16 hours. Solvent was evaporated *in vacuo*, water (50 mL) was added, and the separated solid was filtered. The solid was washed with ether to give the title compound as a light brown solid. Yield: 0.30 g (16%). MP 201.2-203.1°C. ¹H NMR (400 MHz, CDCl₃): δ 7.73 (m, 4H), 7.39 (m, 1H), 3.98 (t, *J* = 6.0 Hz, 3H), 3.94 (s, 3H), 2.97 (t, *J* = 6.0 Hz, 2H), 2.69 (br s, 4H), 2.41 (s, 6H), 1.86 (br s, 4H). MS (ES) *m/z*: 394.21 (*M*⁺+1).

Example 85. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-*d*]pyrimidin-4(3*H*)-one




[0352] To a solution of 2-amino-4,6-dimethoxy-nicotinamide (0.60 g, 3.00 mmol) and 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (0.59 g, 3.00 mmol) in *N,N*-dimethylacetamide (8 mL) was added NaHSO₃ (58.5 wt%, 0.59 g, 3.30 mmol) and *p*-TSA (0.22 g, 1.20 mmol). The reaction mixture was heated to 145-148 °C for 16 hours, then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure, the residue was diluted with sodium

bicarbonate solution (50 mL), and the solid separated was filtered and dried under vacuum. The crude compound was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane as eluent) to give 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-pyrido[2,3-*d*]pyrimidin-4-one as a white solid. Yield: 0.50 g (49%).

[0353] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-pyrido[2,3-*d*]pyrimidin-4-one (0.50 g, 1.34 mmol) in anhydrous DMF (6 mL) was added carbon tetrabromide (0.53 g, 1.61 mmol) and triphenylphosphine (0.42 g, 1.61 mmol). The reaction mixture was stirred at 25 °C for 16 hours. DMF was removed under vacuum and dichloromethane (200 mL) was added. The organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. Solvent was removed and the residue was washed with ether (100 mL) to give 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-pyrido[2,3-*d*]pyrimidin-4-one as a white solid. Yield: 0.23 g (40%).

[0354] A solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-pyrido[2,3-*d*]pyrimidin-4-one (0.20 g, 0.46 mmol) in pyrrolidine (2 mL) was stirred at room temperature for 3 hours. The excess pyrrolidine was removed under reduced pressure, and the residue was purified by column chromatography (silica gel 230-400 mesh; eluting with 2% 2.0 M ammonia in methanol solution and dichloromethane) to give the title compound as a white solid. Yield: 0.17 g (87%). MP 228-230°C. ¹H NMR (400 MHz, CDCl₃): δ 10.06 (s, 1H), 7.83 (s, 2H), 6.22 (s, 1H), 4.12 (s, 3H), 4.00 (s, 3H), 3.95 (t, J = 6.0 Hz, 2H), 2.93 (t, J = 6.0 Hz, 2H), 2.64 (m, 4H), 2.37 (s, 6H), 1.80 (m, 4H). MS (ES⁺) *m/z*: 425.19 (M+1).

Example 86. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3*H*)-one




[0355] A mixture of 2-amino-4,6-difluoro-benzamide (0.96 g, 5.60 mmol), 4-(2-hydroxy-ethoxy)-3,5-dimethyl-benzaldehyde (1.09 g, 5.60 mmol), NaHSO₃ (58.5wt%, 1.00 g, 5.60 mmol) and p-toluenesulfonic acid monohydrate (1.44 g, 7.06 mmol) in *N,N*-dimethylacetamide (25 mL) was stirred at 120 °C for 16 hours, then cooled to room temperature. Solvent was removed under reduced pressure. The residue was diluted with water (100 mL). The solid separated was filtered and washed with water and dried under vacuum to give 5,7-difluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-3*H*-quinazolin-4-one as a white solid. Yield: 1.55g (79%).

[0356] A mixture of 5,7-difluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-3*H*-quinazolin-4-one (1.54 g, 4.44 mmol), PPh₃ (1.52 g, 5.78 mmol), and CBr₄ (1.92 g, 5.78 mmol) in anhydrous DMF (30 mL) was stirred at room temperature for 36 hours. DMF was evaporated under vacuum, water (100 mL) was added, and stirred for 30 minutes. The solid separated was filtered, washed with water, then ether, and dried under vacuum to give 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-difluoro-3*H*-quinazolin-4-one as pale yellow solid. Yield: 1.38 g (crude). This product was used in the next step without further purification.

[0357] A solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-difluoro-3*H*-quinazolin-4-one (1.38 g, crude) and pyrrolidine (10 mL) was stirred at room temperature for 16 hours. Excess pyrrolidine was evaporated, the residue was purified by column chromatography (silica gel 230-400 mesh; 30-50% ethyl acetate in hexanes as eluent). The compound was further purified by preparative HPLC to give the title compound as a white solid. Yield: 260 mg (13% for two steps). MP 206.6-206.8°C. ¹H NMR (400 MHz, DMSO-d₆): δ 11.85 (s, 1H), 6.63 (d, *J* = 8 Hz, 1H), 6.51 (d, *J* = 12 Hz, 1H), 3.90 (t, *J* = 4 Hz, 2H), 2.83 (t, *J* = 4 Hz, 2H), 2.50 (s, 6H), 2.30 (s, 4H), 1.89 (s, 4H), 1.70 (s, 4H).

Example 87. Preparation of 5-Chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3*H*)-one



[0358] To a solution of 2-amino-6-chlorobenzoic acid (2.00 g, 11.65 mmol) in anhydrous THF (20 mL) were added 4-methylmorpholine (1.40 mL, 12.82 mmol), HOBT (1.73 g, 12.82 mmol), and EDCI (2.45 g, 12.82 mmol); the reaction mixture was stirred at room temperature for 30 minutes. 50% (v/v) Ammonium hydroxide solution (10 mL, 132.0 mmol) was added and the mixture was stirred at room temperature for 23 hours. Solvent was evaporated to about 20 mL, poured into aqueous NaHCO₃ solution (200 mL) and extracted with ethyl acetate (7×100 mL). The organic phase was washed with water (3×100 mL), dried (Na₂SO₄), filtered, and evaporated, to give 2-amino-6-chlorobenzamide as a white solid. Yield: 1.65 g (83%).


[0359] 4-(2-Hydroxyethoxy)-3,5-dimethylbenzaldehyde (0.70 g, 3.58 mmol), 2-amino-6-chlorobenzamide (0.60 g, 3.51 mmol), sodium bisulfite (0.71 g, 3.86 mmol) and *p*-toluenesulfonic acid monohydrate (0.133 g, 0.699 mmol) in anhydrous *N,N*-dimethyl acetamide (14 mL) were heated at 120 °C under nitrogen for 23 hours. The solvent was evaporated and the white solid was triturated with water (50 mL), filtered, and washed with water (20 mL). The solid was dried *in vacuo* and triturated with Et₂O (20 mL), filtered, and dried to give 5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3*H*)-one as a white solid. Yield: 0.77 g, (64%).

[0360] To a solution of 5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3*H*)-one (0.40 g, 1.16 mmol) in anhydrous DMF (10 mL) was added carbon tetrabromide (0.42 g, 1.27 mmol) and triphenylphosphine (0.33 g, 1.27 mmol). The reaction mixture was stirred at room temperature for 27 hours. Solvent was evaporated to dryness *in vacuo* and the residue triturated with Et₂O (15 mL)/EtOAc (15 mL) to give 2-(4-(2-bromoethoxy)-3,5-dimethylphenyl)-5-chloroquinazolin-4(3*H*)-one (0.42 g). It was used without further purification. The ¹H NMR indicated a purity of about 45%.

[0361] To a solution of 2-(4-(2-bromoethoxy)-3,5-dimethylphenyl)-5-chloroquinazolin-4(3*H*)-one (0.40 g, crude) in anhydrous DMF (10 mL) was added pyrrolidine (0.36 mL, 4.35 mmol) and the reaction mixture was stirred at room temperature, under nitrogen, for 25 hours. Solvent was evaporated to dryness *in vacuo*. The residue was triturated with water (50 mL), filtered, and the brown solid washed with Et₂O (20 mL). The crude material was purified by column


chromatography (silica gel 230-400 mesh; 6% methanol in dichloromethane as the eluent) and then by reverse-phase HPLC (0.1% aqueous trifluoroacetic acid/acetonitrile as the eluent), to give a white solid. The solid was dissolved in CH_2Cl_2 (20 mL)/MeOH (4.5 mL), washed with 1 M Na_2CO_3 (4.5 mL) and the organic phase separated. The aqueous phase was extracted with CH_2Cl_2 (4×20 mL). The combined organic phase was washed with water (10 mL), dried (Na_2SO_4), filtered, and evaporated to give the title compound as a white solid. Yield: 0.091 g (21%, for two steps). MP 179-180°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 12.30 (br s, 1H), 7.89 (s, 2H), 7.77-7.66 (m, 1H), 7.66-7.60 (m, 1H), 7.47 (d, $J = 7.42$ Hz, 1H), 3.89 (t, $J = 5.85$ Hz, 2H), 2.80 (t, $J = 5.85$ Hz, 2H), 2.53 (br s, 4H), 2.30 (s, 6H), 1.68 (br s, 4H). MS (ES⁺) m/z : 398.11 (100%), 400.13, 401.07.

Example 88. Preparation of 2-(4-(2-(Azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0362] To a suspension of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one (0.22 g, 0.50 mmol) in DMF (2 mL) was added hexamethyleneimine (azepane) (0.22 mL, 2.0 mmol) and the reaction mixture was stirred at room temperature for 17 hours. Saturated aqueous NaHCO_3 solution (2 mL) was added and stirred for 2 hours. Water (10 mL) was added and stirred for another 0.5 hours. The solid was filtered, washed with water, and dried under vacuum to give the title compound as a white solid. Yield: 0.22 g (95%). MP 198-199°C. ^1H NMR (400 MHz, CD_3OD): δ 7.70 (s, 2H), 6.79 (s, 1H), 6.55 (s, 1H), 3.97 (t, $J = 6.0$ Hz, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 2.98 (t, $J = 6.0$ Hz, 2H), 2.82 (t, $J = 5.2$ Hz, 4H), 2.37 (s, 6H), 1.72 (m, 4H), 1.66 (m, 4H). MS (ES⁺) m/z : 452.27 (M+1). Analysis calculated for $\text{C}_{26}\text{H}_{33}\text{N}_3\text{O}_4$ (451.56), %: C 69.16, H 7.37, N 9.31. Found, %: C 68.94, H 6.90, N 9.30.

Example 89. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one



[0363] To a solution of 2-amino-4,6-difluoro-benzamide (0.80 g, 4.60 mmol) and 3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (1.14 g, 4.60 mmol) in *N,N*-dimethylacetamide (60 mL) were added sodium hydrogen sulfite (58.5 wt%, 1.25 g, 6.9 mmol) and *p*-toluenesulfonic acid monohydrate (3.50 g, 18.4 mmol). The reaction mixture was stirred at 145 °C for 16 hours under nitrogen atmosphere, then cooled to room temperature. Solvent was evaporated under reduced pressure. Water (50 mL) was added, followed by saturated aqueous sodium bicarbonate solution (15 mL). The mixture was extracted with CH₂Cl₂ (2×100 mL) and washed with water. The organic phase was evaporated and the residue was washed with hexane/ether (90:10, 100 mL). The solid was filtered and dried under vacuum to give the title compound as a brown solid. Yield: 1.48 g (80%). MP 234-235°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.36 (s, 1H), 7.90 (s, 1H), 7.32 (m, 2H), 3.91 (t, *J* = 4 Hz, 2H), 2.83 (t, *J* = 4 Hz, 2H), 2.55 (s, 4H), 2.31 (s, 6H), 1.70 (s, 4H).


Example 90. Preparation of 2-(4-(2-(Azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0364] To a suspension of 2-[4-(2-bromoethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (216 mg, 0.50 mmol) in DMF (5 mL) was added azetidine (154 mg, 2.70 mmol). The reaction mixture was stirred at room temperature for 2 days. The solid was collected by filtration, washed with methanol, ethyl acetate, and water, and dried under vacuum to give the title compound as a white solid. Yield: 58 mg (28%). MP 204-205°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.85 (s, 2H), 6.71 (d, *J* = 2.4 Hz, 1H), 6.49 (d, *J* = 2.4 Hz, 1H),

3.86 (s, 3H), 3.81 (s, 1H), 3.70 (t, $J = 6.0$ Hz, 2H), 3.18 (t, $J = 6.8$ Hz, 4H), 2.70 (t, $J = 6.0$ Hz, 2H), 2.26 (s, 6H), 1.97 (m, 2H). MS (ES) m/z : 410.20 ($M+1$) (100%).

Example 91. Preparation of N-(1-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide




[0365] To a solution of N-(1-benzhydryl-azetidin-3-yl)-acetamide (1.00 g, 3.57 mmol) in ethanol (20 mL) were added palladium hydroxide on carbon (20 wt%, 0.20 g) and concentrated HCl (0.6 mL). The reaction mixture was hydrogenated at 50 psi at 40 °C for 2 hours. Then, the solid was filtered and washed with methanol (50 mL). The filtrate was collected; the solvent was evaporated to give N-azetidin-3-yl-acetamide as a green gummy material. Yield: 0.40 g (crude). This product was used in next step without further purification.

[0366] To a suspension of N-azetidin-3-yl-acetamide (0.30 g crude, 1.99 mmol) and 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one (0.43 g, 1.00 mmol) in anhydrous DMF (10 mL) was added triethylamine (3 mL). The reaction mixture was stirred at room temperature for 3 days under nitrogen. Solvent was evaporated under reduced pressure, water (50 mL) was added, and the precipitated solid was filtered. The aqueous phase was extracted with ethyl acetate (2×100 mL). The organic phase was dried over anhydrous Na₂SO₄. Solvent was evaporated, and crude compound was purified by the Simpliflash system (0-5% 7 N ammonia in methanol and CH₂Cl₂ as eluent) to give the title compound as a white solid. Yield: 0.30 g (63%). MP

111.8-113.6°C. ¹H NMR (400 MHz, CDCl₃): δ 9.60 (br s, 1H), 7.69 (s, 2H), 6.82 (d, $J = 2.34$ Hz, 1H), 6.46 (d, $J = 2.34$ Hz, 1H), 6.10 (d, $J = 7.81$ Hz, 1H), 4.71 - 4.44 (m, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.85 - 3.67 (m, 4H), 3.26 - 3.13 (m, 2H), 2.90 (t, $J = 5.46$ Hz, 2H), 2.36 (s, 6H), 2.01 (s, 3H). MS (ES⁺) m/z : 467.20 ($M+1$).


Example 92. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one



[0367] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3*H*-quinazolin-4-one (0.73 g, 1.70 mmol) in DMF (10 mL) were added PPh₃ (0.49 g, 1.87 mmol) and CBr₄ (0.62 g, 1.87 mmol). The reaction mixture was stirred at room temperature for 16 hours. Then, solvent was removed under reduced pressure. The residue was triturated with ether and ethyl acetate. The solid was dried and purified by the Simpliflash system (2% methanol in CH₂Cl₂ as eluent) to give 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3*H*-quinazolin-4-one as a white solid. Yield: 0.39 g (47%).

[0368] To a solution of 2-[4-(2-bromo-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3*H*-quinazolin-4-one (0.39 g, 0.79 mmol) in DMF (10 mL) was added pyrrolidine (0.45 g, 6.37 mmol). The reaction mixture was stirred at room temperature for 4 hours. Then, water was added and product was extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with water, then brine, and dried over anhydrous Na₂SO₄. Solvent was evaporated to give the title compound as a white solid. Yield: 0.32 g (83%). MP 65-68°C. ¹H NMR (400 MHz, CDCl₃): δ 9.05 (br s, 1H), 7.63 (s, 2H), 6.78 (s, 1H), 6.42 (s, 1H), 4.70 (m, 1H), 4.63 (m, 1H), 3.94 (m, 2H), 2.94 (m, 2H), 2.64 (br s, 4H), 2.38 (s, 6H), 1.84 (m, 4H), 1.46 (m, 3H), 1.42 (m, 3H). MS (ES) *m/z*: 480.29 (M+1).

Example 93. Preparation of 8-Chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3*H*)-one




[0369] To a solution of 2-amino-3-chloro-benzoic acid (2.57 g, 15.0 mmol) in THF (100 mL) were added EDCI (3.16 g, 16.5 mmol), HOBt (2.23 g, 16.5 mmol) and N-methylmorpholine (1.67 g, 16.5 mmol). The reaction mixture was stirred at

room temperature for 20 minutes then 50% (v/v) aq. NH_4OH solution (4.2 mL, 60.0 mmol) was added. The mixture was stirred for 20 hours at room temperature. Solvent was evaporated and the residue was taken in ethyl acetate (200 mL). Water (100 mL) was added. The organic phase was separated; the aqueous phase was extracted with ethyl acetate (200 mL). The combined organic phase was washed with water (100 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. Solvent was evaporated and dried under vacuum to give 2-amino-3-chloro-benzamide as a white solid. Yield: 2.07 g (81%).

[0370] To a solution of 2-amino-3-chloro-benzamide (0.85 g, 5.00 mmol) and 3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (1.23 g, 5.00 mmol) in *N,N*-dimethylacetamide (20 mL) were added sodium hydrogen sulfite (58.5 wt%, 1.37 g, 7.50 mmol) and *p*-toluenesulfonic acid monohydrate (3.80 g, 20.0 mmol). The reaction mixture was stirred at 140 °C for 16 hours under nitrogen, then cooled to room temperature. Solvent was evaporated under reduced pressure. Water (100 mL) was added, and the mixture was neutralized, to pH approximately 8 with 2 N aqueous NaOH solution. The separated solid was filtered, washed with water (50 mL), and dried under vacuum. Crude compound was purified by the Simpliflash system (0-5% methanol in CH_2Cl_2 and then 5% 7.0 M ammonia in methanol and CH_2Cl_2 as eluent) to give the title compound as a brown solid. Yield: 0.49 g (25%). MP 216-217°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.07 (d, J = 7.81 Hz, 1H), 8.01-7.87 (m, 3H), 7.43 (t, J = 7.81 Hz, 1H), 3.89 (t, J = 5.85 Hz, 2H), 2.81 (t, J = 5.85 Hz, 2H), 2.53 (br s, 4H), 2.30 (s, 6H), 1.75 - 1.60 (m, 4H). MS (ES+) m/z 398.11 (100%), 400.13 (40%).

Example 94. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one



[0371] Chloral hydrate (15.29 g, 92.42 mmol) was taken in water (335 mL). Sodium sulfate (78.14 g, 550.13 mmol) was added at room temperature. Then, a suspension of hydroxylamine hydrochloride (18.35 g, 264.06 mmol), 3.5-

dimethylaniline (10.0 g, 82.52 mmol) and concentrated hydrochloric acid (36.5%, 10 mL) was added. The mixture was heated at 45 °C for 1.5 hours, then 75 °C for 1 hour. The reaction mixture was cooled to room temperature. The precipitated brown solid was filtered and washed with cold water (50 mL) and hexane (50 mL). The crude compound was dried under vacuum to give N-(3,5-dimethyl-phenyl)-2-hydroxyimino-acetamide as a brown solid. Yield: 13.7 g (86%). The crude compound was used in the next step without further purification.

[0372] N-(3,5-Dimethyl-phenyl)-2-hydroxyimino-acetamide (13.7 g, 71.3 mmol) was added to concentrated sulfuric acid (70 mL) in a 250 mL flask. The reaction mixture was then heated at 80 °C for 30 minutes, then cooled to room temperature, and poured into ice-water (200 mL). The precipitated solid was filtered and washed with water (100 mL) and dried under vacuum to give 4,6-dimethyl-1*H*-indole-2,3-dione as an orange solid. Yield: 5.53 g (44%).


[0373] To a heated (70 °C bath temperature) deep red solution of 4,6-dimethyl-1*H*-indole-2,3-dione (1.00 g, 5.71 mmol) in 33% aqueous sodium hydroxide (35 mL) was added 35% hydrogen peroxide (3.33 g, 34.3 mmol) over a period of 5 minutes. The reaction mixture was heated for another 15 min, then cooled to room temperature, and ice was added. The pH was adjusted to approximately 8 with concentrated HCl at 0 °C and acidified further to pH approximately 6 with glacial acetic acid. The solid precipitated was filtered, washed well with cold water, and dried under vacuum at 40 °C overnight to obtain 2-amino-4,6-dimethyl-benzoic acid as a pale brown solid. Yield: 0.35 g (37%).

[0374] To a solution of 2-amino-4, 6-dimethyl-benzoic acid (0.35 g, 2.08 mmol) in anhydrous THF (10 mL) was added EDCI (0.80 g, 4.17 mmol), HOBt (0.80 g, 5.22 mmol) and N-methyl-mopholine (0.7 mL, 6.24 mmol). The reaction mixture was stirred at room temperature for 30 minutes, then ammonium hydroxide (50% v/v, 2.5 mL) was added. The mixture was stirred at room temperature for 17 hours. The solvent was removed under reduced pressure. Water (50 mL) was added, and the mixture was extracted with dichloromethane (2×100 mL). The combined organic phase was washed with water, and dried over anhydrous Na₂SO₄. Removal of the solvent gave the crude product. The crude product was purified by column chromatography (silica gel 230-400 mesh; 3%

methanol in dichloromethane as eluent) to give 2-amino-4,6-dimethyl-benzamide. Yield: 0.20 g (59%).


[0375] To a solution of 2-amino-4,6-dimethyl-benzamide (0.20 g, 1.22 mmol) and 3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (0.36 g, 1.46 mmol) in *N,N*-dimethylacetamide (10 mL) was added NaHSO_3 (58.5 wt%, 0.55 g, 3.05 mmol) and *p*-TSA (0.46 g, 2.44 mmol). The reaction mixture was heated to 110 °C for 2 hours, then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure, the residue was diluted with sodium bicarbonate solution (50 mL), and the solid separated was filtered and dried under vacuum. The crude compound was purified by column chromatography (silica gel 230-400 mesh; 6% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 0.145 g (30%). MP 181-182°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.62 (s, 1H), 7.75 (s, 2H), 7.44 (s, 1H), 7.03 (s, 1H), 3.95 (t, $J = 6.0$ Hz, 2H), 2.94 (t, $J = 6.0$ Hz, 2H), 2.85 (s, 3H), 2.65 (s, 4H), 2.44 (s, 3H), 2.39 (s, 6H), 1.84 (s, 4H). MS (ES^+) m/z : 392.13 ($\text{M}+1$).

Example 95. Preparation of 2-(2-(4-(6,8-Dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione



[0376] To a suspension of 3-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-6,8-dimethoxy-2H-isoquinolin-1-one (0.80 g, 2.16 mmol), isoindole-1,3-dione (0.35 g, 2.38 mmol), and triphenylphosphine (0.85 g, 3.25 mmol) in THF (30 mL), was added diethyl azodicarboxylate (0.56 g, 3.25 mmol) and the reaction mixture was stirred at room temperature for 16 hours. The solvent was evaporated *in vacuo* and the residue was washed with ether to give the title compound as an off-white solid. Yield: 1.11 g (crude). ^1H NMR (400 MHz, CDCl_3): δ 8.34 (s, 1H), 7.89 (m, 2H), 7.77 (m, 2H), 7.21 (s, 2H), 6.49 (br s, 2H), 6.44 (s, 1H), 4.16 (m, 2H), 4.08 (m, 2H), 3.97 (s, 3H), 3.89 (s, 3H), 2.25 (s, 6H). MS (ES) m/z : 499.06 ($\text{M}+1$) (100%).

Example 96. Preparation of 2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one



[0377] To a suspension of 2-amino-4-hydroxy-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester (7.0 g, 38.04 mmol), 2-iodopropane (14.22 g, 83.69 mmol), and K_2CO_3 (11.56 g, 83.69 mmol) in DMF (200 mL), was heated at 60 °C for 48 hours, then cooled to the room temperature and filtered. Water (400 mL) was added to the filtrate and the product was extracted with ethyl acetate (3×200 mL). The combined organic layer was washed with water, then brine, dried over Na_2SO_4 , and evaporated to give crude product. The crude product was purified by Simpliflash, using 10% ethyl acetate in hexane, to give 2-amino-4, 6-diisopropoxy-nicotinic acid methyl ester as a colorless oil. Yield: 1.30 g (13%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 6.91 (s, 2H), 5.57 (s, 1H), 5.19 (m, 1H), 4.59 (m, 1H), 3.66 (s, 3H), 1.23 (d, J = 2.0 Hz, 6H), 1.21 (d, J = 1.2 Hz, 6H).

[0378] To the solution of 2-amino-4, 6-diisopropoxy-nicotinic acid methyl ester (1.6 g, 5.97 mmol) in methanol (9.0 mL) and water (1.0 mL), was added lithium hydroxide (750 mg, 17.91 mmol). The reaction mixture was heated to 50 °C for 8 hours. The solvent was removed; the residue was diluted with water and neutralized with 2 N HCl. The product was extracted with ethyl acetate (3×100 mL). The combined organic layer was washed with water, then brine, dried over Na_2SO_4 , and evaporated, to give crude 2-amino-4,6-diisopropoxy-nicotinic acid as a light yellow solid. Yield: 1.48 g (98%, crude).


[0379] To a solution of 2-amino-4,6-diisopropoxy-nicotinic acid (1.48 g, 5.83 mmol) in THF (30 mL) were added EDCI (1.34 g, 6.99 mmol), HOBt (0.94 g, 6.99 mmol), NMM (0.70 g, 6.99 mmol) and liquid NH_3 (10 mL). Then, the reaction mixture was stirred at room temperature for 24 hours. Then, water (100 mL) was added and the products were extracted with ethyl acetate (2×200 mL). The combined organic phase was washed with water, then brine, and dried over

anhydrous Na_2SO_4 . Removal of solvent gave crude 2-amino-4,6-diisopropoxy-nicotinamide as a yellow oil. Yield: 450 mg (26%, crude).

[0380] To a solution of 2-amino-4,6-diisopropoxy-nicotinamide (450 mg, 1.78 mmol) and 3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (440 mg, 1.78 mmol) in *N,N*-dimethyl acetamide (10 mL) were added NaHSO_3 (790 mg, 4.44 mmol) and *p*-TSA (845 mg, 4.44 mmol). The reaction mixture was heated at 120 °C for 16 hours, then cooled to room temperature. The solvent was removed under reduced pressure. Then, water (100 mL) was added and stirred for 30 min at room temperature. The separated solids were filtered and dried to give crude product, which was purified by the Simpliflash system, using 2% methanol in dichloromethane, to give a yellow oil, which dissolved in ether. 2N HCl in ether was added, and the separated solids were filtered and dried to give the hydrochloride salt of the title compound as a yellow solid. Yield: 59 mg (6%).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.7 (br s, 1H), 7.88 (s, 2H), 6.31 (s, 1H), 5.41 (m, 1H), 4.80 (m, 1H), 4.14 (t, $J = 4.8$ Hz, 2H), 3.61 (m, 2H), 3.16 (m, 4H), 2.34 (s, 6H), 2.03 (m, 2H), 1.91 (m, 2H), 1.32 (s, 6H), 1.30 (s, 6H). MS (ES) m/z : 481.18 ($M+1$).

Example 97. Preparation of (S)-2-(3,5-Dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0381] To a solution of (S)-5-(hydroxymethyl)pyrrolidin-2-one (3.85 g, 33.5 mmol) in acetonitrile (60 mL) under nitrogen was added PPh_3 (9.16 g, 34.8 mmol). The mixture was cooled to 0 °C and CBr_4 (11.55 g, 34.8 mmol) added dropwise as a solution in acetonitrile (40 mL) over 15 minutes. Then, the reaction mixture was warmed to room temperature and stirred for 18 hours. The mixture was then concentrated and heptane (100 mL) and water (100 mL) added. After stirring for 1 hour, the solids were filtered and washed with 1:1 heptane/water (100 mL). The filtrate layers were separated and the aqueous layer extracted with Et_2O (2×100

mL) and CHCl_3 (2×100 mL). The combined organic phase was dried over anhydrous Na_2SO_4 , filtered, concentrated, and purified by silica gel chromatography, eluting with 100% CHCl_3 to 10% $\text{MeOH}/\text{CHCl}_3$, to afford (S)-5-(bromomethyl)pyrrolidin-2-one as a white solid (3.15 g, 53%).

[0382] To a solution of 4-hydroxy-3,5-dimethylbenzaldehyde (2.65 g, 17.7 mmol) in DMF (100 mL) was added K_2CO_3 (3.66 g, 26.6 mmol). The mixture was stirred at room temperature under nitrogen for 30 minutes. Then, a solution of (S)-5-(bromomethyl)pyrrolidin-2-one (3.15 g, 17.7 mmol) in DMF (100 mL) was added, and the mixture heated at reflux for 16 hours. The mixture was then concentrated, ethyl acetate (250 mL) added, and the organic phase washed sequentially with water (2×150 mL), and brine (200 mL), dried (Na_2SO_4), filtered, and concentrated. The residue was purified by silica gel chromatography, eluting with 100% ethyl acetate to 10% $\text{MeOH}/\text{ethyl acetate}$, followed by a second chromatography, eluting with 1:1 $\text{CH}_2\text{Cl}_2/92:7:1 \text{ CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$ to 100% 92:7:1 $\text{CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$, to afford (S)-3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)benzaldehyde as a white solid (0.200 g, 5%).

[0383] A mixture of (S)-3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)benzaldehyde (0.200 g, 0.81 mmol), 2-amino-4,6-dimethoxybenzamide (0.159 g, 0.81 mmol), NaHSO_3 (0.093 g, 0.89 mmol), and *p*-TsOH (0.015 g, 0.08 mmol) in DMA (10 mL) was heated at 150 °C for 48 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (200 mL), washed with water (2×200 mL), dried over anhydrous Na_2SO_4 , filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 1:1 $\text{CH}_2\text{Cl}_2/92:7:1 \text{ CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$ to 100% 92:7:1 $\text{CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$ to 6:3:1 $\text{CHCl}_3/\text{MeOH}/\text{concentrated NH}_4\text{OH}$, to afford the title compound as an off-white solid (0.108 g, 31%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 11.85 (s, 1H), 7.79-7.91 (m, 3H), 6.74 (d, $J = 2.2$ Hz, 1H), 6.52 (d, $J = 2.2$ Hz, 1H), 3.88-3.94 (m, 4H), 3.84 (s, 3H), 3.63-3.75 (m, 2H), 2.30 (s, 6H), 2.09-2.27 (m, 3H), 1.91-2.00 (m, 1H). APCI MS m/z 424 $[\text{M}+\text{H}]^+$.


Example 98. Preparation of 2-(4-((4-Isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0384] To a mixture of 4-(bromoethyl) benzaldehyde (0.200 g, 1.0 mmol) and K_2CO_3 (0.277 g, 2.0 mmol) in DMF (5 mL) was added *N*-isopropylpiperazine (0.129 g, 1.0 mmol) and the reaction was stirred at room temperature for 5 hours, then concentrated *in vacuo*. The resulting mixture was diluted with H_2O and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo* to afford 4-((4-isopropylpiperazin-1-yl)methyl)benzaldehyde (0.240 g, 97%).

[0385] A mixture of 4-((4-isopropylpiperazin-1-yl)methyl)benzaldehyde (0.240 g, 0.97 mmol), $NaHSO_3$ (0.155 g, 1.50 mmol), and *p*-TsOH (0.019 g, 0.10 mmol) was added to a solution of 2-amino-4,6-dimethoxybenzamide (0.190 g, 0.97 mmol) in DMA (7 mL). The reaction was stirred at 130 °C overnight. Then, the mixture was diluted with H_2O and extracted with CH_2Cl_2 . The organics were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 2% to 10% MeOH/ CH_2Cl_2 , afforded the title compound (0.122 g, 30%) as a light yellow solid. ^1H NMR (300 MHz, $DMSO-d_6$): δ 12.02 (s, 1H), 8.12 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 6.74 (s, 1H), 6.53 (s, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.51 (s, 2H), 2.54-2.71 (m, 1H), 2.27-2.44 (m, 8H), 0.95 (d, J = 6.4 Hz, 6H). ESI MS m/z 423 $[M+H]^+$.

Example 99. Preparation of *N*-(1-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-*N*-isopropylacetamide




[0386] To a mixture of 4-(bromoethyl) benzaldehyde (0.840 g, 4.2 mmol) and K_2CO_3 (1.75 g, 12.6 mmol) in DMF (15 mL) was added *N*-isopropyl-*N*-(piperidin-4-yl)acetamide (0.92 g, 4.2 mmol) and the reaction was stirred at room temperature 5 hours, then concentrated *in vacuo*. The resulting mixture was

diluted with H₂O and extracted with EtOAc. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 1% to 10% MeOH/CH₂Cl₂, afforded *N*-(1-(4-formylbenzyl)piperidin-4-yl)-*N*-isopropylacetamide (0.770 g, 61%).

[0387] A mixture of *N*-(1-(4-formylbenzyl)piperidin-4-yl)-*N*-isopropylacetamide (0.770 g, 2.5 mmol), NaHSO₃ (0.350 g, 3.3 mmol), and *p*-TsOH (0.100 g, 0.51 mmol) was added to a solution of 2-amino-4,6-dimethoxybenzamide (0.500 g, 2.5 mmol) in DMA (20 mL). The reaction was stirred at 130 °C for 5 hours and concentrated *in vacuo*. The residue was diluted with H₂O and saturated NaHCO₃, then extracted with CH₂Cl₂. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 1% to 10% MeOH/CH₂Cl₂, afforded the title compound (0.670 g, 56%) as a light yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.02 (s, 1H), 8.13 (d, *J* = 8.1 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 6.74 (d, *J* = 1.9 Hz, 1H), 6.54 (d, *J* = 2.0 Hz, 1H), 3.85-3.95 (m, 7H), 3.43-3.71 (m, 3H), 2.55-3.00 (m, 3H), 1.97-2.09 (m, 5H), 1.70-1.77 (m, 1H), 1.58-1.61 (m, 1H), 1.25-1.30 (m, 4H), 1.11-1.13 (m, 3H). ESI MS *m/z* 479 [M+H]⁺.


Example 100. Preparation of 2-(4-((4-(Isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0388] A solution of 2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one (0.470 g, 0.98 mmol) in 2N HCl (20 mL) was refluxed for 3 days. The resulting mixture was basified with 2N NaOH and extracted with CH₂Cl₂. The organics were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel, eluting with 30% to 100% of 92:7:1 CHCl₃/MeOH/concentrated NH₄OH in CH₂Cl₂, afforded the title compound (0.090 g, 21%) as a light yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.12 (d, *J* = 8.3 Hz, 2H), 7.42 (d, *J* = 8.3 Hz, 2H), 6.73 (d, *J* = 2.3 Hz, 1H), 6.53 (d, *J* = 2.3 Hz,

1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.50 (s, 2H), 2.86-2.92 (m, 1H), 2.73-2.77 (m, 2H), 1.85-2.01 (m, 2H), 1.72-1.77 (m, 2H), 1.09-1.38 (m, 4H), 0.94 (d, $J = 6.2$ Hz, 6H). ESI/APCI MS m/z 437 $[M+H]^+$.

Example 101. Preparation of 2-(4-((1H-Tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0389] To a solution of 4-cyanomethyl benzoic acid methyl ester (2.63 g, 15 mmol) in anhydrous toluene (100 mL) was added sodium azide (1.95 g, 30 mmol) and triethylamine hydrochloride (4.13 g, 30 mmol). The reaction mixture was stirred at 100 °C for 24 hours under nitrogen. The reaction mixture was cooled to room temperature, then extracted with water (2×100 mL). The aqueous layer was acidified with concentrated HCl to pH approximately 4. The white solid was filtered off, washed with water, and dried under vacuum at 40 °C overnight, to give methyl-4-(1H-tetrazol-5-ylmethyl) benzoate (2.88 g, 88%) as an off-white solid.

[0390] Lithium aluminium hydride (0.142 g, 3.75 mmol) was taken in a dry, three-necked flask, fitted with a reflux condenser. Anhydrous ether (10 mL) was added. A solution of methyl-4-(1H-tetrazol-5-ylmethyl) benzoate (0.654 g, 3.0 mmol) in anhydrous THF (5 mL) was added dropwise. After the addition was complete, the mixture was heated to reflux for 2 hours. Then, the reaction mixture was cooled to 0 °C and quenched by cautious addition of water (10 mL) and 15% sodium hydroxide solution (10 mL). The reaction mixture was stirred for 30 minutes and then allowed to warm to room temperature. The aqueous phase was acidified to pH 4 and left for 2 days. A white precipitate was formed and filtered off, washed with water, and dried under vacuum, to give [4-(1H-tetrazol-5-ylmethyl)-phenyl]-methanol as a white solid. Yield: 0.290 g (51%).

[0391] IBX (0.437 g, 1.562 mmol) was dissolved in anhydrous DMSO (5 mL) and [4-(1H-tetrazol-5-ylmethyl)-phenyl]-methanol (0.270 g, 1.562 mmol) was added. The reaction mixture was stirred at room temperature under nitrogen for 4 hours. Water (20 mL) was added. The white precipitate was filtered off, washed

with water, and dried under vacuum. The crude compound was mixed with methanol (20 mL) and stirred for 30 minutes, before being filtered. The filtrate was concentrated to give 4-(1*H*-tetrazol-5ylmethyl)-benzaldehyde as a white solid. Yield: 0.267 g (99%). To a solution of 2-amino-4,6-dimethoxybenzamide (0.157 g, 0.8 mmol) in *N,N*-dimethyl acetamide (5 mL) were added 4-(1*H*-tetrazol-5ylmethyl)-benzaldehyde (0.260 g, 1.4 mmol), sodium hydrogen sulfite (58.5%, 0.159 g, 0.88 mmol) and *p*-toluenesulfonic acid (19 mg, 0.08 mmol). The reaction mixture was stirred at 150°C for 3 h, then cooled to room temperature. Water (40 mL) was then added. A yellow precipitate was formed and filtered off, washed with water, and small amount of methanol. It was triturated with 10% methanol in ether to give 0.107 g of solid, which was further purified by preparative HPLC, to give the title compound (0.082 g, 28%) as a white solid. MS (ES) *m/z*: 365.1 (M+1). MP 295-296°C.


Example 102. Preparation of 1-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione



[0392] To a solution of 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.50 g, 1.35 mmol) in anhydrous THF (20 mL) were added triphenyl phosphine (0.53 g, 2.02 mmol), pyrrolidine-2,5-dione (0.20 g, 2.02 mmol), and *N,N*-diisopropylethyl amine (0.44 g, 3.38 mmol). To this stirred solution was added diethylazodicarboxylate (0.35 g, 2.02 mmol). The reaction mixture was stirred at room temperature for 8 hours under nitrogen. Ethyl acetate (400 mL) was added. The organic phase was separated, washed with water (100 mL), then brine (100 mL), and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure. The crude material was purified by the Simpliflash system (4:96 methanol:CH₂Cl₂ as eluent) to give the title compound as a white solid. Yield: 0.3 g. (49%). ¹H NMR (400 MHz, CDCl₃): δ 9.30 (br s, 1H), 7.66 (s, 2H), 6.82 (d, *J* = 2.4 Hz, 1H), 6.46 (d, *J* = 1.6 Hz, 1H), 3.99 (s, 3H), 3.97

(s, 3H), 3.92 (s, 4H), 2.78 (s, 4H), 2.31 (s, 6H). MS (ES) m/z : 452.51 (M+1) (100%).

Example 103. Preparation of 7-(2-(Benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one




[0393] To a stirred solution of 2-amino-4,6-difluoro-benzamide (0.50 g, 2.9 mmol) and pyridine-4-carbaldehyde (0.35 g, 3.2 mmol) in *N,N*-dimethylacetamide (10 mL) were added sodium hydrogen sulfite (0.63 g, 3.5 mmol) and *p*-toluenesulfonic acid (0.06 g, 0.3 mmol); the reaction mixture was stirred at 115 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid was filtered off to obtain 5,7-difluoro-2-pyridin-4-yl-3*H*-quinazolin-4-one as a yellow solid, which was used in the next step without further purification. Yield: 0.4 g (53%).

[0394] To a suspension of 5,7-difluoro-2-pyridin-4-yl-3*H*-quinazolin-4-one (0.20 g, 0.80 mmol) in DMF (3 mL) was added sodium methoxide in methanol (0.43 g, 8.0 mmol) and the reaction mixture was stirred at room temperature for 16 hours. Water was added, the mixture was acidified with acetic acid to pH approximately 4-5, and the precipitated solid was filtered off to obtain 7-fluoro-5-methoxy-2-pyridin-4-yl-3*H*-quinazolin-4-one as a yellowish solid. Yield: 0.20 g (83%).

[0395] To a solution of 2-benzyloxy-ethanol (2 mL) in dimethyl sulfoxide (3 mL) was added sodium hydride (0.30 g, 7.4 mmol) in portions, and the reaction mixture was stirred at room temperature for 45 minutes. To this mixture was added 7-fluoro-5-methoxy-2-pyridin-4-yl-3*H*-quinazolin-4-one (0.20 g, 0.74 mmol) and the reaction mixture was heated at 80 °C for 16 hours. Water was added, the mixture was acidified with acetic acid to pH approximately 4-5, and the precipitated solid was filtered off, to obtain a crude product, which was purified by preparative HPLC to obtain the title compound as a light yellow solid. Yield: 0.12 g (40%). MP 228.2-229.9°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.29 (s, 1H), 8.77

(d, 2H), 8.08 (d, 2H), 7.36 (m, 5H), 6.82 (s, 1H), 6.62 (s, 1H), 4.58 (s, 2H), 4.32 (t, 2H), 3.87 (s, 3H), 3.83 (t, 2H). MS (ES⁺) *m/z*: 404.51 (M+1).

Example 104. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one



[0396] A solution of 2,6-lutidine N-oxide (24.0 g, 0.20 mol) in anhydrous dichloromethane (400 mL) was added to trimethyloxonium tetrafluoroborate (29.6 g, 0.20 mol) at room temperature under nitrogen atmosphere and the reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated *in vacuo* to give the crude product, 1-methoxy-2,6-dimethylpyridinium tetrafluoroborate.


[0397] The crude product was dissolved in MeOH (300 mL) and heated to reflux under nitrogen. Then, a solution of ammonium persulfate (14.2 g, 0.06 mol) in water (57 mL) was added. The mixture was stirred under reflux for 16 hours; TLC showed completion of the reaction. Half of the solvent was removed *in vacuo*, then quenched with 10% aqueous NaOH solution to pH 7, and evaporated to dryness *in vacuo*. The residue was dissolved in methanol and filtered, the filtrate was concentrated *in vacuo*, and the crude compound was purified by column chromatography (silica gel 230-400 mesh; 5-15 % methanol in CH₂Cl₂ as eluent) to give 4-hydroxymethyl-2,6-dimethylpyridine as a white solid. Yield: 11.0 g (40.0 %).

[0398] 4-Hydroxymethyl-2,6-dimethylpyridine (1.00 g, 7.28 mmol) was dissolved in ethanol (20 mL), and activated MnO₂ (2.24 g, 21.8 mmol) was added; the reaction mixture was refluxed for 17 hours. The mixture was cooled and concentrated, purified by column chromatography (silica gel 230-400 mesh; 20% ethyl acetate in hexanes as eluent) to give 2,6-dimethyl-4-pyridinecarboxaldehyde as a yellow oil. Yield: 0.14 g (14 %).

[0399] To a solution of 2,6-dimethylpyridine-4-carbaldehyde (0.14 g, 1.00 mmol) in *N,N*-dimethyl acetamide (10 mL) were added 2-amino-4,6-

dimethoxybenzamide (0.20 g, 1.00 mmol), sodium hydrogen sulfite (0.21 g, 2.00 mmol), and *p*-toluenesulfonic acid (0.28 g, 1.50 mmol). The reaction mixture was stirred at 110 °C for 16 hours under nitrogen. After cooling to room temperature, solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated NaHCO₃ solution (30 mL), water (30 mL), and brine (30 mL), and dried over anhydrous sodium sulfate. Solvent was evaporated, and the residue was purified by column chromatography (silica gel 230-400 mesh; 2-5% methanol in dichloromethane as eluent) to give the title compound as a yellow solid. Yield: 0.030 g (10%). MP 291-292°C. ¹H NMR (400 MHz, CDCl₃): δ 9.86 (br s, 1H), 7.60 (s, 2H), 6.87 (d, *J* = 2.2 Hz, 1H), 6.53 (d, *J* = 2.2 Hz, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 2.66 (s, 6H). MS (ES) *m/z*: 312.50 (*M*+1) (100%).

Example 105. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one



[0400] To a suspension of 2,6-dimethyl-pyridin-4-yl)-methanol (1.00 g, 7.30 mmol) in acetonitrile (20 mL), 1,2-benziodoxol-3(1*H*)-one-1-hydroxy-1-oxide (IBX) (2.00 g, 7.30 mmol) was added and the reaction mixture was refluxed for 6 hours. The solid was filtered off and washed with acetonitrile. The filtrate was evaporated *in vacuo* to give 2,6-dimethyl-pyridine-4-carbaldehyde as a brown liquid. Yield: 0.81 g (82%).


[0401] To a stirred solution of 2-amino-4,6-difluoro-benzamide (1.03 g, 6.00 mmol) and 2,6-dimethyl-pyridine-4-carbaldehyde (0.81 g, 6.00 mmol) in *N,N*-dimethyl acetamide (15 mL), sodium hydrogen sulfite (58.5 wt%, 1.31 g, 7.20 mmol), and *p*-toluenesulfonic acid monohydrate (0.11 g, 0.60 mmol) were added and the reaction mixture was stirred at 115 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid was filtered, to give 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one as a yellow

solid, which was used in the next step without further purification. Yield: 0.72 g (42%).

[0402] To a suspension of 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one (0.72 g, 2.51 mmol) in DMF (10 mL), a solution of sodium methoxide in methanol (25 wt%, 1.36 g, 25.1 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. Water was added, the mixture was acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered and dried under vacuum to give 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one as a light yellow solid. Yield: 0.28 g (37%).

[0403] To a solution of 2-methoxyethanol (3 mL) in dimethyl sulfoxide (8 mL), sodium hydride (60% suspension in mineral oil, 0.40 g, 9.40 mmol) was added in portions and the reaction mixture was stirred at room temperature for 1 hour. To this reaction mixture was added 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (0.28 g, 0.94 mmol) and the reaction mixture was stirred at 90 °C for 16 hours. Water was added, acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered to give crude product, which was purified by preparative HPLC, to obtain the title compound as a white solid. Yield: 0.12 g (36%). MP 228.8-230.4°C. MS (ES) *m/z*: 356.05 ($M^+ + 1$). ¹H NMR (400 MHz, CDCl₃): δ 10.45 (s, 1H), 7.65 (s, 2H), 6.85 (d, *J* = 1.6 Hz, 1H), 6.61 (d, *J* = 1.6 Hz, 1H), 4.27 (t, *J* = 4.8 Hz, 2H), 3.97 (s, 3H), 3.82 (t, *J* = 4.8 Hz, 2H), 3.49 (s, 3H), 2.66 (s, 6H).

Example 106. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3*H*)-one



[0404] To a suspension of 2,6-dimethyl-pyridin-4-yl-methanol (1.00 g, 7.30 mmol) in acetonitrile (20 mL), 1,2-benziodoxol-3(1*H*)-one-1-hydroxy-1-oxide (IBX) (2.00 g, 7.30 mmol) was added and the reaction mixture was refluxed for 6 hours.


The solid was filtered off and washed with acetonitrile. The filtrate was evaporated *in vacuo*, to give 2,6-dimethyl-pyridine-4-carbaldehyde as a brown liquid. Yield: 0.81 g (82%).

[0405] To a stirred solution of 2-amino-4,6-difluoro-benzamide (1.03 g, 6.00 mmol) and 2,6-dimethyl-pyridine-4-carbaldehyde (0.81 g, 6.00 mmol) in *N,N*-dimethyl acetamide (15 mL), sodium hydrogen sulfite (58.5 wt%, 1.31 g, 7.20 mmol) and *p*-toluenesulfonic acid monohydrate (0.11 g, 0.60 mmol) were added and the reaction mixture was stirred at 115 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid was filtered to give 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one as a yellow solid, which was used in the next step without further purification. Yield: 0.72 g (42%).

[0406] To a suspension of 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one (0.72 g, 2.51 mmol) in DMF (10 mL), a solution of sodium methoxide in methanol (25 wt%, 1.36 g, 25.1 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Water was added, the mixture was acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered and dried under vacuum, to give 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one as a light yellow solid. Yield: 0.28 g (37%).

[0407] To a solution of 2-methoxyethanol (3 mL) in dimethyl sulfoxide (8 mL), sodium hydride (60% suspension in mineral oil, 0.40 g, 9.40 mmol) was added in portions and the reaction mixture was stirred at room temperature for 1 hour. To this reaction mixture was added 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (0.28 g, 0.94 mmol); the reaction mixture was stirred at 90 °C for 16 hours. Water was added, the mixture was acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered, to give crude product, which was purified by preparative HPLC to obtain the title compound. Yield: 0.03 g (8%). MP 149.8-151.4°C. MS (ES) *m/z*: 400.13 ($M^+ + 1$). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (s, 2H), 6.85 (s, 1H), 6.61 (s, 1H), 4.24 (m, 4H), 3.87 (t, *J* = 5.2 Hz, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 3.49 (br s, 6H), 2.65 (s, 6H).

Example 107. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one




[0408] To a solution of 2,6-dimethyl-pyridine-4-carbaldehyde (0.99 g, 7.32 mmol) and 2-amino-4,6-difluorobenzamide (1.26 g, 7.32 mmol) in *N,N*-dimethyl acetamide (20 mL) were added sodium hydrogen sulfite (58.5 wt%, 1.59 g, 8.78 mmol) and *p*-toluenesulfonic acid (0.21 g, 1.09 mmol). The reaction mixture was stirred at 115 °C for 16 hours under nitrogen. After cooling to room temperature, the solvent was evaporated under reduced pressure. Water (50 mL) was added, the precipitated solid was filtered, washed with water, and dried under vacuum, to give 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one as a yellow solid. Yield: 0.63 g (30%).

[0409] To a solution of 2-pyrrolidin-1-yl-ethanol (5.09 g, 44.2 mmol) in DMF (10 mL) was added sodium hydride (60% suspension in mineral oil, 0.88 g, 22.1 mmol) in small portions and the reaction mixture was stirred at room temperature for 30 minutes. To this mixture was added 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one 0.63 g, 2.21 mmol) and the reaction mixture was stirred at room temperature for 16 hours. Water (20 mL) was added, and the mixture was neutralized, to pH approximately 6 with acetic acid. Solvent was evaporated, and the residue was dissolved in ethyl acetate, washed with water, and dried over anhydrous sodium sulfate, and concentrated *in vacuo*. The crude compound was purified by the Simpliflash system (0-4% methanol in CH₂Cl₂ as eluent) to give 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-(2-pyrrolidin-1-yl-ethoxy)-3*H*-quinazolin-4-one as a yellow solid. Yield: 0.61 g (72%).

[0410] To a solution of 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-(2-pyrrolidin-1-yl-ethoxy)-3*H*-quinazolin-4-one (0.30 g, 0.80 mmol) in anhydrous DMF (5 mL) was added a solution of sodium methoxide in methanol (25 wt%, 0.43 g, 8.00

mmol) and the reaction mixture was stirred at 70°C for 16 h. After cooling to room temperature, water (10 mL) was added, and the mixture was neutralized to pH approximately 6 with acetic acid. The solvent was evaporated, and the residue was purified by the Simpliflash system (2% methanol in CH₂Cl₂ and then 4% 7.0 M ammonia in methanol and CH₂Cl₂ as eluent) to give the title compound as a yellow solid. Yield: 0.100 g (32%). MP 190-191°C. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (s, 2H), 6.86 (d, *J* = 1.95 Hz, 1H), 6.53 (d, *J* = 1.95 Hz, 1H), 4.25 (t, *J* = 6.05 Hz, 2H), 3.93 (s, 3H), 3.03 (t, *J* = 6.24 Hz, 2H), 2.69 (br s, 4H), 2.64 (s, 6H), 1.93-1.70 (m, 4H). MS (ES⁺) *m/z*: 395.22 (M+1) and 298.12 (100%).

Example 108. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-6-((4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one



[0411] To a mixture of 5-methyl-2-nitrobenzoic acid (45.0 g, 0.248 mol) and potassium carbonate (138.2 g, 1.0 mol) in acetonitrile (700 mL), methyl iodide (78 mL, 1.25 mol) was added. The reaction mixture was stirred at room temperature for 12 hours, then the solution was filtered. The filtrate was concentrated under reduced pressure. The resulting solid was dissolved in ethyl acetate and washed with water and brine. The crude 5-methyl-2-nitrobenzoic acid methyl ester was used in the next step without further purification. Yield: 27.1 g (56 %).

[0412] 5-Methyl-2-nitrobenzoic acid methyl ester (27.1 g, 138.8 mmol) was dissolved in carbon tetrachloride (500 mL), and N-bromosuccinimide (29.6 g, 166.6 mmol) was added, followed by benzoyl peroxide (6.72 g, 27.7 mmol). The mixture was illuminated and gently refluxed for 4 hours. Then, the mixture was cooled and concentrated, then purified by column chromatography silica gel 230-400 mesh; 10% ethyl acetate in hexanes as eluent) to give 5-bromomethyl-2-nitrobenzoic acid methyl ester. Yield: 17.9 g (47%).

[0413] To a solution of 5-bromomethyl-2-nitrobenzoic acid methyl ester (3.00 g, 10.9 mmol) in CH₂Cl₂ (100 mL) was added triethylamine (3.30 g, 33.0 mmol) and 1-methylpiperazine (3.30 g, 33.0 mmol). The mixture was heated at 50

°C under nitrogen for 16 hours, then concentrated to give crude 5-(4-methylpiperazin-1-ylmethyl)-2-nitrobenzoic acid methyl ester, which was purified by column chromatography (silica gel 230-400 mesh; 1~5 % methanol in dichloromethane as eluent). Yield: 3.0 g (93%). It was further converted to its hydrochloride salt (3.7 g) by stirring in 1 M HCl in ether and was isolated by filtration.

[0414] To a solution of 5-(4-methylpiperazin-1-ylmethyl)-2-nitrobenzoic acid methyl ester hydrochloride salt (3.70 g, 10.0 mmol) in acetic acid (50 mL) was added iron powder (1.80 g, 32.1 mmol), and the mixture was stirred at 70 °C for 2 hours; TLC indicated completion of the reaction. The mixture was cooled and concentrated; the residue was taken in 7 N ammonia in methanol (50 mL) and filtered. The filtrate was evaporated to dryness and purified by column chromatography (silica gel 230-400 mesh; 5-10% methanol in dichloromethane as eluent). Yield: 4.3 g (crude). The crude 2-amino-5-(4-methyl-piperazin-1-ylmethyl)benzoic acid methyl ester was used in the next step without further purification.


[0415] To a suspension of 2-amino-5-(4-methyl-piperazin-1-ylmethyl)benzoic acid methyl ester (4.30 g, 10.0 mmol) in water (30 mL) and methanol (10 mL) was added lithium hydroxide (1.26 g, 30.0 mmol); the mixture was stirred at room temperature for 12 hours. An additional amount of lithium hydroxide (0.6 g, 15.0 mmol) was added, and heated at 40 °C for 15 hours; TLC indicated completion of the reaction. The mixture was cooled, concentrated, the residue was adjusted to pH ~5 with 6 N HCl, and evaporated to dryness, to provide crude 2-amino-5-(4-methyl-piperazin-1-ylmethyl)benzoic acid. Yield: 6.2 g, along with inorganic salt. It was used in the next step without further purification.

[0416] To a suspension of 2-amino-5-(4-methyl-piperazin-1-ylmethyl)benzoic acid (crude 1.28 g, 3.00 mmol) in THF (18 mL) and DMF (7 mL), EDCI (0.77 g, 4.00 mmol), and HOBT (0.50 g, 3.30 mmol) were added and stirred at room temperature for 20 minutes. Then, N-methylmorpholine (0.33 g, 3.30 mmol) and NH₄OH (aq. 50 %v/v, 3.50 mL, 50.0 mmol) were added. The mixture was stirred at room temperature for 48 hours. The solvent was evaporated, the residue was purified by column chromatography (silica gel 230-400 mesh; 5-10% 2 M ammonia in methanol and dichloromethane as eluent) to give 2-amino-5-(4-

methyl-piperazin-1-ylmethyl)benzamide as a white solid. Yield: 0.416 g (55 % for two steps).

[0417] To a solution of 2,6-dimethylpyridine-4-carbaldehyde (0.14 g, 1.00 mmol) in *N,N*-dimethyl acetamide (8 mL) were added 2-amino-5-(4-methyl-piperazin-1-ylmethyl)benzamide (0.25 g, 1.00 mmol), sodium hydrogensulfite (0.18 g, 1.20 mmol), and *p*-toluenesulfonic acid (0.057 g, 0.30 mmol). The reaction mixture was stirred at 115 °C for 20 hours under nitrogen, then cooled to room temperature. Solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane, washed with sat. NaHCO₃, water, then brine, and dried over anhydrous sodium sulfate. Solvent was evaporated and the residue was purified by column chromatography (silica gel 230-400 mesh; 2-3% 7 M ammonia in methanol and dichloromethane as eluent) to give the title compound. Yield: 0.035 g (9.6%). MP 229-230°C. ¹H NMR (400 MHz, CDCl₃): δ 8.30 (br s, 1H), 7.88 (s, 2H), 7.84 (m, 2H), 3.66 (s, 2H), 2.72 (s, 6H), 2.50 (br s, 8H), 2.30 (s, 3H). MS (ES) *m/z*: 364.17 (M+1), 182.67 (100%).


Example 109. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one



[0418] To a solution of 2-phenoxy-ethanol (0.90 g, 6.50 mmol) in DMSO (5 mL) was added sodium hydride (60% in mineral oil, 0.16 g, 4.00 mmol) in small portions. The reaction mixture was stirred at room temperature under nitrogen for 1 hour. 2-(2,6-Dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (0.20 g, 0.67 mmol) was added and stirring continued at 90 °C for 17 hours. The reaction was then cooled to room temperature, water (100 mL) was added, and was extracted with ethyl acetate (200 mL). The organic phase was washed with brine and dried over anhydrous Na₂SO₄. Solvent was removed and the crude compound was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in CH₂Cl₂ as eluent) to give the title compound as a white solid. Yield: 70 mg (25%). MP 223-224°C. ¹H NMR (400 MHz, CDCl₃): δ 11.35 (s, 1H), 7.75 (s,

2H), 7.32 (t, $J = 8.0$ Hz, 2H), 7.02-6.97 (m, 3H), 6.91 (d, $J = 2.0$ Hz, 1H), 6.60 (d, $J = 1.6$ Hz, 1H), 4.49-4.47 (m, 2H), 4.41-4.39 (m, 2H), 3.97 (s, 3H), 2.67 (s, 6H). MS (ES⁺) m/z : 418.08 (M+1).

Example 110. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one



[0419] A solution of 2,6-lutidine N-oxide (41.6 g, 0.337 mol, 1.0 equiv.) in dry DCM (650 mL) was added to a flask containing trimethyloxonium tetrafluoroborate (50.0 g, 0.337 mol, 1.0 equiv.) at room temperature. under a nitrogen atmosphere. The mixture was stirred at room temperature for 3.0 hours, then concentrated *in vacuo* to give 78 g of crude 4-hydroxymethyl-2,6-dimethylpyridine. The crude product was dissolved in methanol (500 mL) and the solution was heated to reflux under a nitrogen atmosphere, then a solution of ammonium persulfate (24.6 g, 0.101 mol) in water (100 mL) was added dropwise. The mixture was stirred at reflux for 16 hours; TLC indicated complete reaction. Half of the solvents were removed *in vacuo*, then quenched with 10% NaOH solution to pH approximately 7, and evaporated to dryness. The residue was dissolved in methanol and filtered, the filtrate was concentrated in vacuum, and purified by column chromatograph (eluting with methanol: DCM = 5-15%) to give the title compound as a white solid. Yield: 24.7 g (52%).

[0420] 4-Hydroxymethyl-2,6-dimethylpyridine (24.7 g, 180 mmol, 1.0 equiv.) was dissolved in DMSO (200 mL), and IBX (53.0 g, 189 mmol, 1.05 equiv.) was added in portions, the mixture was stirred at room temperature for 2 hours; TLC indicated complete reaction. The mixture was filtered, washed with water and ether. The filtrate was extracted with ether (4 × 150 mL); the combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, and

concentrated to give the crude product, which was purified by column chromatography (20% ether in hexanes as eluent) to give 2,6-dimethyl-4-pyridinecarboxaldehyde as a yellow oil. Yield: 20.0 g (82%).


[0421] To a solution of 2,6-dimethyl-pyridine-4-carbaldehyde (5.0 g, 36.5 mmol) and 2-amino-4,6-difluorobenzamide (6.28 g, 36.5 mmol) in *N,N*-dimethyl acetamide (80 mL) were added sodium hydrogen sulfite (7.95 g, 43.8 mmol) and *p*-toluenesulfonic acid (0.7 g, 3.65 mmol). The reaction mixture was stirred at 115 °C for 16 hours under nitrogen. The reaction mixture was cooled to room temperature, diluted with water, the precipitate was collected by filtration, washed with sat. NaHCO₃ and brine, and dried *in vacuo* to give 2-(2,6-dimethylpyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one as a white solid. Yield: 2.82 g (26.8%).

[0422] To a solution of 2-phenoxyethanol (4.81 g, 34.8 mmol) in DMF (20 mL) was added sodium hydride (60% suspension in mineral oil, 0.70 g, 17.4 mmol) in portions and the reaction mixture was stirred at room temperature for 1 hour. To this mixture was added 2-(2,6-dimethylpyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one (0.50 g, 1.74 mmol) and the reaction mixture was stirred at room temperature for 16 hours. Water (1 mL) was added, neutralized to pH approximately 6-7 with acetic acid, concentrated, dissolved in ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated *in vacuo*. The residue was purified by column chromatography (eluted with 50% ethyl acetate in hexanes, then 5% methanol in DCM) to give 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-phenoxyethoxy)-3H-quinazolin-4-one as a light yellow solid. Yield: 0.59 g (83%).

[0423] To a suspension of 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-phenoxyethoxy)-3H-quinazolin-4-one (0.59 g, 1.45 mmol) in DMF (10 mL) was added a solution of sodium methoxide in methanol (25 wt%, 3.15 g, 14.5 mmol) and the reaction mixture was stirred at approximately 70-80 °C for 48 hours, then cooled to room temperature. Water (1 mL) was added, the mixture was neutralized to pH approximately 6-7 with acetic acid, concentrated, dissolved in DCM, washed with water and brine, dried over anhydrous sodium sulfate, concentrated *in vacuo*, and the residue was passed through a column (eluted with 2% methanol in DCM), to give 0.12 g of the desired product. The crude product was washed with acetonitrile, then solubilized in dioxane, and precipitated by

adding water to afford the title compound as a white solid. Yield: 70 mg (11%). ^1H NMR (400 MHz, DMSO- d_6): δ 12.08 (br s, 1H), 7.77 (s, 2H), 7.31 (t, J = 7.81 Hz, 2H), 7.04 (d, J = 8.20 Hz, 2H), 6.96 (t, J = 7.42 Hz, 1H), 6.83 (d, J = 1.56 Hz, 1H), 6.69 (s, 1H), 4.40-4.53 (m, 2H), 3.90 (s, 3H), 3.33 (s, 6H). MS (ES $^+$) m/z : 418.14 ($M+1$) $^+$; MP 172.3-173.2°C.

Example 111. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one




[0424] To a solution of 2-methoxyethanol (2.65 g, 34.8 mmol) in DMF (38 mL) was added sodium hydride (60% suspension in mineral oil, 0.70 g, 17.4 mmol) in portions and the reaction mixture was stirred at room temperature for 0.5 hours. To this mixture was added 2-(2,6-dimethylpyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one (0.50 g, 1.74 mmol) and the reaction mixture was stirred at room temperature for 16 hours. Water (1.5 mL) was added, the mixture was neutralized to pH approximately 6-7 with acetic acid, concentrated, dissolved in ethyl acetate (200 mL), washed with water and brine, dried over anhydrous sodium sulfate, and concentrated *in vacuo*. The residue was washed with hexanes to give 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-methoxyethoxy)-3H-quinazolin-4-one) as a pale solid. Yield: 0.52 g (87 %).

[0425] To a suspension of 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-methoxyethoxy)-3H-quinazolin-4-one (0.42 g, 1.22 mmol) in DMF (10 mL) was added a solution of sodium methoxide in methanol (25 wt%, 2.8 g, 12.8 mmol) and the reaction mixture was stirred at 70 °C for 16 hours, then cooled to room temperature. Water (1 mL) was added, the mixture was neutralized to pH approximately 6 with acetic acid, diluted with water (50 mL), and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, and concentrated *in vacuo*, to give 0.30 g of crude compound. Further purification by crystallization in acetone:Et $_2$ O (1:3) gave the

title compound as a white solid. Yield: 91 mg (15%). ^1H NMR (400 MHz, CDCl_3): δ 10.08 (br s, 1H), 7.60 (br s, 2H), 6.87 (d, $J = 1.95$ Hz, 2H), 6.55 (d, $J = 1.95$ Hz, 2H), 4.25 (t, $J = 4.88$ Hz, 2H), 3.93 (s, 3H), 3.83 (d, $J = 4.29$ Hz, 2H), 3.44 (s, 3H), 2.64 (s, 6H). MS (ES^+) m/z : 356.11 ($\text{M}+1$) $^+$

Example 112. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one



[0426] To a suspension of 2,6-dimethyl-pyridin-4-yl)-methanol (6.00 g, 0.043 mol) in acetonitrile (150 mL), 1,2-benziodoxol-3(1H)-one-1-hydroxy-1-oxide (IBX) (14.8 g, 0.0503 mol) was added and the reaction mixture was refluxed for 2 hours. The solid was filtered off and washed with acetonitrile. The filtrate was evaporated *in vacuo* to give 2,6-dimethyl-pyridine-4-carbaldehyde as a brown liquid. Yield: 4.30 g (72.7%).


[0427] To a stirred solution of 2-amino-4,6-difluoro-benzamide (4.00 g, 0.0237 mol) and 2,6-dimethyl-pyridine-4-carbaldehyde (3.20 g, 0.0237 mol) in *N,N*-dimethyl acetamide (15 mL), sodium hydrogen sulfite (58.5 wt%, 5.05 g, 0.0284 mol) and *p*-toluenesulfonic acid monohydrate (0.90 g, 4.74 mmol) were added and the reaction mixture was stirred at 130 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid was filtered to give 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one as a yellow solid, which was used in the next step without further purifications. Yield: 3.70 g (42%).

[0428] To a suspension of 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one (2.70 g, 9.4 mmol) in DMF (15 mL), a solution of sodium methoxide in methanol (25 wt%, 6.0 g, 28.2 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Water was added, the mixture was acidified to pH approximately 4-5 with acetic acid, and the precipitated solid was filtered and dried under vacuum to give crude 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3H-quinazolin-4-one (2.40 g), which was

further purified by column chromatography (silica gel 230-400 mesh; eluting with 2% methanol solution in dichloromethane) to yield pure compound as a light yellow solid. Yield: 0.35 g (12.4%).

[0429] To a solution of 2-pyrrolidin-1-yl-ethanol (1.15 g, 10 mmol) in dimethyl sulfoxide (4 mL), sodium hydride (60% suspension in mineral oil, 0.20 g, 5.0 mmol) was added in portions and the reaction mixture was stirred at room temperature for 20 minutes. To this reaction mixture was added 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (0.30 g, 1.0 mmol) and the reaction mixture was stirred at 75 °C for 16 hours. The reaction mixture was loaded onto a column and purified by column chromatography (silica gel 230-400 mesh; eluting with 5% 7.0 M ammonia in methanol solution in dichloromethane), to obtain the title compound as a white solid. Yield: 0.163 g (41.3%). MP 227-229°C. MS (ES) *m/z*: 395.15 ($M^+ + 1$). ¹H NMR (400 MHz, CDCl₃): δ 7.78 (s, 2H), 6.87 (d, *J* = 2.4 Hz, 1H), 6.58 (d, *J* = 2.4 Hz, 1H), 4.25 (t, *J* = 6.0 Hz, 2H), 3.95 (s, 3H), 2.97 (t, *J* = 6.0 Hz, 2H), 2.66 (s, 6H), 2.63 (m, 4H), 1.83 (m, 4H).

Example 113. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3*H*)-one




[0430] To a suspension of 2-(2,6-dimethylpyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one (0.97 g, 3.38 mmol) in anhydrous DMF (10 mL) was added a solution of sodium methoxide in methanol (25 wt%, 1.09 g, 20.3 mmol). The reaction mixture became clear. The reaction mixture was stirred at room temperature for 16 hours. Water (100 mL) was added, neutralized to pH approximately 6 with aqueous 2N HCl. The separated solid was filtered, washed with water (50 mL), and dried under vacuum to give an off-white solid. Yield: 0.94 g (93%).

[0431] To a suspension of sodium hydride (60% suspension in mineral oil, 0.24 g, 6.00 mmol) in anhydrous DMSO (10 mL) was added 2-isopropoxy-ethanol


at room temperature under nitrogen. The mixture was stirred for 20 minutes at room temperature, then 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3H-quinazolin-4-one (0.30 g, 1.00 mmol) was added and the reaction mixture was stirred at 80 °C for 16 hours, then cooled to room temperature. Water (50 mL) was added, and the mixture was extracted with a mixture of ethyl acetate and THF (4:1, 200 mL). The organic phase was washed with brine and dried over anhydrous sodium sulfate. Solvent was evaporated, and the crude compound was purified by the Simpliflash system (3:15:82 methanol, ethyl acetate and dichloromethane as eluent) to give the title compound as a white solid. Yield: 127 mg (33%). MP 188-189°C. ¹H NMR (400 MHz, CDCl₃): δ 11.14 (br s, 1H), 7.72 (s, 2H), 6.86 (d, J = 2.34 Hz, 1H), 6.59 (d, J = 2.34 Hz, 1H), 4.35 - 4.15 (m, 2H), 3.97 (s, 3H), 3.89 - 3.79 (m, 2H), 3.78 - 3.64 (m, 1H), 2.66 (s, 6H), 1.23 (d, J = 5.85 Hz, 6H). MS (ES⁺) *m/z*: 384.20 (100%).

Example 114. Preparation of 2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one



[0432] The title compound was isolated using the process described for Example 113 as a white solid. Yield: 124 mg (27%). MP 124-125°C. ¹H NMR (400 MHz, CDCl₃): δ 10.04 (br s, 1H), 7.60 (s, 2H), 6.85 (d, J = 2.34 Hz, 1H), 6.63 (d, J = 2.34 Hz, 1H), 4.23 (t, J = 4.88 Hz, 4H), 3.85 (dt, J = 10.54 and 5.27 Hz, 4H), 3.80 - 3.64 (m, 2H), 2.64 (s, 6H), 1.23 (d, J = 6.24 Hz, 6H), 1.17 (d, J = 6.24 Hz, 6H). MS (ES⁺) *m/z*: 456.17 (100%).

Example 115. Preparation of 7-(2-(Benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one



[0433] To a suspension of 2,6-dimethyl-pyridin-4-yl-methanol (6.00 g, 0.043 mol) in acetonitrile (150 mL), 1,2-benziodoxol-3(1*H*)-one-1-hydroxy-1-oxide (IBX) (14.8 g, 0.0503 mol) was added and the reaction mixture was refluxed for 2 hours. The solid was filtered off and washed with acetonitrile. The filtrate was evaporated *in vacuo* to give 2,6-dimethyl-pyridine-4-carbaldehyde as a brown liquid. Yield: 4.30 g (72.7%).


[0434] To a stirred solution of 2-amino-4,6-difluoro-benzamide (4.00 g, 0.0237 mol) and 2,6-dimethyl-pyridine-4-carbaldehyde (3.20 g, 0.0237 mol) in *N,N*-dimethyl acetamide (15 mL), sodium hydrogen sulfite (58.5 wt%, 5.05 g, 0.0284 mol), and *p*-toluene sulfonic acid monohydrate (0.90 g, 4.74 mmol) were added and the reaction mixture was stirred at 130 °C for 16 hours. The solvent was evaporated *in vacuo*, water was added, and the precipitated solid was filtered to give 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one as a yellow solid, which was used in the next step without further purification. Yield: 3.70 g (54.3%).

[0435] To a suspension of 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3*H*-quinazolin-4-one (2.70 g, 9.4 mmol) in DMF (15 mL), a solution of sodium methoxide in methanol (25 wt%, 6.0 g, 28.2 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. Water was added, acidified to pH approximately 4-5 with acetic acid and the precipitated solid was filtered and dried under vacuum to give crude 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (2.40 g), which was further purified by column chromatography (silica gel 230-400 mesh; eluting with 2% methanol solution in dichloromethane) to yield pure compound as a light yellow solid. Yield: 0.35 g (12.4%).

[0436] To a solution of 2-benzyloxy-ethanol (1.15 g, 10.0 mmol) in dimethyl sulfoxide (4 mL), sodium hydride (60% suspension in mineral oil, 0.20 g, 5.0 mmol) was added in portions and the reaction mixture was stirred at room


temperature for 20 minutes. To this reaction mixture was added 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-methoxy-3*H*-quinazolin-4-one (0.30 g, 1.0 mmol) and the reaction mixture was stirred at 85 °C for 24 hours. Water was added, and the mixture was acidified to pH approximately 4-5 with acetic acid and the precipitated solid was filtered to give crude product, which was purified by column chromatography (silica gel 230-400 mesh; eluting with hexane and ethyl acetate 10:1) to obtain the title compound as a white solid. Yield: 0.140 g (32.4%). MP 178-180°C. MS (ES) *m/z*: 432.18 ($M^+ + 1$). ¹H NMR (400 MHz, CDCl₃): δ 10.90 (s, 1H), 7.69 (s, 2H), 7.29-7.40 (m, 5H), 6.85 (d, *J* = 2.0 Hz, 1H), 6.59 (d, *J* = 2.0 Hz, 1H), 4.66 (s, 2H), 4.29 (m, 2H), 3.97 (s, 3H), 3.89 (m, 2H), 2.66 (s, 6H).

Example 116. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-6-(2-morpholinoethyl)quinazolin-4(3*H*)-one



[0437] To a solution of 2-amino-5-(2-morpholin-4-yl-ethyl)-benzamide (0.18 g, 0.70 mmol) in *N,N*-dimethyl acetamide (7 mL) under nitrogen atmosphere were added 2,6-dimethylpyridine-4-carbaldehyde (0.10 g, 0.70 mmol), sodium hydrogensulfite (58.5 wt%, 0.15 g, 1.40 mmol) and *p*-toluenesulfonic acid (0.34 g, 1.80 mmol). The resulting mixture was heated at 120 °C for 16 hours, then cooled to room temperature. The solvent was removed under reduced pressure, and the residue was diluted with methylene chloride (100 mL). The organic phase was washed with saturated aqueous sodium bicarbonate solution, then water, and dried over anhydrous sodium sulfate. The crude orange solid (0.21 g) was purified by column chromatography (silica gel 230-400 mesh; 95:5 methylene chloride and MeOH as eluent) to give the title compound as a yellow solid. Yield: 0.11 g (42%). MP 248.5-249.3°C. ¹H NMR (400 MHz, CDCl₃): δ 11.6 (s, 1H), 8.18 (s, 1H), 7.87-7.76 (m, 3H), 7.76-7.65 (m, 1H), 3.76 (t, *J* = 4.49 Hz, 4H), 2.99 (t, *J* = 8.01 Hz, 4H), 2.71 (s, 6H), 2.75-2.65 (m, 2H), 2.56 (br s, 4H). MS (ES⁺) *m/z*: 363.16 ($M + 1$).


Example 117. Preparation of 2-(2-methylpyridin-4-yl)-6-(morpholinomethyl)quinazolin-4(3H)-one



[0438] A solution of n-butyllithium (1.6 M solution in hexanes, 6.32 mL, 12.6 mmol) in THF (50 mL) was cooled to -78 °C. A solution of 4-bromo-2-methylpyridine (2.00 g, 11.6 mmol) in anhydrous THF (5 mL) was added. The resulting mixture was stirred for 5 minutes, then anhydrous *N,N* dimethylformamide (3.39 g, 46.4 mmol) was added. The solution was stirred for 90 min at -78 °C and quenched with saturated aqueous NH_4Cl solution (30 mL). The reaction mixture was warmed to room temperature. The mixture was extracted with ethyl acetate (3×100 mL), and the combined organic phase was washed with brine (100 mL) and dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure to give 2-methylpyridine-4-carbaldehyde. Yield: 1.20g, (85%).

[0439] To a solution of 2-amino-5-morpholin-4-ylmethyl-benzamide (0.58 g, 2.4 mmol) and 2-methylpyridine-4-carbaldehyde (0.3 g, 2.4 mmol) in *N,N*-dimethylacetamide (10 mL) were added NaHSO_3 (58.5 wt%, 0.48 g, 2.7 mmol) and p-TSA (0.23 g, 1.2 mmol) and the reaction mixture was heated at 115 °C for 16 hours, and the solvent was removed under reduced pressure. The crude compound was purified by column chromatography (silica gel 230-400 mesh; eluting with 4% methanolic ammonia in dichloromethane) to give the title compound as a white solid. Yield: 0.18 g (22%). MP 267-268°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.74 (br s, 1H), 8.77 (d, J = 5.4 Hz, 1H), 8.29 (s, 1H), 8.07 (s, 1H), 7.94-7.83 (m, 3H), 3.75 (t, J = 4.2 Hz, 4H), 3.74 (s, 2H), 2.77 (s, 6H), 2.53-2.46 (m, 4H). MS (ES^+) m/z : 337.41(M+1).

Example 118. Preparation of 5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one




[0440] To a solution of 2-amino-4,6-difluoro-benzamide (0.71 g, 4.10 mmol) and 2-methyl-pyridine-4-carbaldehyde (0.50 g, 4.10 mmol) in *N,N*-dimethylacetamide (10 mL) were added NaHSO₃ (58.5 wt%, 1.00 g, 5.70 mmol) and p-TSA (0.16 g, 0.08 mmol). The reaction mixture was heated at 115 °C for 30 hours, then cooled to room temperature. The solvent was removed under reduced pressure. The crude compound was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane) to afford 5,7-difluoro-2-(2-methyl-pyridin-4-yl)-3*H*-quinazolin-4-one as a light yellow solid. Yield: 0.30 g (26%).

[0441] To a suspension of 5,7-difluoro-2-(2-methyl-pyridin-4-yl)-3*H*-quinazolin-4-one (0.30 g, 1.09 mmol) in anhydrous DMF (8 mL) was added a solution of sodium methoxide in methanol (25 wt%, 0.59 g, 10.9 mmol) and the reaction mixture was stirred at room temperature for 3 hours. Water was added, the mixture was acidified to pH approximately 5 with acetic acid, and the precipitated solid was filtered and dried under vacuum to give 7-fluoro-5-methoxy-2-(2-methyl-pyridin-4-yl)-3*H*-quinazolin-4-one as a light yellow solid. Yield: 0.24 g (76%).

[0442] To a solution of 2-methoxy-ethanol (0.64 g, 8.40 mmol) in anhydrous DMSO (4 mL) was added sodium hydride (60% suspension in mineral oil, 0.12 g, 5.00 mmol) in small portions and the reaction mixture was stirred at room temperature for 30 minutes. To this mixture was added a solution of 7-fluoro-5-methoxy-2-(2-methyl-pyridin-4-yl)-3*H*-quinazolin-4-one (0.24 g, 0.84 mmol) in anhydrous DMSO (12 mL). The reaction mixture was stirred at 80 °C for 3 hours, then cooled to room temperature, and diluted with ether (500 mL). The solid was filtered and washed with ether. The crude compound was purified by column chromatography (silica gel 230-400 mesh; 4% methanol in dichloromethane). The compound was further purified by preparative HPLC to give the title compound as a white solid. Yield: 60 mg (21%). MP 260-262°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.62 (d, *J* = 5.07 Hz, 1H), 7.98 (s, 1H), 7.88 (d, *J* = 5.07 Hz, 1H), 6.80 (d, *J* =

2.34 Hz, 1H), 6.61 (d, $J = 2.34$ Hz, 1H), 4.25 (t, $J = 4.68$ Hz, 2H), 3.86 (s, 3H), 3.71 (t, $J = 3.90$ Hz, 2H), 3.33 (s, 3H), 2.57 (s, 3H). MS (ES) m/z : 342.07 ($M+1$) (100%).

Example 119. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-6-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H)-one



[0443] To a suspension of 1H-benzotriazole (10.0 g, 83.9 mmol) in water (84 mL) was added pyrrolidine 2 (6.3 mL, 226.6 mmol). After 10 minutes of vigorous stirring at room temperature, formaldehyde 37% aqueous solution was added. The reaction mixture was stirred for 1 hour, then the precipitate was filtered off, and washed with water to afford 1-pyrrolidin-1-ylmethyl-1H-benzoimidazole as an off-white solid. Yield: 14.58 g (85.9%).

[0444] To a mixture of zinc powder (1.05 g, 16.05 mmol) and 1-pyrrolidin-1-ylmethyl-1H-benzoimidazole (2.95 g, 14.59 mmol) in *N,N*-dimethyl formamide (40 mL) under a nitrogen atmosphere was added 5-bromomethyl-2-nitro-benzoic acid methyl ester (4.0 g, 14.59 mmol). The reaction mixture was stirred at room temperature for 24 hours, then quenched at 0 °C with an ice-cold 25% aqueous solution of ammonium hydroxide (108 mL). The stirring was continued until most of the solid had dissolved. Undissolved solid was filtered off and the filtrate was extracted with diethyl ether. The combined organic layers were washed with 1 N aqueous sodium hydroxide, then water, and were dried over anhydrous sodium sulfate and concentrated under high vacuum to give 2-nitro-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid methyl ester as an orange oil. Yield: 1.3 g (32%). The crude material was used for the next step without further purification.

[0445] To a solution of 2-nitro-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid methyl ester in THF (16 mL) was added 10% palladium on charcoal (0.23 g). The resulting reaction mixture was hydrogenated under 40 psi for 2 hours, then the catalyst was filtered off and the filtrate concentrated under high vacuum to give 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid methyl ester as a yellow oil. Yield:

1.04 g (89.6 %). The crude material was used in the next step without further purification.


[0446] To a solution of 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid methyl ester (1.04 g, 4.19 mmol) in a mixture of THF (8 mL) and methanol (5 mL) was added lithium hydroxide (0.36 g), followed by water (3 mL). The reaction mixture was stirred at room temperature overnight, and then refluxed for 4 hours. After cooling to room temperature, the solvent was concentrated. The pH was adjusted to approximately 5 with 2 N aqueous hydrochloric acid and the residue was evaporated to dryness to give 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid as a chloride salt. Yield: 1.84 g. The crude material was used in the next step without further purification.

[0447] To a solution of 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzoic acid (0.41 g, 1.75 mmol) in a mixture of THF (5.1 mL) and *N,N*-dimethyl formamide (1.75 mL) was added EDCI (0.84 g, 4.37 mmol), followed by HOBt (0.71 mL, 5.25 mmol). The reaction mixture was stirred for 30 minutes. Then, *N*-methyl morpholine (0.67 mL, 6.12 mmol) was added, followed by 50% aqueous ammonium hydroxide (1.2 mL, 17.5 mmol). The resulting mixture was stirred at room temperature for 24 hours. Then, the solvent was reduced and the residue was extracted with methylene chloride. The combined organic layers were washed with brine, water, and dried over sodium sulfate. After solvent evaporation under high vacuum, the crude orange oil (0.72 g) was purified by column chromatography (silica gel 230-400 mesh; 5/95 methylene chloride/7 N ammonia in MeOH as eluent) to give pure 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzamide as a light yellow viscous oil. Yield: 0.16 g (39.2%).

[0448] To a solution of 2-amino-5-(2-pyrrolidin-1-yl-ethyl)-benzamide (0.16 g, 0.69 mmol) in *N,N*-dimethyl acetamide (7 mL) under a nitrogen atmosphere was added 2,6-dimethyl-pyridine-4-carbaldehyde (0.09 g, 0.68 mmol), followed by sodium hydrogensulfite (0.14 g, 1.36 mmol) and *p*-toluenesulfonic acid (0.32 g, 1.7 mmol). The resulting mixture was heated at 120 °C overnight. Then, the solvent was removed under reduced pressure, the residue was diluted with ethyl acetate, and was extracted with water. The pH of the water layer was made basic by adding sodium bicarbonate, then the layer was extracted with methylene chloride, dried over anhydrous sodium sulfate, and was evaporated under high

vacuum. The crude yellow solid (0.09 g) was purified by column chromatography (silica gel 230-400 mesh; 95/5 methylene chloride/MeOH as eluent) to afford the title compound as a yellow solid. Yield: 54 mg (23%). MP 212.3-213.2°C. ^1H NMR (400 MHz, CDCl_3): δ 8.19 (s, 1H), 8.19 (br s, 1H), 7.83-7.77 (m, 1H), 7.76-7.70 (m, 3H), 3.0-3.15 (m, 2H), 2.78-2.88 (m, 2H), 2.7 (s, 6H), 2.58-2.68 (m, 4H), 1.8-1.95 (m, 4H). MS (ES^+) m/z : 347.11 ($\text{M}+1$).

Example 120. Preparation of 2-(2,6-Dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one




[0449] To a solution of 2-pyrrolidin-1-yl-ethanol (5.09 g, 44.2 mmol) in DMF (10 mL) was added sodium hydride (60% suspension in mineral oil, 0.88 g, 22.1 mmol) in small portions and the reaction mixture was stirred at room temperature for 30 minutes. To this mixture was added 2-(2,6-dimethyl-pyridin-4-yl)-5,7-difluoro-3H-quinazolin-4-one (0.63 g, 2.21 mmol) and the reaction mixture was stirred at room temperature for 16 hours. Water (20 mL) was added, and the mixture was neutralized to pH approximately 6 with acetic acid. Solvent was evaporated, the residue was dissolved in ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated *in vacuo*. Crude compound was purified by the Simpliflash system (0-4% methanol in CH_2Cl_2 as eluent) to afford 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-(2-pyrrolidin-1-yl-ethoxy)-3H-quinazolin-4-one as a yellow solid. Yield: 0.61 g (72%).

[0450] To a solution of 2-methoxy-ethanol (1.35 g, 17.8 mmol) in DMF (10 mL) was added sodium hydride (60% suspension in mineral oil, 0.36 g, 8.89 mmol) in small portions and the reaction mixture was stirred at room temperature for 30 minutes. To this mixture was added 2-(2,6-dimethyl-pyridin-4-yl)-7-fluoro-5-(2-pyrrolidin-1-yl-ethoxy)-3H-quinazolin-4-one (0.34 g, 0.89 mmol) and the reaction mixture was stirred at 70-80°C for 16 h, then cooled to room temperature.

Water (10 mL) was added, and the mixture was neutralized to pH approximately 6 with acetic acid. Solvent was evaporated; the residue was purified by the Simpliflash system (2-5% 7.0M ammonia in methanol and CH₂Cl₂ as eluent). The compound was further purified by preparative HPLC to give the title compound as a yellow solid. Yield: 72 mg (18%). MP 60.4-62.3°C. ¹H NMR (400 MHz, CDCl₃): δ 10.23 (br s, 1H), 8.50 (br s, 1H), 7.60 (s, 2H), 6.76 (br s, 1H), 6.43 (br s, 1H), 4.35 (m., 2H), 4.21 (m, 2H), 3.79 (s, 3H), 3.47- 3.38 (m, 6H), 2.64 (s, 6H), 1.99 (m, 4H). MS (ES) *m/z*: 437.09 (M-1) (100%).

Example 121. Preparation of 2-(3-(2-Hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one




[0451] To a suspension of sodium hydride (0.426 g, 10.7 mmol) in DMF (30 mL) at room temperature was added 3-hydroxybenzaldehyde (1.00 g, 8.20 mmol). The resulting suspension was stirred at room temperature for 1 hour and (2-bromo-ethoxy)-*tert*-butyl-dimethyl-silane (4.4 mL, 20.5 mmol), was then added. The resulting mixture was stirred at 60 °C under nitrogen for 14 hours, cooled to room temperature, diluted with water (100 mL), extracted with ethyl acetate (250 mL), and concentrated. The crude product was purified by column chromatography (SiO₂, hexane /ethyl acetate = 4:1) to afford 3-[2-(*tert*-butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde. It was re-dissolved in THF (50 mL), mixed with 1 N *tetra-n*-butylammonium fluoride in THF (15 mL), and stirred at room temperature for 8 h. The reaction mixture was then concentrated and the residue was purified by column chromatography (SiO₂, hexane /ethyl acetate = 4:1) to afford 3-(2-hydroxy-ethoxy)-benzaldehyde as a colorless oil. Yield: 0.68 g (50% for two steps).

[0452] A mixture of 2-amino-4,6-dimethoxy-benzamide (195 mg, 1.00 mmol), 3-(2-hydroxy-ethoxy)-benzaldehyde (166 mg, 1.00 mmol), *p*-toluenesulfonic acid monohydrate (38 mg, 0.20 mmol), and sodium bisulfite (264 mg, 1.50 mmol) in *N,N*-dimethylacetamide (10 mL) was stirred at 130 °C under nitrogen for 14 hours, cooled to room temperature, and diluted with 0.2 N

potassium carbonate aqueous solution (50 mL). It was extracted with ethyl acetate (250 mL), dried over sodium sulfate, and concentrated. The solid residue was re-dissolved in dichloromethane (5 mL), and precipitated with ethyl acetate (15 mL) and hexanes (50 mL). It was filtered and washed with hexanes to afford the title compound as a yellow solid. Yield: 70 mg (20%). MP 244.8-246.0°C. ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, 1H), 7.60 (d, 1H), 7.45 (t, 1H), 7.12 (dd, 1H), 6.84 (d, 1H), 6.48 (d, 1H), 4.21 (t, 2H), 4.03 (t, 2H), 3.99 (s, 3H), 3.94 (s, 3H). MS (ES⁺) *m/z*: 343.55 (M+1).

Example 122. Preparation of 2-(3-(2-Hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one



[0453] To a solution of 3,5-dimethyl-phenol (3.000 g, 24.55 mmol) in *N,N*-dimethylformamide (120 mL) under nitrogen were added potassium carbonate (16.96 g, 122.7 mmol) and (2-bromoethoxy)-*tert*-butyldimethylsilane (7.90 mL, 36.8 mmol). The resulting slurry was heated at reflux for 20 hours; then, the solvent was removed under high vacuum. The residue was dissolved in ethyl acetate and the solution was backwashed with 0.2 N aqueous sodium hydroxide, water, and then brine, dried over sodium sulfate, and concentrated. The crude material (5.69 g) was purified by column chromatography (silica gel 230-400 mesh; methylene chloride as eluent) to give *tert*-butyl-[2-(3,5-dimethyl-phenoxy)-ethoxy]-dimethylsilane as light yellow oil. Yield: 3.72 g (47%).


[0454] To a solution of *tert*-butyl-[2-(3,5-dimethyl-phenoxy)-ethoxy]-dimethylsilane (2.22 g, 7.91 mmol) in carbon tetrachloride (50 mL) under nitrogen was added *N*-bromosuccinimide (1.57 g, 8.70 mmol) and benzoyl peroxide (0.38 g, 1.58 mmol). The resulting mixture was heated at reflux for 3 hours with simultaneous illumination by a sun lamp. The precipitate was filtered off and the filtrate was concentrated under reduced pressure. The crude material (3.99g) was purified by column chromatography (silica gel 230-400 mesh; 1/0 to 4/1 hexanes /

EtOAc as eluent) to give [2-(3-bromomethyl-5-methyl-phenoxy)-ethoxy]-*tert*-butyl-dimethyl-silane as a light yellow oil. Yield: 2.17 g (75%).

[0455] To a solution of [2-(3-bromomethyl-5-methyl-phenoxy)-ethoxy]-*tert*-butyl-dimethyl-silane (2.17 g, 6.04 mmol) under nitrogen in 2-nitopropane (2.0 mL, 20 mmol) was added sodium ethoxide (0.620 g, 9.06 mmol). The resulting mixture was heated at 90 °C for 15 hours, and was then diluted with ethyl acetate and quenched with saturated aqueous ammonium chloride. The aqueous layer was extracted with ethyl acetate and the combined organic layers were backwashed with water and brine, dried over sodium sulfate, and concentrated. The crude material (1.81 g) was purified by column chromatography (silica gel 230-400 mesh; 1/0 to 4/1 hexanes / EtOAc as eluent) to give 3-[2-(*tert*-butyl-dimethyl-silanyloxy)-ethoxy]-5-methyl-benzaldehyde as a yellow oil. Yield: 0.97 g (55%).

[0456] To a solution of 2-amino-4,6-dimethoxy-benzamide (0.350 g, 1.78 mmol) in *N,N*-dimethylacetamide (20 mL) under nitrogen was added 3-[2-(*tert*-butyl-dimethyl-silanyloxy)-ethoxy]-5-methyl-benzaldehyde (0.520 g, 1.78 mmol) followed by sodium hydrogensulfite (0.270 g, 2.67 mmol), and *p*-toluenesulfonic acid (0.033 g, 0.18 mmol). The resulting mixture was heated at 120 °C for 24 hours, then the solvent was concentrated to 5 mL under reduced pressure, and water was added to obtain a precipitate, which was filtered off and washed with Et₂O and methylene chloride. The resulting solid was dissolved in hot CH₂Cl₂ / MeOH, and then precipitated by adding Et₂O, and purified by preparative thin-layer chromatography (DC-Fertigplatten SIL G-100 UV, 9/1 methylene chloride / MeOH as eluent) to give the title compound as a yellow solid. Yield: 81 mg (13%). MP 106.9-109.1°C. ¹H NMR (400 MHz, CDCl₃): δ 7.86 (s, 1H), 7.41 (d, 2H), 6.82 (s, 1H), 6.57 (s, 1H), 4.15-4.13 (m, 2H), 3.94-3.90 (m, 8H), 2.43 (s, 3H). MS (ES⁺) *m/z*: 357.53 (M+1).

Example 123. Preparation of 5,7-Dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one



[0457] To a 1.0-L three-neck flask was added sodium ethanethiolate (80%, 28.5 g, 271.0 mmol) and anhydrous DMF (225 mL). The mixture was heated to 145 °C for 1.5 hours. Then, 3,5-dimethoxy-benzaldehyde (15.0 g, 90.0 mmol) in anhydrous DMF (350 mL) was added over a period of 8 minutes. The reaction was kept at 145 °C for another 1 hour, then cooled to room temperature. Saturated sodium chloride solution (2.5 L) and formaline (37%, 240 mL) together with acetic acid (500 mL) was added. The resulting solution was thoroughly extracted with ethyl acetate, the organic phase was dried with sodium sulfate, and the solvent was removed under vacuum. The crude compound was purified by column chromatography (silica gel 230-400 mesh; eluting with dichloromethane and ethyl acetate 7:1) to give 3-hydroxy-5-methoxy-benzaldehyde as a white solid. Yield: 12.0 g (88%).

[0458] 3-Hydroxy-5-methoxy-benzaldehyde (12.0 g, 78.9 mmol) and [1,3]dioxolan-2-one (13.9 g, 157.0 mmol) in anhydrous DMF (50 mL) was added potassium carbonate (21.6 g, 157.0 mmol). The mixture was then heated to 110 °C for 16 hours. The reaction mixture was cooled to room temperature. Solid potassium carbonate was filtered and washed with ethyl acetate. The organic phase was collected and solvent was removed. The residue was purified by column chromatography (silica gel 230-400 mesh; eluting with dichloromethane and ethyl acetate 7:1), to give 3-(2-hydroxy-ethoxy)-5-methoxy-benzaldehyde as a brown liquid. Yield: 10.0 g (65%).


[0459] To a solution of 2-amino-4,6-dimethoxy-benzamide (7.50 g, 38.2 mmol) and 3-(2-hydroxy-ethoxy)-5-methoxy-benzaldehyde (7.50 g, 38.2 mmol) in *N,N*-dimethylacetamide (30 mL) was added NaHSO₃ (58.5 wt%, 4.37 g, 42.0 mmol) and *p*-TSA (0.72 g, 3.8 mmol). The reaction mixture was heated to 115-120 °C for 16 hours, and then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure, the residue was diluted with water (50 mL), and the solid was filtered, collected, and mixed with ether (50 mL), then filtered and dried under vacuum, to give 2-[3-(2-hydroxy-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 10 g (70%).

[0460] To a solution of 2-[3-(2-hydroxy-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (8.00 g, 21.5 mmol) in anhydrous DMF (30 mL) was added carbon tetrabromide (9.80 g, 29.5 mmol) and triphenylphosphine (7.78

g, 29.5 mmol). The reaction mixture was stirred at 40 °C for 7 hours. DMF was removed under vacuum and dichloromethane (200 mL) was added. The organic phase was washed with water (150 mL), brine (100 mL), and dried over anhydrous sodium sulfate. Solvent was removed and the residue was washed three times with a mixture of ether and dichloromethane (20:1, 200 mL) to give 2-[3-(2-bromo-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (5) as a white solid. Yield: 8.9 g (95%).

[0461] To a solution of 2-[3-(2-bromo-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (7.10 g, 16.0 mmol) in THF (20 mL) was added pyrrolidine (11.38 g, 160.0 mmol) and the reaction mixture was stirred at room temperature for 15 hours. THF was removed under reduced pressure, the residue was purified by column chromatography (silica gel 230-400 mesh; eluting with 5% 2.0 M ammonia in methanol solution in dichloromethane) to give the title compound as a white solid. Yield: 3.2 g (47 %). MP 159-160°C. ¹H NMR (400 MHz, CDCl₃): δ 10.66 (s, 1H), 7.25 (m, 2H), 6.84 (d, J = 2.0 Hz, 1H), 6.67 (t, J = 2.4 Hz, 1H), 6.45 (d, J = 2.0 Hz, 1H), 4.21 (t, J = 6.0 Hz, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H), 2.93 (t, J = 6.0 Hz, 2H), 2.64 (m, 4H), 1.80 (m, 4H). MS (ES⁺) *m/z*: 426.20 (M+1).

Example 124. Preparation of N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide



[0462] To a 1.0-L three-neck flask was added sodium ethanethiolate (80%, 28.5 g, 271.0 mmol) and anhydrous DMF (225 mL). The mixture was heated to 145 °C for 1.5 hours; then, a solution of 3,5-dimethoxy-benzaldehyde (15.0 g, 90.0 mmol) in anhydrous DMF (350 mL) was added over a period of 8 minutes. The reaction was kept at 145 °C for 1 hour, then cooled to room temperature. Saturated sodium chloride solution (2.5 L) and formaline (37%, 240 mL), together with acetic acid (500 mL), was added. The resulting solution was thoroughly extracted with ethyl acetate, and the organic phase was dried over anhydrous

sodium sulfate. Solvent was removed under vacuum, and the crude compound was purified by column chromatography (silica gel 230-400 mesh; eluting with 7:1 dichloromethane and ethyl acetate) to give 3-hydroxy-5-methoxy-benzaldehyde as a white solid. Yield: 12.0 g (88%).

[0463] To a solution of 3-hydroxy-5-methoxy-benzaldehyde (12.0 g, 78.9 mmol) in anhydrous DMF (50 mL) was added [1,3]dioxolan-2-one (13.9 g, 157.0 mmol) and potassium carbonate (21.6 g, 157.0 mmol). The reaction mixture was then heated to 110 °C for 16 hours, then cooled to room temperature. Solid potassium carbonate was filtered and washed with ethyl acetate. The organic phase was collected and solvent was removed. The residue was purified by column chromatography (silica gel 230-400 mesh; eluting with 7:1 dichloromethane and ethyl acetate) to give 3-(2-hydroxy-ethoxy)-5-methoxy-benzaldehyde as a brown liquid. Yield: 10.0 g (65%).


[0464] To a solution of 2-amino-4,6-dimethoxy-benzamide (7.50 g, 38.2 mmol) and 3-(2-hydroxy-ethoxy)-5-methoxy-benzaldehyde (7.50 g, 38.2 mmol) in *N,N*-dimethylacetamide (30 mL) were added NaHSO₃ (58.5 wt%, 4.37 g, 42.0 mmol) and *p*-TSA (0.72 g, 3.8 mmol). The reaction mixture was heated to 115-120 °C for 16 hours, and then cooled to room temperature. *N,N*-dimethylacetamide was removed under reduced pressure, the residue was diluted with water (50 mL), and the solid was filtered, collected and mixed with ether (50 mL), filtered, and dried under vacuum, to give 2-[3-(2-hydroxy-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 10 g (70%).

[0465] To a solution of 2-[3-(2-hydroxy-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (8.00 g, 21.5 mmol) in anhydrous DMF (30 mL) was added carbon tetrabromide (9.80 g, 29.5 mmol) and triphenylphosphine (7.78 g, 29.5 mmol). The reaction mixture was stirred at 40 °C for 7 hours. DMF was removed under vacuum and dichloromethane (200 mL) was added. The organic phase was washed with water (150 mL), then brine (100 mL), and dried over anhydrous sodium sulfate. Solvent was removed and the residue was washed three times with a mixture of ether and dichloromethane (20:1, 200 mL) to give 2-[3-(2-bromo-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one as a white solid. Yield: 8.9 g (95%).

[0466] To a solution of 2-[3-(2-bromo-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (0.37 g, 0.84 mmol) in DMF (10 mL) was added sodium azide (0.14 g, 2.11 mmol) and the reaction mixture was stirred at 70 °C for 7 hours. DMF was removed under reduced pressure and dichloromethane (100 mL) was added. The organic phase was washed with water (50 mL), then brine (50 mL), and dried over anhydrous sodium sulfate. Solvent was removed and the residue was purified by column chromatography (silica gel 230-400 mesh; 30-40% ethyl acetate in dichloromethane as eluent) to give a white solid. Yield: 0.23 g (69 %).

[0467] 2-[3-(2-Azido-ethoxy)-5-methoxy-phenyl]-5,7-dimethoxy-3*H*-quinazolin-4-one (90 mg, 0.22 mmol) was taken in thioacetic acid (2 mL) and the reaction mixture was stirred at room temperature for 2 hours. Thioacetic acid was removed under reduced pressure, and the residue was purified by column chromatography (silica gel 230-400 mesh; 3.5% methanol in dichloromethane as eluent) to give the title compound as a white solid. Yield: 45 mg (49%). MP 264-265°C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.05 (s, 1H), 8.13 (t, *J* = 5.86 Hz, 1H), 7.39 (d, *J* = 1.56 Hz, 2H), 6.76 (d, *J* = 2.34 Hz, 1H), 6.69 (t, *J* = 2.15 Hz, 1H), 6.55 (d, *J* = 2.34 Hz, 1H), 4.07 (t, *J* = 5.67 Hz, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 3.43 (q, *J* = 5.47 Hz, 2H), 1.84 (s, 3H). MS (ES⁺) *m/z*: 414.11 (M+1).

Example 125. Preparation of 2-(3,5-Dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3*H*)-one




[0468] To a mixture of 2-amino-5-nitro-benzoic acid (12.9 g, 81.9 mmol), 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) (17.3 g, 90.1 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (12.2 g, 90.1 mmol) in THF (200 mL) was added 4-methylmorpholine (NMM) (9.91 mL, 90.1 mmol). After 10 minutes, ammonium hydroxide (50% v/v, 50 mL) was added. The mixture was stirred at room temperature under nitrogen for 17 hours. Solvent was removed under reduced pressure. Water was added. The solid separated was filtered,

washed with aqueous NaHCO_3 solution, and with water, and dried in air, to afford 2-amino-5-nitro-benzamide as a yellow solid. Yield: 9.88 g (66%).

[0469] A mixture of 2-amino-5-nitro-benzamide (1.81 g, 10.0 mmol), 3,5-dimethoxy-benzaldehyde (1.83 g, 11.0 mmol), sodium hydrogen sulfite (58.5 wt%, 3.94 g, 22.0 mmol), and *p*-toluenesulfonic acid monohydrate (0.38 g, 2.00 mmol) in *N,N*-dimethylacetamide (20 mL) was stirred at 150 °C for 17 hours under nitrogen and then cooled to room temperature. Saturated aqueous NaHCO_3 (approximately 1 mL) was added. The mixture was stirred at room temperature for 2 hours, then concentrated to dryness. Water (80 mL) was added, stirred for 0.5 hours, and filtered. The solid was air dried. The crude compound was purified by column chromatography (silica gel 230-400 mesh; ethyl acetate as eluent) to give 6-amino-2-(3,5-dimethoxy-phenyl)-3*H*-quinazolin-4-one as a yellow solid. Yield: 1.50 g (50%).

[0470] 6-Amino-2-(3,5-dimethoxy-phenyl)-3*H*-quinazolin-4-one (297 mg, 1.00 mmol), 4-bromopyridine hydrochloride (194 mg, 1.00 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), 1,1'-bis(diphenylphosphino)ferrocene (17 mg, 0.03 mmol), sodium tert-butoxide (230 mg, 2.40 mmol) and pyridine (3 mL) were heated at 140 °C in microwave oven (150 W) for 1 hour. The mixture was concentrated under vacuum to dryness. The residue was purified by column chromatography (silica gel 230-400 mesh; 5% methanol in dichloromethane and then 10% 2 N NH_3 in methanol and dichloromethane as eluent) to give the title compound as a brown/beige solid. Yield: 176 mg (47%). MP 289-290°C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 9.24 (s, 1H), 8.29 (d, J = 5.6 Hz, 2H), 7.90 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.38 (s, 2H), 7.03 (d, J = 5.2 Hz, 2H), 6.69 (s, 1H), 3.85 (s, 6H). MS (ES^+) m/z : 375.13 ($\text{M}+1$).

Example 126. Preparation of 5,7-Dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3*H*)-one



[0471] A mixture of 2-amino-4,6-dimethoxybenzamide (0.0600 g, 0.306 mmol), 3-methoxybenzaldehyde (0.306 mmol), NaHSO₃ (94%, 0.0474 g, 0.428 mmol), and *p*-TsOH·H₂O (0.0175 g, 0.0918 mmol) in DMA (3.06 mL) was heated at 140 °C for 20 hours. The mixture was diluted with EtOAc (300 mL), washed with water (3×75 mL), then brine (75 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on silica gel (40 g, CH₂Cl₂/MeOH) and the product was freeze-dried from MeCN/H₂O to provide the title compound (69%) as an off-white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.04 (s, 1H), 7.82–7.70 (m, 2H), 7.43 (t, *J* = 7.98 Hz, 1H), 7.13 (dd, *J* = 8.19, 2.46 Hz, 1H), 6.76 (d, *J* = 2.19 Hz, 1H), 6.55 (d, *J* = 2.19 Hz, 1H), 3.92–3.82 (m, 9H); MS (APCI) *m/z* 313 [C₁₇H₁₆N₂O₄+H]⁺.

Example 127. Quantification of hIL-6 mRNA

[0472] In this example, hIL-6 mRNA in tissue culture cells was quantitated to measure the transcriptional inhibition of hIL-6 when treated with a compound of the invention.

[0473] A human leukemic monocyte lymphoma cell line (U937) was plated (3.2×10⁵ cells per well) in a 96-well plate in 100 μL RPMI-1640, and differentiated for 3 days prior to the addition of the compound of interest. The cells were pretreated for 1 h with the test compound prior to stimulation with lipopolysaccharide from *Escherichia coli*. The cells were incubated at 37°C for 3 h before the cells were harvested. At time of harvest, the spent media was removed from the cells and the cells were rinsed in 200 μL PBS. Cell lysis solution (70 μL) was added the cells in each well and incubated for 5-10 min at room temperature, to allow for complete cell lysis and detachment. mRNA was then prepared using the “mRNA Catcher PLUS plate” (Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible was aspirated without allowing the wells to dry. Elution buffer (E3, 70 μL) was then added to each well. mRNA was then eluted by incubating the mRNA Catcher PLUS plate with Elution Buffer for 5 min at 68°C and then immediately placing the plate on ice.

[0474] The eluted mRNA isolated was then used in a one-step quantitative real-time PCR reaction, using components of the Ultra Sense Kit together with Applied Biosystems primer-probe mixes. Real-time PCR data was analyzed,

normalizing the Ct values for hIL-6 to an internal control, prior to determining the fold induction of each unknown sample, relative to the control.

[0475] In Table 2, an active compound is one that causes a $\geq 20\%$ inhibition in IL-6 mRNA at a concentration less than or equal to 10 μM .

Table 2.

Example	Inhibition of IL-6 expression
5,7-dimethoxy-2-(4-morpholinophenyl)quinazolin-4(3H)-one	Active
2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(4-(4-hydroxypiperidin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one	Active
2-(4-(4-isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)methanesulfonamide	Active
3-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-1,1-dimethylurea	Active
2-(4-(4-hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(4-fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide	Active
5,7-dimethoxy-2-(4-(4-picolinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-nicotinoypiperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
2-(4-(4-isonicotinoypiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active

2-(4-(4-(5-chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
2-(4-(4-(2,5-dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(4-fluorobenzyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-benzylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide	Active
2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide	Active
2-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methoxyquinazolin-4(3H)-one	Active
2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-isopropylacetamide	Active
5-chloro-2-(4-(4-isopropylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
2-(4-((3R,5S)-4-isopropyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(3-(methylamino)pyrrolidin-1-yl)phenyl)quinazolin-4(3H)-one	Active

2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(isopropylamino)piperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(1-acetylpiperidin-4-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(3-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
N-benzyl-N-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide	Active
2-(6-(4-(benzylamino)piperidin-1-yl)pyridin-3-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperazine-1-carbaldehyde	Active
5,7-dimethoxy-2-(4-(4-oxopiperidin-1-yl)phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one	Active
tert-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate	Active
2-(4-(dimethylamino)naphthalen-1-yl)-6,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(2-(hydroxymethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(2-(2-hydroxyethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1H-indol-5-yl)quinazolin-4(3H)-one	Active
2-(3-(hydroxymethyl)-1H-indazol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one	Active
2-(2-((dimethylamino)methyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)methanesulfonamide	Active
5,7-dimethoxy-2-(4-(pyridin-4-ylamino)phenyl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(p-tolylamino)phenyl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one	Active
3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one	Active
2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one	Active

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)quinazolin-4(3H)-one	Active
7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one	Active
5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one	Active
2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide	Active
2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one	Active
5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one	Active
2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione	Active
2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one	Active
3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione	Active
3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one	Active
5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one	Active
2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one	Active
8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one	Active
2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione	Active

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide	Active
2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione	Active
7-(2-(benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-6-((4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one;	Active
7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-6-(2-morpholinoethyl)quinazolin-4(3H)-one	Active
2-(2-methylpyridin-4-yl)-6-(morpholinomethyl)quinazolin-4(3H)-one	Active
5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-6-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H)-one	Active

2-(2,6-dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Active
2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide	Active
2-(3,5-dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one	Active

Example 128. Quantification of hVCAM mRNA

[0476] In this example, hIL-6 mRNA in tissue culture cells was quantitated to measure the transcriptional inhibition of hVCAM when treated with a compound of the invention.

[0477] Human umbilical vein endothelial cells (HUVECs) were plated in a 96-well plate (4.0×10^3 cells/well) in 100 μ L EGM media and incubated for 24 h prior to the addition of the compound of interest. The cells were pretreated for 1 h with the test compound prior to stimulation with tumor necrosis factor- α . The cells were incubated for an additional 24 h before the cells were harvested. At time of harvest, the spent media was removed from the HUVECs and rinsed in 200 μ L PBS. Cell lysis solution (70 μ L) was then added to the cells in each well and incubated for ~5-10 min at room temperature, to allow for complete cell lysis and detachment. mRNA was then prepared using the "mRNA Catcher PLUS plate" (Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible was aspirated without allowing the wells to dry. Elution buffer (E3, 70 μ L) was then added to each well. mRNA was then eluted by incubating the mRNA Catcher PLUS plate with elution buffer for 5 min at 68°C and then immediately placing the plate on ice.

[0478] The eluted mRNA so isolated was then used in a one-step quantitative real-time PCR reaction, using components of the Ultra Sense Kit together with Applied Biosystems primer-probe mixes. Real-time PCR data was analyzed, normalizing the Ct values for hVCAM to an internal control, prior to determining the fold induction of each unknown sample, relative to the control.

[0479] In Table 3, an active compound is one that causes a $\geq 20\%$ inhibition in VCAM-1 mRNA at a concentration less than or equal to 10 μM .

Table 3.

Example	Inhibition of VCAM-1 expression
2-(4-(4-isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide	Active
2-(4-(4-hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Inactive
2-(4-(4-isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(4-fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide	Active
2-(4-(4-(5-chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Active
2-(4-(4-(2,5-dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one	Inactive
2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide	Active
2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active


2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide	Active
2-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methoxyquinazolin-4(3H)-one	Active
2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(dimethylamino)naphthalen-1-yl)-6,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1H-indol-5-yl)quinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one	Active
2-(2-((dimethylamino)methyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)quinazolin-4(3H)-one	Active
7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one	Active
2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one	Active
5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one	Active

2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione	Active
2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one	Active
3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione	Active
3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one	Active
5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one	Active
2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione	Active
(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione	Active
7-(2-(benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one	Active

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one	Inactive
2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Inactive
2-(2,6-dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one;	Active
7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-6-(2-morpholinoethyl)quinazolin-4(3H)-one	Inactive
2-(2-methylpyridin-4-yl)-6-(morpholinomethyl)quinazolin-4(3H)-one	Inactive
5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-6-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4(3H)-one	Active
2-(2,6-dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one	Active
2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one	Active
5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one	Active
N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide	Active
2-(3,5-dimethoxyphenyl)-6-(pyridin-4-ylamino)quinazolin-4(3H)-one	Inactive
5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one	Active

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of at least one compound of Formula III:

**(III)**

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, for treating or preventing a disease by reducing IL-6 and/or VCAM-1 in a subject wherein:

Q is CR₁₂ or nitrogen;

V is CH or nitrogen;

U is C=O, C=S, SO₂, S=O, SR₁, CR₁R₂, CR₁OR₂, or CR₁SR₂;

X is oxygen, sulfur, SR₁, nitrogen, NR₆R₇, or CR₆R₇;

Z is unsubstituted C₁-C₆ alkyl or C₁-C₆ alkyl substituted with one or more groups which is C₁-C₃ alkyl, C₁-C₃ alkoxy, cyclopropyl, hydroxyl, amino, or halogen;
n is 0, 1, 2, 3, 4, or 5;

G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl;

R₁ and R₂ are independently hydrogen or C₁-C₆ alkyl;

R₆, R₇, and R₁₂ are independently hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocycle, C₁-C₆ alkoxy, or halogen;

R_c is hydrogen, C₁-C₆ alkyl optionally substituted with heterocyclyl, or C₃-C₆ cycloalkyl;


Ra₁, Ra₂, and Ra₃ are independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, or heterocycle, wherein Ra₁ and Ra₂ and/or Ra₂ and Ra₃ may be connected to form a cycloalkyl or a heterocycle;

Rb₂ and Rb₆ are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, hydroxyl, or amino; and

Rb₃ and Rb₅ are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, or amino, wherein

Rb₂ and Rb₃ and/or Rb₅ and Rb₆ may be connected to form a cycloalkyl or a heterocycle;

provided that



at least one of Ra₁, Ra₂, and Ra₃ is not hydrogen; and

if Ra₂ or Ra₃ is chloro, then Ra₁ is not hydrogen.

2. The use according to claim 1, wherein

U is C=O;

Q is CR₁₂ or nitrogen;

V is nitrogen;

Z is unsubstituted C₁-C₆ alkyl;

R₁₂ is C₁-C₆ alkoxy or halogen;

R_c is hydrogen or C₁-C₆ alkyl optionally substituted with heterocyclyl;

Ra₂ is hydrogen or C₁-C₆ alkoxy;

Ra₁ and Ra₃ are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, or heterocycle;

Rb₂ and Rb₆ are both hydrogen;

Rb₃ and Rb₅ are independently hydrogen or C₁-C₆ alkyl;

X is oxygen or CH₂;

n is 0, 1, 2, 3, or 4; and

G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl.

3. The use according to claim 2, wherein

U is C=O;

Q is CR₁₂ or nitrogen;

V is nitrogen;

R₁₂ is methoxy or chlorine;

R_c is hydrogen or (pyrrolidin-1-yl)propyl;

R_{a2} is hydrogen or methoxy;

R_{a1} and R_{a3} are independently hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, or pyrrolidin-1-yl;

R_{b2} and R_{b6} are both hydrogen;

R_{b3} and R_{b5} are independently hydrogen or methyl; and

$\begin{array}{c} \sim \\ \sim \\ \sim \end{array} X \begin{pmatrix} Z \end{pmatrix}_n^G$ is (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, or (1H-tetrazol-5-yl)methyl.

4. The use of claim 1, comprising a therapeutically effective amount of at least one compound that is:

3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one;

5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;

2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;

5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one;

2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one;
 3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;
 3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;
 5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
 2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;
 2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;
 8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;

2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;


2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;

2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; or

2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one, or a pharmaceutically acceptable salt or hydrate thereof.

5. A compound of Formula III:



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is CR₁₂ or nitrogen;

V is CH or nitrogen;

U is C=O, S=O, or SO₂;

X is oxygen, nitrogen, sulfur, NR₆R₇, or CR₆R₇;

Z is unsubstituted C₁-C₆ alkyl or C₁-C₆ alkyl substituted with one or more groups which is C₁-C₃ alkyl, C₁-C₃ alkoxy, cyclopropyl, hydroxyl, amino, or halogen;

n is 0, 1, 2, 3, 4, or 5;

G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl;

R₆, R₇, and R₁₂ are independently hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, or halogen;

R_c is hydrogen, C₁-C₆ alkyl optionally substituted with heterocyclyl, or C₃-C₆ cycloalkyl;

Ra₁, Ra₂, and Ra₃ are independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, or heterocycle, wherein Ra₁ and Ra₂ and/or Ra₂ and Ra₃ may be connected to form a cycloalkyl or a heterocycle;

Rb₂ and Rb₆ are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, hydroxyl, or amino; and

Rb₃ and Rb₅ are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, or amino, wherein



Rb₂ and Rb₃ and/or Rb₅ and Rb₆ may be connected to form a cycloalkyl or a heterocycle;

provided that

if X = oxygen and n is 3, then R_c is hydrogen;

at least one of Ra₁, Ra₂, and Ra₃ is not hydrogen;

if Ra₂ or Ra₃ is chloro, then Ra₁ is not hydrogen



2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one,

2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione, 3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one, 2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one, 5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one, or 5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one.

6. The compound according to claim 5, wherein:

Q is CR₁₂ or nitrogen;

V is nitrogen;

R₁₂ is C₁-C₆ alkoxy or halogen;

R_c is hydrogen or C₁-C₆ alkyl optionally substituted with heterocyclyl;

R_{a2} is hydrogen or C₁-C₆ alkoxy;

R_{a1} and R_{a3} are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, or heterocycle;

R_{b2} and R_{b6} are both hydrogen;

R_{b3} and R_{b5} are independently hydrogen or C₁-C₆ alkyl;

X is oxygen or CH₂;

n is 0, 1, 2, 3, or 4; and

G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl.

7. The compound according to claim 6, wherein:

Q is CR₁₂ or nitrogen;

V is nitrogen;

R₁₂ is methoxy or chlorine;

R_c is hydrogen or (pyrrolidin-1-yl)propyl;

R_{a2} is hydrogen or methoxy;

R_{a1} and R_{a3} are independently hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, or pyrrolidin-1-yl;

R_{b2} and R_{b6} are both hydrogen;

Rb₃ and Rb₅ are independently hydrogen or methyl; and

$\begin{matrix} \text{X} \\ \text{Z} \end{matrix} \begin{matrix} \text{G} \\ \text{n} \end{matrix}$ is (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, or (1H-tetrazol-5-yl)methyl.

8. The compound according to claim 5, wherein the compound is:

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;

2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;

5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one;

2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;

5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;

2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;
 8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;
 2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;
 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one;
 (S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;
 2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;
 2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; or
 1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione, or
 pharmaceutically acceptable salts and hydrates thereof.

9. The use according to any one of claims 1-4, wherein the disease is non-cardiovascular inflammatory diseases or cancer, and that is characterized by altered expression of IL-6 and/or VCAM-1 proliferation.


10. The use according to claim 9, wherein the non-cardiovascular inflammatory disease is arthritis, rheumatoid arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular

inflammation, uveitis, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Grave's disease, gastrointestinal allergies, or conjunctivitis.

11. The use according to claim 9, wherein the cancer is multiple myeloma, lymphoma, leukemia, solid tumors, prostate and bladder cancers, cardiac myxoma, tumor-induced cachexia, cancer-associated depression, cerebral edema secondary to brain tumors, hormone-independent prostate cancer, B cell lymphoma, AIDS-associated lymphoma, or metastatic renal cell carcinoma.

12. The use according to any one of claims 1-4 or 9-11, wherein the subject is a human.

13. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula III:



(III)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, for treating or preventing a disease by reducing IL-6 and/or VCAM-1 in a subject wherein:

Q is CR₁₂ or nitrogen;

V is CH or nitrogen;

U is C=O, C=S, SO₂, S=O, SR₁, CR₁R₂, CR₁OR₂, or CR₁SR₂;

X is oxygen, sulfur, SR₁, nitrogen, NR₆R₇, or CR₆R₇;

Z is unsubstituted C₁-C₆ alkyl or C₁-C₆ alkyl substituted with one or more groups which is C₁-C₃ alkyl, C₁-C₃ alkoxy, cyclopropyl, hydroxyl, amino, or halogen;

n is 0, 1, 2, 3, 4, or 5;

G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl;

R₁ and R₂ are independently hydrogen or C₁-C₆ alkyl;

R₆, R₇, and R₁₂ are independently hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, heterocycle, C₁-C₆ alkoxy, or halogen;

R_c is hydrogen, C₁-C₆ alkyl optionally substituted with heterocyclyl, or C₃-C₆ cycloalkyl;


R_{a1}, R_{a2}, and R_{a3} are independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, halogen, amino, amide, hydroxyl, or heterocycle, wherein R_{a1} and R_{a2} and/or R_{a2} and R_{a3} may be connected to form a cycloalkyl or a heterocycle;

R_{b2} and R_{b6} are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, hydroxyl, or amino; and

R_{b3} and R_{b5} are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, hydroxyl, or amino, wherein

R_{b2} and R_{b3} and/or R_{b5} and R_{b6} may be connected to form a cycloalkyl or a heterocycle;

provided that



at least one of R_{a1}, R_{a2}, and R_{a3} is not hydrogen; and

if R_{a2} or R_{a3} is chloro, then R_{a1} is not hydrogen,

and a pharmaceutically acceptable carrier,

for use in reducing IL-6 and/or VCAM-1 in a subject, wherein the composition is adapted for administration, such that IL-6 and/or VCAM-1 in a subject is reduced.

14. The pharmaceutical composition according to claim 13, wherein

U is C=O;

Q is CR₁₂ or nitrogen;
 V is nitrogen;
 Z is unsubstituted C₁-C₆ alkyl;
 R₁₂ is C₁-C₆ alkoxy or halogen;
 R_c is hydrogen or C₁-C₆ alkyl optionally substituted with heterocyclyl;
 R_{a2} is hydrogen or C₁-C₆ alkoxy;
 R_{a1} and R_{a3} are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, or heterocycle;
 R_{b2} and R_{b6} are both hydrogen;
 R_{b3} and R_{b5} are independently hydrogen or C₁-C₆ alkyl;
 X is oxygen or CH₂;
 n is 0, 1, 2, 3, or 4; and
 G is heterocycle, cycloalkyl, or aryl, wherein the heterocycle is optionally substituted with one or more alkyl, amide, amino, aryl, oxo, or acyl, or is fused to an aryl.

15. The pharmaceutical composition according to claim 13, wherein

U is C=O;
 Q is CR₁₂ or nitrogen;
 V is nitrogen;
 R₁₂ is methoxy or chlorine;
 R_c is hydrogen or (pyrrolidin-1-yl)propyl;
 R_{a2} is hydrogen or methoxy;
 R_{a1} and R_{a3} are independently hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, or pyrrolidin-1-yl;
 R_{b2} and R_{b6} are both hydrogen;
 R_{b3} and R_{b5} are independently hydrogen or methyl; and

$\begin{matrix} \text{X} \\ \text{Z} \end{matrix} \begin{matrix} \text{G} \\ \text{n} \end{matrix}$ is (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-

yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, or (1H-tetrazol-5-yl)methyl.

16. The pharmaceutical composition according to claim 13, comprising a therapeutically effective amount of at least one compound that is:

3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one;

5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;

2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;

5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxy-3-(3-(pyrrolidin-1-yl)propyl)quinazolin-4(3H)-one;

2-(4-(2-(4-acetypiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-8-methoxyquinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;

5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;

2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;

8-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;

2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;

2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; or


2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one, or a pharmaceutically acceptable salt or hydrate thereof.

17. The pharmaceutical composition according to any one of claims 13-16, wherein the disease is non-cardiovascular inflammatory diseases or cancer, and that is characterized by altered expression of IL-6 and/or VCAM-1 proliferation.

18. The composition according to claim 17, wherein the non-cardiovascular inflammatory disease is arthritis, rheumatoid arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular inflammation, uveitis, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Grave's disease, gastrointestinal allergies, or conjunctivitis.

19. The composition according to claim 17, wherein the cancer is multiple myeloma, lymphoma, leukemia, solid tumors, prostate and bladder cancers, cardiac myxoma, tumor-induced cachexia, cancer-associated depression, cerebral edema secondary to brain tumors, hormone-independent prostate cancer, B cell lymphoma, AIDS-associated lymphoma, or metastatic renal cell carcinoma.

20. The pharmaceutical composition according to any one of claims 13-19, wherein the subject is a human.



(III)